var title_f6_52_6976="Bladder tumor cystogram";
var content_f6_52_6976=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Characteristics of bladder cancer on IVP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intravenous pyelogram (IVP) study, which demonstrates a bladder tumor (arrows) on the cystogram (panel A) and postvoid phases (panel B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Machele Donat, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_52_6976=[""].join("\n");
var outline_f6_52_6976=null;
var title_f6_52_6977="Normal bone scan";
var content_f6_52_6977=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypertrophic pulmonary osteoarthropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 315px; height: 516px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIEATsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApkkqRtGrHBc7V470+qV9/x9WPvIf/QTQBdooooAKKKKACiiigAooooAKKKKACiijmgAooooAKM0lFAC5opKKAFooFFABRRRQAUUUUAFFFFABRRUN3cR2sLSzMFQdTQBNRXm3iT4padp04gtkeeQfe2Y49M1xtl8aLybVGhk0q4SNSRuHSgD3uivPvDHxM0zVXSC53W9y3AV+Oa76GRZEVlIIIzxQA+iiigAooooAKKKKACqV/8A8fdj/wBdT/6Cau1Svv8Aj7sf+uh/9BNAF0UUCigAooooAKKKKACiiigApCwBAzyaxPEHiaw0O3kmvpAip6968v1n42WNkzvHa3Lque2MH/P86APbKK8q8PfFrSdS8gzCeGRyBt2kj616ZY3sN5CskLAhlDfgaALNB6UUUAIaKXFIaACiikBzQAo60tIKWgAooooAKKKKACiiigBHbapPJx6V4f8AGPxRfXBbS9PWQJuHmyKSP4uAP617ZdNtt5G6YUmvGtcgM9y13syA5wCepzQByvhLw1I9+0l0sbRgZU4J+b1rtX0C3kt2WSBS5wQw/ixXS+H7KNLSNkVA7AFh149609iOxWRlXOVAB7UAfPnjTSGtA065WQEH5CTtHrmvVPg34nuNQgjsrwhgseUfJOfaqfj3RPtFg8isz449GyORWN8KlGmTxoS3nSNypbOB1/KgD3uimxnKKeOnanUAFFFFABRRRQAVSvebyx/66N/6Aau1Svf+Pywz/wA9G/8AQDQBdooooAKKKKACiiigArF8U6kNN02SY5wFPQ457VtGuF8ey+ZbrA5JDvtx60AeRTG717UBLqUzu5cYVvuqM9PQ0zxLoUaWE6sqlcDbhM4/H3rpI0WOWGCBl3yPtXJxz61pajpbCxZnked4wSBgBf8A9XagDitB06M27N9nVWGFIVsnOP6VseEtUv8AQPEESPLLJZOTlGOdvuK0LXSms1S5hDuhXlMUhgQsjhSAPmbjkHqKAPa7OcXFukgP3hmp6wfCdwZNMiDkMWHBWt6gAoooFABikKilooARRg0tFFABRRRQAUUUUAFFFFAFfUf+PGfH9w15Bqt8ljAZJFJt9x3AfN+dex3ADQOCMjHSvHPiGYNLRhJ5YQnOCAf0oAbba6l5aKdOkym35m387R/9atSLXrCGe1330Ks6HALe3TrxXi2o+OorPR9TWytghxgZ65zycfjXh11qepX2pPqBjlWVTk7AQv8A9agD7D8T6lJBYzXqgNZgEDBLFmHcVS+Hqf2jf/bHQxIx+X2H415Vo3jS/u/C9usyFgrEHYp49vc16p8K9Wtne2hAkMkiE89Bzk0Ae7w/6tc9cU+mQHMKEDGR0p9ABRRRQAUUUUAFUrz/AI/bHk/6xv8A0A1dqlef8ftj/vt/6AaALtFFFABRRRQAUUUUAB6GvMPinK9tBBMpwVJzkn869PPSvMPisvmaTOrqCApYc53e3t2oA5jwnqMUqC5nCth8c9QMVu6nrllHZSkuCCpAIPT8a8z8D6hDHpqW86hJgpODyCKx9Wlla6YQ+YkTEtgZwRk9qAPWdG162ktETzAc9Scc+uKxbjUoo9ZaAgeSRvwvUZrA8OR2j2zzMVjAGw8kcHrn8qgtFW78WWsEMnmWwDHcuDu4GB+dAHv/AIHw2mKyghei5FdLWP4XgEGmRoECgDAHtWxQAUUUUAFFFFABRRRQAUUUUABGRg0UUUAFFFFACMMqRXn/AMQ9Ah1Ww5jR3j9RzXoNZer23mQsMFiQcHPIoA+U/ix5XhzwghigXz528tj6HvXI6JJpj+EpLSaeVbi6Xf8AIM4OOh9yRXq/xBFiBd23iezc2GR5c0YyQRXDWVv4Ut2jlhuJzZs2VLoefb1oAp/BbWoZNSuNBubNmxuKuw4H1r6S8CeHIrFfPdd0ki7V7Ec57V4nokekpqFwnhq1uJLxwPOncYBGegPavpDwfG66PaRuMOqDcDzQB0cShY1A6ACn0UUAFFFFABRRRQAVTu+L2xx/fb/0A1cqnd/8f1jx/G34fIaALlFFFABRRRQAUUUUAIwyCK5bxRp4vLR43UYOQa6qs3UkGw5H3vUZoA8K8V6Xpuk+H7yVkK3KwlRt7nHFcl4Smii0RjqLym524HGOPT65NeoeLInW0uzIi5VWO5+w9a8bvNYgs57e2JMonbJZUJOCcZBoAveBrUatey2t9PKYpGyqkbQcc16f4N8JQ6ZqCbYTszkuRyPQ+3WsjwULQ26PbxAurEM/Qn/DpXquiw7kUjuP4u+KAOj02IRW4Azj3q13pkS7EAOM98U+gAoooNABRRRQAUUUUAFFFFABRQeOtZWra9p2lJuvblI19SwFAGrRXHD4i+Hjqq6eLxTOyB1xyCD05rpYNQgnUNG4I+tAFyoZ13LjihpTg7ec9KjJO7kgkDmgDgPiLpNtcadIJkiIY/LuXpXh13oFouoRREjcpO1Vx+Hevffik/l+H2kCEsp9M18m674oml8RxxZMEmGHlqOp7EigD6I8AeHIoIQCqmQYJKjqc9TXrOlxLHF8oA7V5V8Gppp9PRryMo4UZ7A/hXrUJIIyDn86ALNFRiT5cng+lCyBlzQBJRULXEQYAuBn1NSI6uMqQcUAOooooAKqXX/H9Zc/xN/6Cat1Uuji+sh6u3/oJoAt0UUUAFFFNZggLE4FADqKg+0xk8MKPtMZBI3flQBPVe8XdHjpmmm8QLnHTt6VDLN5i/MMY7g0AcX42sg2k3Y7shy392vmLXLdYvFVmCcKjqFXOQxzz07V9T+OJV/sG7YAkhMEY5NfMOt3MLa/EduDvCn5cAn/AD6UAezfDiGNpJoiMndk8dPfNes6XGquigHcK8n+GZzdtIiyqg+Uq3Y//qr1iFyj5QDAGCR3oA2OcjFLVP7U+MhVIB5OaaL7gnaM9uaAL1FYlz4is7RttzKit6Z6VZg1qynOI5lJ9M0AaVFIrBlDKcg0tAAKKKKACiigntnmgClqVwIbaR2baFGTXyH4z8YL4v1+6truKX7LbyFYlRsE89fSvqvxbYTahoF3bwSFZHjZVK8YOK+KB4P1mLXp7a1Lu+8sevPNAHVX2veGfCcUM9xby3E+0bAMhh6f0ruvCHiC58TaMb7SLia1ZlPDdmx+orldE+HsuoXdtFr8CyMCNwOT368+1fQvh/wvp2kaclrZ2kccSr0CjBoA8a0P4l+MPC93DZeLhHeW2/H2lV+YLnqccV7xZeILC7sPtkdwjRldxINcx4l8N6ff2dxayQwMsysOgJr548aaV4k8EarHcaHdST2mdpt3kJB9sUAes/ETxo1/vtYo5IoE+YPjJavl3V7ySbxqJUcN82SMc59K7e4+J9nqVtFaXdlNZ6icrJlfkyf1rzOdVXXfNOcqxJY9OKAPqL4deKJbJrePy3k81SJHOFANeuap420LRdNF7q2oQWkZHAkbBJx0A6mvjXSPiHcSCCx0ewlkvWBRW65J74rf8LfCvVfE2sC78W6k0kO7cYvMLNz256elAHsafHaHW71LTwxplzOxfDTy/Kir6+tdJfeOprK2WfUZYbaHb87sOAT6VJ4V8HaPpMJisLSOBdu0HaA2Peo/iB4CtvEOhvZoCGODySATQBxeoeJx4guBqGm66wMAK7UxtGemRT/CXj29sr9U1PUWmgdwCCowPTB9K8svfB9z4MlmWPzbgTZyqg5GP6VzV5q+qXcsURtWj2khflIP4igD70027S9tY5ojlHGQfWrVcF8HTft4H086hnzwvcnle1d6OnPWgAqndZ+3WXpub/0E1cqndD/T7L/eb/0E0AXKKKRmCjJIAoAguZyh2qPmxnpxXkPxI8c3ml3BtrJyrqSSSCQR6V6pMSSW7k9BzXzV8R727tvE1wr2zODJwyjdx7UAT2XxIvZL1H1e5ktkTklUOCPSvRtH+IdhfxxNbX0Uu7g545/GvBtSu5NbgW3j8xLiRSHG3G3njr0rtfAPw2ZbJ5NQmdxKMEZwQPwoA9Y1DxdBZWz3Fxukj5/1a7iateGvE1jr1it1aOQhPIYYx7V5v4g8BC00tv7PvpolUbtjOWBx2waxdP0jUbHQLb7PdeTKzsXbfhW98UAegeOPEUcM0llGjSJIuGZRnH0r5u8ZOD4jsWB81VmUkKdoAyOteh+J9ZewtwtzeKk2QV3YIYe59DXj3ia4t7rVC5uCjrIpXacgn0+lAH0L4U106YsDAGRXfazKP1r1nT9RimtFm3gDHIPHNfNuh6ja2zWL6vcCBGXMUMOfn57jtXZW2tS3OpGKwmckLjYxwp6dB3oA7qfx9F9uubeFVKxcZPTPrmsTUviTb2ltPvnEsij7kPJX6muX0XwyLrU7+DUp5FG7fhSenXr6V2UPgPRRayRQ2qoZVGWPJPoTmgDyDX/HK+I7lrKymVJsnmQkH6VVsbjWNIv7e9+13U6qwMiEnaozTvE/gOTw/wCInvbWMSKXIU5wQeoOKtrp+vhIjIm1JH3AAADpxmgD6b8Kayuo6dDOpOwqMgDvXSowdQw6V5r8MLW6tNLxdsGzxkc/lXoUDKsgG75SOOaALVFFFABSY5JzS0nfNAFW/by7SRieQpya8s8E2Jn1e8nYEhXY5x056V6XrpP2ORc8MpH0rn/A1sY7W4cgbvMwPegB2u6eRGksIJZTjd3+tacc4SxSRy3K+uP0q9dQ74ew4/CuO1XVUWaO2k37lPO08FaAM/Tb4LrLR3RKmRztyeBVrxRoFprHkSTKp8tt2egz60/WNE/tGHzIisTqNysOo71mLqd1aQx2V9CZd7bC4PQepoA+d/2ivDo0/ULLULS23TSEo0sfsOMivEhJceb1cvnkGvsH4t6fDeeHr4pLGPKTcryAnZXy54Psn1Pxdb2jXCr5kuC7Dg4oA9i/Zq8Hw3CXWr3aEStmJFZcYHXK19BeF/D8GkTTyuQXfk56c+5rH8NaY2kaN5FgivKkeVGAuT/+utWyttV1KFftoFvuX5kVs4NAE8V7J/wkSJabmiU/vG6j6Zrs0CyQMwK89RnNcdqEdvolm7kkkc5z1Na/hfUPPsBkEt6HkgUAR3Ph+C8uhK8agA5PoR9K86+IHhi2ttVjlSJE+QcBeOCfzr2qIBl4/wDrVx3xJsxPbwTglWjbqB19jQB0nhVQNAtUXDAIB0wK2axfCQdNFt0kzuVcEE1srnncMGgBap3X/H/Zf7zf+gmrhqndf8f1l/vN/wCgmgC5UM6iQAZHB5qaoSSZGCr2wSRQBFICowwyMYzXl2v6bHd+I5Nqrkvg/Lk16k/Ck85rjIbWRvEU8uSYySxwc49sUAc/qngy1iH2pI1MkQyfk6962tLJltAAyqWG4gcYxXVSRBkkXPBHSvLzrEWlNdwXLbfLYknrn6fpQBifEzVpjJBaWbFlkcbmzkfjXTNaW9xpMag73VAVZBkLXm8N8Nd1O23OAFmzsI5x7ivSTb3FoipahY4mAIJ/woA4L4j6SzeFbjztOa4jiTeQq4k/A9q+btRmjEwNvA3lAgqj8MK+q/GX9oDS7k2V7F54UgRMeH9vrXzF4zMyanJJdwCC57ohGDQB2XgKGO88Q6fHbWE81wx2tLMMxqMZB+lfQlhoLx3iXTCIMqlQEXp9OK8c+GrX1zZW7R3sdraAhXAxu57fWvaYXUQxx21429RjOeG7ZoA5j4h3X9l31jcQO63BJiwmSG+tdr4T1N7qx2yMonTAZT1rk/EelX0sBuLgJMQfkxzz71nR65FpEZuDIAqId+48jj1+tAHQWH/E88ZXkQB8q3JH+zXReKNLVLFZEXhfQZPSsn4NWz3OnXGpyoAty5ILDqM5z713niC0FzpUqgYYcjHbvQBB4OZZLBSgOOOoxj8K6jbggDDY5ANcp4RPl/uCc8DJIxXUgbGOX69NtAFgY7UtIoHbvzS0AFIR+dLSMcAmgDE8ROTalEIDtgdak0i1+z2CJu5bkjHQ1R1WUTXMUQPzlvujqfet0DCRhCcfSgBQuVXJNeT660Y8S3tuThmb5Np9v05r1tgck+3SvKNctWvdaurq2GLiNycEc8e1AGzb6k1jElvfROM4IYHoPU1YF/YXg/0ULI4G4cAnHrUNrdWmrWvlyy4n24PYg9xVXTvDcOm6ob6CeZgU2+WenPWgDiviYsT+GtSZDscRsSHyqE47ivmT4VKlz8QdO85QAHYgkcZ54r6h+LYP/CK6nG8AbMZPJwAMV80fC25W38Yab8oRXm25IyKAPsrQ/LjiUk8lcEeh9KfH4ns5Jp0ttztC21uO4/nS6LCjW6iQ4wCT6k+tWbbSNPtLh7hIkQuxZt3r64oAzdT0+e+X7ZqEgW1TkRg596XwPcx3epXAgRvLAIRh0qbxHqCT27WlivmSSnGRz+NN8K2kWj3sFupw0gJYYAFAHfAYjG0HrzUGoW32m0dGGTjNWtxKc4zS9V5OaAMXw1KCksAwNhwQDW91HpXN2ki2niCWLp5nOfrXSigAqndY+32Weu5v/QTVyqd1n+0LLB4y2f8Avk0AXKjMgJO3lqkqLbwcEZJzQBVuGCRlz0/nWPptuFlkuFyBI3zDt+FX9YkCW2wY3kcDoaktEVLOMdCRkgc4oAUAAcg8j8814B+0PZXWlRx6xZZIDBZI1HOM9fpX0IFOAx6j1rhfiPbQXkC2l4oNvOrK3GcCgDw/4R3M+uXdze2UYkuIwGJk6HPX8a9TuJwHJ1O5+YkAxoe5/rWd4L8NR6HYPZaWPIgOWZu/XvWq8FlZAZke4ZjhR3BoA474hy6PJotyjzzQMV+SYZODXzR4klMd4Atx9r4wJCOuPrX1R4/kjl8L3vm6SssXlN5jHAKjHb3r5J1iK187FqTEmOj5JxnvQB6V8O1s7l7Vb68MZZg5hjX7x5719A6X/Zgs4hErpH93O0gk/U183/DGSCPWLKNIhcXbNtjYE4OO1fTUru8KG4s2jhGCMCgBk6hYZF0258xiu0BzmvA/FNxfax4hGiralZ2bBH94Zr6CtrSzP7y3dopVbpnrXMTaNAmvPqElpi6kwqyIev1oA9L8B6aumeGdOtgpDxxAMM9+9dGU81CrEgHjkVneH2LadE7L82Oec1r4wBgCgDDsIja36gjcA2B7CumVeAx4PX1rntQPk6hEW4yR9DW9ATIgbHXkAHpQBZTGOM4PNOpEztG7rS0AFRzuFiYkj0qQ1T1Jttu7dMDJoAyLBVvNZeR85jHHpW8TtU549+wrD8KqWWeVxyx6+tbnAjzjA7D1oAHJOcjjHNeXyXRtNXu7uPcVEzLJxkqOn5V6dK22JmwAwBzXjN3qUWl6l5k7KbK/kKMOoGTjJoA6HWfDcGpWrS6ddPDcEb45EPRh9K2tKgms9MgjumeaVUwzt3PrXHaRpGv6b4nRbO8E2hE5MbEfL079675yfLCqOeoGOKAOC+J+lPqvhu+tkG6SSIgKDjn1zXzR8P8Awnq58V2LXVsYYLaU7mfjkcivrfxRHu0uYhtjY79TivHfDPmzeI5X8yRwJjkbeAO1AHtuixt9lUseSuM7ccVDr+lNqsVuBNJAEk3nyz97IwQRU+j/APHosgc8dhWne2rz6ZcRxuUklUhXHBU460Ac9Ott4fsSYdjTMOBI2STVDw5cSXer29zeAedKfuAY2gZ/Kk0nw1DoULajr9297cRpnMjEqPwqjpOonVPFVtPCFS0LbYieNxHP40AeuoQT15/nS45GAR24ojQYHAB9qeaAOP8AE7Pba/YzKfvccnA6110Lh0VhycV5j8Ybx7G80iYOwUyEYU9/eu98NzfaNJt5S25mUZP9KANSqdz/AMhCz+rf+gmrlU7kf8TCz4/vf+gmgC4elQbgSQMtu547VPVac/MOQcfpQByHim536nb2q5BwcnHQ11EA2QRr1G0CvKr7VDffEsWCPuKnBUc4A/8A1161Cu1QBxjsKAF4Ax2rifHKRvc2/mMAACS2fSu5C9c4H4VxvjaDzLi1AGRk5yM5FAHO6bNcanG+SsMKnKgcZA7/AP1q57UdZtrC8kt9Iha+ulHKMeFP1rrBA19G0UcbRwJ97nGRVS30bT9KyNPtlNwx5bG457c0Acv4ok8Sz+Hb1zDaR7oi3lspJJx0xXyf4ilNzqDvcWwin25cA4xz6V9m+J7C8l0G/wD35S8aIlRkBd3avjHxKbhdRuoL3y2uI32u23BJzQB6P8G3vF8Q6YllCpRw37yRMhSB7dK+i7jU9RtLcLPbq8Y4LIh6eteIfAi21C5vY5htjsEUqQpwd2OozX0H5U0MYLlnhUc7ucD+tAGVpqWur/dkkt5gckE459eaTUzJFItjdYReSsqdc471bitYbydpIcxTqSAehPFJJI277HfKXAB2uepNAHXeGG/4lFrg5AUAnPet+MYGdwJ/PFc74XyunrHgAjgj0Oa6KMcAn06CgDC8UovkxTc/IfXjNa2iy+baowBBIxVXxHGraTMxHCru6VV8KTCWzKoflHTLZNAHTqTuIOKWmxj5eTzTqACszWXZLeQdcjgCtGRtkbN6DNZs6iYMAxJYdD2oAdokJi09FI+Y8ntWhjgg023ULGAPQdqkoAo352WkpYnAU5PTjFeK2bxf2le6JrMYNregtbO/3Tnpj8TXr/iMr/Yl6HJRTG2Wz04rymXT08ReF2gtpFXXLMfuiPvA9uKALHwx8PeINDnvotV1GW4t1fbbLIN2V9T6V6PsJTc2evfnFZ/hVb630WzGsHzL4RgSMQB82Kt3t6ETaT8x6AHpQBz/AIvjY6bKY3fIyf8AIryWyub+LVo1bcm5scqMNn0/KvW/EcLy6fKzFwMbf96vN44XWeNZC5x0zyMf57UAeqeHoibGIsu3jkZ4roojmMKiknpzXNaQ8sWkxOd5Vv4c1safqMbbQxHJIOeooA81/sLX9R8YX8nia+Z9AgJaOINtQg9AfXHNWdGv0v8AxjbLpwQaVaAxowIKs5x/KtX4q6frGqw6db6bOYbB5f8ATCCPuY/lXO6NHaDU7KPRznT7ZvLDgkBpO/1oA9tiBCgZ6DFPPUH+lR2+fKXPXFSHPX9KAPLP2g7aR/CUdzArNLBMpyFztB4NdD8KZpZfClp9pP75UAb61ueJrRL/AEi4t3IwykfjXPfD/MOmNCXJIcgk9xQB3FU7j/kIWn/Av5VbByMjpVS4x/aNmP8Ae/lQBcNUbxisbngNjJzV41geILkRWk55AAPvQB4/8Ko7jUvij4murlDthbCHGQTnrn1x2r3fACgjsMn6VwHwp0+K00m5nAHmTzszMODjNegwYKDH0PvQATeozu9K5DxSGm1GzXB2Ll2wT0rsJwccYxXD6/un1kQpuyF52noPegCq1xLPciDT8RQ9XbuPanSSR6dKxCCSYnp1oeNo5hb2Aw5+8wGcAVQ1DUrXR4yQyu6rukctzQBm+L9Ju9X0XUPNupLd3iYRmPquB/OvifWZLpb2db5me4DkiQAcnPevrnxJ4ivda8O6gmiXGJ3iYJMv8J+lfHl29wlzILppTcq/8XrnmgD3X9n/AEvULyM39xftFYwkqIgMZPqa9/tLq4tT8+6eH2H6184/CZNestOa8W8Y2Kt80DJySevFex+GfGEF9L5SXAbAw6ngjnHI9KAOvmjW4ja4tiVcnlc447ZqGQeehhvFEd0i/IwOD+NOViii5tGUt/Gq0TpHqMZuQpWSM5znrjrQB0Hg9XS1kWYnzN2a6uL5oyQMevHNcj4QmadZnkwGJAxj09a7PJEIxknHYUAU7yFZ7GePqGUqe4rkvAp8qJoGGWDFScc5BrtOqkfn2xXLi3NrrRaLcI3bO0cDPrQB10fTOBz6U+oLRiyHNT0AUdclaDTJpEBJAHT61xGneLxNqYtmhdRk/MRwcYFdp4ghkuNHuY4n2Oy8NXHeHPDDRqr3EvmnOd5HI70AdzYzefCGIPFWaitYlhiVF6CpaAMzXYBcaXdRN0dCD+VeJaJp81343tJbKdrSe0cR3KE8SIMH8cgV7xeRebbyoOrKQOe9cl4X01rdJpbyKMXgJUsB1AoA2NRby4zuJAPNYSbpJ/3qgjIPT8q3ryMyWxxn5eRxnIrMS3keQAnEgHUcUAVfEKsNEk2F/lBxzXkEhuJL9i3nbg5wFb24/wAmvYfFPmR6DIpJ3Acn0PrXhtzd3Qu2S2nmWTcOdvX35oA9s0aJn0KEPyvUg9RUM0QhcNtwueADyPepvB0jNo9s0u5twJwe/wBanvW/eBRGcbs7QOCfegDG8Ytcat4aeOK7e3jVv3zqOWTjIH1rE8HweYtmYIhDYwtiCKRcMxHVq7jTbKOW5dX+eErhlIyPpUFtYSnxggkUJZwR/u1A4J70AdrAPkBIwTUlIuMDFLQBn6lOsJ+bowxXKxapZ2Vz9niYK8j4+Xnv39K6XXLFrm2YRthvTOM/jXleoabd6ffpK0DSfOTtJz1NAHstuxaFSeuKr3Gf7RtPTDfypdKZ30+BpE2OVBK+lJcZ/tK09Pmz+VAFtvumvOPE/iKxsJpIL58ZPKg849a9Hb7p+leF/EDS59X8QzBF8tY1VS5wd30oA7XwRqdvcXEsNuQYmHmLtxiu8iB5P6V578P/AA9PpsUc0zZTYFAx/jXokYwo4x7UAJNjyzkZrhtXYxatcTbD5ix/KVHXiu6k+4cVxPiy1cXunzRYwXw+fSgDNnuE0fTzcO5AZOp5JNeTX6XHiYz2g82JQwJ3NtJGc5r03xvH9skghiLLHCS0qnowxgfzrntPtVtpFG3duGSSemaAM6fSZNL8LX0diu3ZbNtYfezjqDXx3cySm6d5ndpQ3VuT+tfdniuKSHwVqRt5Qki27bTn7px618K3ksstw73Eu+YMckjvQB9D/BOzv38NSXEsrTRu2BuzlMen510GpaGLa6e8tBGjyPh+eT7Cqn7O76h/wjEwnZpRI37sjoBiu61GwdJxkAZ9ecHr0+tAFv4d30zX09rPgqRhc8kkf0rc1iGTT9QSSNv9Hk+V1C4BasnQrSWGdrpFUPECSyg/NXR6466poEtxAvzKMqR2PrQBd8KFmWZWwctwcc12IBCepx3rk/B8UselwvPzK6/NXWjkD6UAVbhxEjs3GASa8q8X/EOy0vUIbYpJ5kwO2TGADXq9xGskTR8kMCCBXkni7wQk14bkRRMwBWLcMlc0Ad94E1F9T06Sd8gAgDn2rpq4/wCG9rNZ6Y8M2MKcDHQ12FAEdyu+FlAzkY61VsVChu7DtirNySISR14xUVuCJODkHvQBZU5H60tA4AFFADSMDgVE8aEMABzzUzHCkgZ9qbjOOooAqiEhNo6DiopLZVA24DDrV0Akds0x+mR1xzQByfjy4e28OXbxKDJtyCa+eJdbl83COnmb8jKD5fx71778TLwWXh6STyvOAIGwdea+dF8QwC7LXmnRZ3EBVHX/AGvrQB9CfD25a50aIykHPcDjr2rqLrThK4dCFOPzrlfhpdxXWgQTRRCNCMqAOOvUV3cZPHOQO2KAK1jYrB/wLocVdSCPesoX5wMZzT/lHJJ9cU9SM9ufSgBRjJAFLRRQA1lyOenpWZqNosjgqit65rUYZHNVbpgu4sQB2oAngGIUHAwO1Vrgf8TK0Ps38qswNuhVvWq8/wDyErX6P/KgC233TXIzWiXGpswjHJ9K65vun6VzVnIpvZRGwEiHn2oA3LSHZGoGFAGMCrIPFRgKyZBPvjvUi4wMdKAGyKGHzYxVS7tY7pR5iggdD6VZnQOuOc5yKUZySRjtQBg6lpUFxDJlR5n94Dr9a56y0F47hnYcE5IPQD0Fd26hgeOCKqSIMsCCE7jtQB5Z8Vb6707w9qgtbaMqts23zB8pJ9R6da+Hrm4knfzZFgV1OcKoGTX3n8W7u3tPCesS3MZmWOBvkUcsPQV8Jand2tzeCa2svKTOWQtkN/hQB9Pfs6a5LcaAYbm2iiVXGwRjaMete4y6RFeNHM2FJIJx3rwf9nHWrK+06WD7GLYQsOAc7vxNfRdoilcrjBHAoAhtNMht08uGMspGCT0FWrfToYYnjRQEc5KAcCrsAGBxj2qWPaQcDPsetAEUcHkoqoFCAYGKujoKi28D1zyAetSjpz1oAilGXUdO9Z2r2yzQDrvXnIrTlXkN/F0qrcjcpz940AU/DibFkG7cSMk+9bVZmjDBmG3ocZrToAZNnyzjqKihYkjryamlbahJGR3qJACQV4z1oAmUY7k/WloooAMimOcHj06Zpk0iqDkgADkmvJdb+MWjJro0nSbmO8uTIYmweFPIxn2NAHreRuJz2pJG2oSD1rzRb/VvsscrTn1bPGDVDTfiHLDeS2eoFN46ZBFAGp8VLyzXw+4vJNoZtoYcEH69q8NXSfD0l0J5b+bKAFU3cZ//AF13nxP1ODUtBxLPHbo0nc8ivKIbBJZFZryBrVcNmNxkkUAfSPw3e0j0GCK2feuMKSPeu7gYYGGFePeBNbstN0aMSyRdTuIOQPatRvGiXc4j0+QtEOrAjigD1NcA9+fU1InXvjtXm114g1Oys2n2hgvPII3D1qz4A+JWleKLybTvOSHUYeDEWGWPfHrQB6EKWkUkjnrS0AI4BU56Vz3izzF0iZoiwOM56muhf7pqqYRLE6Pzn+GgBujOX0y3ZvvbeaWf/kJWnPZv5VPbIEhVRgAcVBOP+Jla/wC638qALb/cP0rzfwkZ38U+IGkd2jE6BMdBhRXpDfdP0rE02zSCW7dQC0r7umO1AGtCw2jJ5xgVNUFvhgG4yOuKnoARsAjJqMHJzyvfHrROSAuDjnmsXX9esdDsHutQmEcY6DOSx9AKANc4GDmqlw4XBJ4PXNeM65478S67HMmgW7afAgB8wgM5B/QfrXk198W/FvhLW47fW5XubWQqzB15K9+aAPevi0tlL4U1T7bIFjMBy/piviK8tNPB/wBFvWKiX5vlPA9a988b+O9E8VeGrt4bkqrREFWOOeDXz3PaSsRLC8SRyNgAOOnqaAPoz9nsaTEXFrc+a4TLb/l4+lfRljOrom1kCsOAOgHrXxx8KNY07QVmnu3gMyDpE2citzxv8b5RpsNn4ZYpcO53uR91cY/OgD6+ilB6Hv61ajbJ4Iz9K+SPBl14zvVXUp9RusSAYDM23PsK9Y8D+PzBeDTPEdwFuC37uVuNw9aAPYvMwvYEmpBzVWzmjuI1eNgyMMgjnj1zVsUAMlHH3goPFQuMEgkfWp5F3Lg4x71X6OM9RQAywUCabGBzyKu1WtVAkkP8RqzQAycAxMD0piE/KCAvpjpT5sGM7hkUxgGcquMjrQBNRRQaAKOrxyy6bcwwf6xo2C/Njkivz3077X4T+LBh1SNhPDfbZVc5zls5/lX6IyfMMYBX+dfNfx++EN3rHiH/AISXQtplUCSeNjy2PSgD1D7RHLo5kQjLIecfoa8F+JN29o7PYuwkVyWdeNvtXZ+HfFUSaHHbNKjyIu1/m/SsLWPDsviq/je3G1AuXx19aAMHQbe48T6PKLgMSgDqW6k/nxWHp/hW+OrGAblhJPzAdc9s163oWlW3h6zdCQsYA3DPQ+pzVLT/ABHoTai8P9pWvns3EZYcevHrQBwvim9udDt4tPtODuzgng8ckV2fwnJaNDcRnzW+YheRz3pPGHh+TWnEtqYmIOVIHfsQaTwn52huseoMwYMFx3znr9KAO++JGuWei+FZ7m5yVCYAP5CvA/2ddGv/ABT8T5tZhMsVlZt5jyKeBk/Kv4812nxQNx4za38M6RMhnmbliT0HJzXsXwS+H0PgDwt9lDiW7uCHuJBxuYentQB6QhBXIp1J24paAEboaiQ5BI+bNSt901Xhxh+3OcelAE6DCjt9KqTgnU7U+iv/ACq4vQYqpNn+0rYdtrUAWz0NUYwMPyMZxir56GqB2qp5zg9QaALVtjyh0qWobXDRhh3qY8CgCvcsCuwYyf0ryD4y6DcaiIbxPMaO3AUInI6+ma9ekw7Hqce/aqOpWq3NvNGwUqwI57UAeVeFBbrYgKQZGUZJ7HsPrXhP7RtgVktbpRnLMOB0Fe/S2X9iz+U4VEzke4z1ryD40WL61bSpZndtG4IvOf8APFAHzzYTyo3kplkkOCtRXEMkMzRSKVYHGDWpBoeoW1/bC8s54VaQKCy4z9K1/FOlL/a5VZYkVRkAnn6H3oAw7i2n0+wjk3OjTdRntUegQG51e2j27gXBIrr/ABPo8jaDY+QjSzEgHA6e1N8E+F9TtfEEMmpWM9vCDt3yIQMnpQB9PeD7JbfRYoGA3gA4zwMdq53xRpMupartto8TIQQ+cY/z6V0Wh3CjSViRlDcAA8YrofDujme+kuZlJRu4H9e9AHXeDIZ7LQ7SC4yHjjC811CsGHFZtkvljYgyAMdeoq/FxkHr7dKAHv8AdP0qowbeMntVtgSOKpbsOQCRg8UATWoO5znj0qxUFsMFvWp6AIL6cW1s8rdF61QTUrZsOJFAPGCelT644j02ViobGOPxrzabNqftD/6tXyig85JoA9WjYOgYdCM041R0e4W5sInU9uauPxjHU8UANbGP94/lWdqsYmt5lOOUI/DFXWcDg5/HtXLeJ/EUenxzIm4yAYwO2eKAPknXNC1nw9rV5PEA1usrbU3cMpPU/hXc/BzxUt1qFxZXSbJRGXX/AGsf061F4o1Ca4gmmIQb8gP1x7ZPT615No093ovjGCSFfnZiRjnI9/agDsP2hfFjRzJomnu6M/zXDAkHAxgV4QGIbcCd3XOa9D+MtzBqWtQX8RCzumyZOmCOhx+deeqpZgB1PrQB9N/APxMbzwnMl9+8fTwyb3znacnrXMeJvG1xe6zOmnnK8r6D6/rXJ6DfnRfA9xBYvm6uX/fsj5AXHHSl8BabLHfCe5USK3zYc5PPegD1b4AaNqr+P21XUVKRRxEBT1OR1r6otSDHtXIAxxjpXgHw71tbW+YMuMHbkr1HYV7lo97HeR5RgWA5AoA1wT3BpaYhP19TT+ooAiuZFjiLOcCqVrdwyBgrq3bg0mvPtsnIYAgV5pHful+DHvVerBTxjvj3oA9agcPErA5BqCb/AJCdt/uN/SjSZRNp0Ei9GXIps4/4mlsf9h/6UAW5G2xs3oM1irfRzRF1dSCcAitt/uN9K8k1e72apIloJFhjPzY9aAPTtJlElvw2SCavE4BrmPBtxvgkDPvPUnHNdMcnPPGKAICcIOPlPOM5qGUDB44qV8+wwPWql9cpbwNLK2EXnOaAPP8A4nxMLFZbdWaQnHyjOP614bf65Guo2y31uVjD859vc/nXrvjDxZHNMsNsCecEMMHHc14h8TLZ2mWSIgRsvdec+ooA674sm1ufh7PfQFQ9uoeJ0QevNfLc9xNPKZJpHdyckk19A+GI5/Efw41LSpWUKVZYieG3dea8I1jR77R7pre/gaNx7cH6GgD0D4Pag+qeJLDTLzLxITIBwd2B3r3L4k3dtZWNnHIV3vJuC9CAB2rxD4E6Ldf8JXDqc0ZS1hRsM3G4kYGPzrpfH15cXni77PO5McP3FboSfagDuPB2oXepTIEUiL167hn0r3nQ0KWiKMY6/SvDvC2/T9PSR4jGwJwRyCAK9E8NeLrWS2WJ2LShyOB+v60AemQA8jjgYxViIHLE8HuKzbSdZI1K42kdR3q9A2XI7dqAJpG2IzegzWO97DvbcwBz61f1NwlnIWbAx615RJdi/lkWFmHlyfNuPb2oA9VsLhJmbYcgDn0q7XNeCZvOs5SIygRtvJ6muloAoa7bNd6bLEpAYkEE+xrjLXw/eb2E7hl3ZGSSO9dzqNytpatM3IBAP4mq9vLHPFlWUg4YdqAI9GtmskEZ+6wyOeM960pPu9D+HWqc7HMXljI3YwKty9BkkenvQBma1fR6dp891LjYiFjXzTZeMm1jxbNHcsXinkIAY/KB2wa7/wDaE8UrpmjrpsbYkueCCcZ49a+WdPvJotUhuDhTHIGHpwaAPq6x8PWOpWm6eBNoJ+XuT68VyS+G7LTfFazG1idHJUFl5X1+tdv8NZzqdjb3QCqsgOQO5zXReJfC41OAG3ZkkHPDEcmgDxX42fC/TdTsE1PTUSC7UjcEOAyn29a8q0z4YC5lsopxKkb582QLjn0Ga+pNH8HX5uCdUlDQIMKuenvUHiDw7cuzRWO0kDKB8r68DFAHBSeENB0DwKtta2kbySjD7zkt7k1c8BeBraa1ma8hBwPl4yfapNO8J61LqaLdtGIEOMMxOPoa9bs9NTTNOCqd7AA7sYJ4oA83n0qz0dmaKMRCPhm759fwpfhf4zW58R3VpM5A+6GOTnn1rL+LOoSWOlFTgSTtgEtjaOua8f8ADmoyWGppNHKyM5ywHUgfzoA+5Eb5flFSKcqD6jNcl8Ota/trQI7hmUsp2lQeRx3rqZs+WeP1oAyNTtrmeSTyyu0jAH+frXEtomoLO6qhYDPGQAPpXokLEwsW65waWaRYhvYjkDr3oAj8PI8ejWqSDDqmD9alm/5Cdt67H/pU9qyvAjIMKelQTZ/tO3442N/SgC1Lnynx1wa8vuNNu3uZVA3s+TnPT/Oa9QkOEY+1YVnPHcAMuM5wRj0oAzNCs7qyAY42kYxnkmuuRt8IPqKzX3pDKVHIz+NWrBna1HmelADRgR5BxxXjvxk8YHS4VsYjgSv8xXsPr2r1TVruOw064uJnVUjQsWJ6cV8deOdQn17V5GMrFZCQgyQCM5yR+FAHcaNcreXduRMSr/e357/5FS/GnRjD4VmuLcbvLG4nsBWH4I8zyoo5uGwAA3XjuK9VvLE65oUltcqmyZNpJNAHl3wJ1C0v/DFxbzj9/GSQvQmtPXfC1rfsn2mAzBCW+9nCnnFc5pHw88RaB4wH9nbTbzNtLKTtxn0r3yx0UW2n/PGHcgZPp+NAHG+DtBhtEjITaqrgIRwOOteT+JpF1n4qLZQFfLVgrHoW/L617n4t0DVzaO2jupcjA3EjHbtXMfDz4YS6ZrLatqcgkuivy99h+vWgDQ1nTBpWmK0f7sIgPlg9f8a85uvEa6dLGRmJxkZXvk8fSvW/HtrcLZuyjIVQcgdK+efE9pImp3MkiYiOW49T7CgD6p+HOrtq2h2szsDIFCtjqD713lnycHkgV8yfAjXZY55IJZMxgBQnIwc8CvpPT5CxU4AJHIoAh1pWuYzApwG4z/OuLu9DltoStsgJ5JKgf5xXZyXLfb3jcYA7+lEiqIvMG3PTk9aAKngy1ktbeUTElmOfpXSVl6LPFKZUiYErjcBWpQBS1iAXGnyRliucHI7c1laZYT28TqWLBuQeeK275GktnWP71V7ZmQKXA5GPxoAgthKISCPmU9auSMVQA88Z5FRlJhdHgtG2Oe1N1icW9rLIwO1EJPNAHxn8fPEZ1bx3e2xP7q1bylJbjpzXnlncCKPIH3c4Qc0njW7+0eKNUkJw7yswPcDNSaMizxIuSXAwvHUf/XoA+kv2fNbjMdtYsrBnBfDnOB9a+gY0z0A574r5P+DOoi28Y6ZEsjMj5Cj0GDx+dfWEPKBh/F70AJLESoHp0qg6bwYxw2d2a1j2pnlgOWUfMeuaAMuDS44XDsuD1P1qW8iyhGcDGM9a0SvOOfTNUNVG2ymbPRScjtxQB8s/GrWFvtQEESIwhY5DN07frXlkd9l1BkDMAfkA7dhmuk8R3X2zxDeq8W/52wOn4+1cPeBbcnluG5TPAoA+mP2Z/ECTQahYudrBlYKTnnnNfQM+4w/u8HFfF37P+tLZ+JA8zBNxCkY6+xr7RtWWW2RwBtYZ5oAoXXmsUMSck8mqtxb3MrqJD8q8Nj+layscseMdu9MO+RhsHfnNAE1nGIraNB0AqKb/AJCdv/uN/SrajAAqpN/yFLf/AHH/AKUAWpACjA9CK4xrOW3naWEllLEgA4rta5+58yG7mUldjHgd6AG2ssy3G2bd84AAPYVo2TMYnWRcBWOPpVQzF7NJtpO3gj0q8m37MrhSS43UAeZ/GvWRp3hW4hZyDOdmR1xXzNZTEz+fE7FiCy7iDgd69P8A2h9a8zUGtlR2KKNpBwF968Y8Mzo2sW4lBfu2OKAPQ/DNzLFq9v56hVPzBsdM+wr2/R0UBd3zKTg5/wA9K8ktozH9nlAj2Mw4J5xnvXt/h20JtoXYLtIyrEc0AadlYF5hO6tt4wCeBVubaibHHU9BzWjDESMY6cmh7QM5O0n1/wDrUAVxGsi7TngYJ9aasDIwCrkj3q8IFQApwPc02VcDcCcg0AcF4/uzaaa0eMs42jI96+fvF1qy2s8mdowWA9v617x8QZVN5BGyqygE49K8W8dRRDT53ZQr7c4Y84PoaAOX8E6udO8QWzwl0R2UEZ6jPIzX2Zoc4ktoWPIZAfXtXwppsojvYH3gHcPvdFHrxX2r4DuBdaXbt5pK7ACcd8UAbF2xnEoRf3gGOuKzZYrxLRUCsxI57HFbFxHKlzHHChOeS2OKfM4EhQZJVePSgCj4PgEEVyMqzF8kg8/SuirG8NRyLbzyTIqs8hI2+lbNABUbQhsDoBzUlFACAYGB0rmfHUwttCv5C2P3Lck47V09cT8Vwx8LXihioZMFvagD8+9eZv7ZumByd+cMc7q2/DpAhMqtggY4zgcVg+JFxqcjAdT1rX0TjTwzZKMCCBx0/rQB6N8MtSMXjDR1kIX958rbe3rmvtSwO62jfcGJXOa+AfC10sXiXSQ8jBvOHQZ2jPavvjRsPp8BXGDGO3tQBoDByATkUvT60AgnAPNBHORQAxvQk/jWdrfGk3h5wImOPwrRk4YHt0rG8Wu0Xhy/dOW8luv0oA+FZbxv+EhnA++zsMufes3xjZJBtkjJVnOdvf61Ck6TazMTmNixOSc55p3itHa0gaSVSrE4GeRigC98OL022t2xBPzSAkd8V97+FZjcaJbyMCCVxg1+efguVV1i3V/lXzQK+/vh1L53hi2ZcFP4SO4oA6NkG0BQMelCJtOcnpin0UAFU5T/AMTO3H+w39KuVTl/5Clv/wBc2/pQBcqrc2izTJIT909DVqigCjawbfPjcblJ6HoakkVbe1VV+6owPYVZIGDnpVLUmH2ORgx+6efTigD4q+NepNLr9wGj2hXb5um7Brz7wxMJNYh3Rjk9D2rb+KV4J/EFyI23hGO5yOp5zXL+FW3amjMSVVgFDHgZoA+grdftFzDGG2opGAp4468V754eJewtw7BlAABx0FfP3h2c2xgTbkEhSM9R69ete/eEm32SFgRg845NAHSou0qOo7GrbDKg9+lV4hlgfQVaxx0+tAERXPUYHoaqygIDknFXGHpjGOtVLxsQv1OBQB4/8RZANRY8D+E9x681418Q7oRWxYSsZHAz7Dtj1r1fxpcAXbl1D7mPy1418R3WS3VEwoA3AFsk0AcHY3bzyqischskdelfZ3wdu2utHhLBkG0YJPXiviGyVvPjCHbuA7Y6V9pfAeRv7AjBIfCg7qAPXcHDDP0qguntukLOCW/lWgM45OTS0ARwRiKNUHapKKKACiiigArjPinC0vha9VfvGMhSexrs6xPFlsLrR7mMjJZCB7HFAH5zeKrXydQnIG7EhG4Vr6TAw0qMFGXKEg54qTx9aPaa9cKP73zFDnmr+kkf2eQI2P7vlieRx1oAydDYp4r05RziYcnnvX6C+FMnRrb5sgxjmvz38LBB4st7jBfZLkBh1r7/APA7+Z4etGHUoAcDFAHRjgAUppAPUDNLQBGybiRnjuKwvF8ir4b1MMNyiB+PXiuhNc34yPl+HdRZRz5LY/KgD89Fk3a4+xto3EjIxitfWyBYRhwCyMfmB61j6hGbbxEJBuKSOeCea3Naj/0HIQuCB81AGb4LAGtRr94LIDyOvNff/wAOCW8LWrbdoOeK+Efh/Yu+sQoDy7DIIyT6V96eA4fs/hq1j7gc/kKAOhooooAKpy5/tS3x/wA82z+lXKpS/wDIVt/+ub/0oAu0UUUAFZ2r7TaXG4cCM8j6GtEjnPeqOqKTZzqi9UPT1xQB+e/xEH/E1neNSAWPzZzn1zWb4JhEmqAy7Qg5IHWtz4k2Lwa7dIE2/OcIeTn3/Wq/w+jjfUwXUKR22kq34fWgD1bTxEl/BIX3KAM/NwxHp6V9C+D8Q6amMcsCec4B96+fbK0261CDGFReSWXqT3OK+h/CiZso8jA64A4oA6i1AxkgfSrYA7DFQRdACQ2anHSgBmOMEdOlU74Awsfzq6/3hxnvWfqnyW0jAAkLmgD5/wDHtwYdalijBBYnLdc/hXlnxCg8uFGfBbZzlcH8f/rV6f4wz/a4eNQWySSCeuelcZ8QrUXXh1Z0XMqt8wJySKAPH9NU/alJOWPYHHWvs74Dw+RoSLuwu0d/0r4/0W1aa+QRggEgkj9eK+2fhPYCy0lM42soIxjHSgD0MUUgwQMdKWgAooooAKKKKACoL2NXt3DY5BFT02QZU5x+NAHxV8b/AA59l8TXEqReWjsCzE9TXJARwaLLsO1toOcjP5CvpH41+HRfszMq7XwxwDkYFeDXuigwONyoXcjAOM45oA4/w9b7tThdzlw+R/n6V95fDqRpfC1kZAodUA2gdOK+MPD2nBvFFsig7GcDJHT619nfD1Vj0YRqCAuMZ+lAHV0UUUAIRwc/pXP+NcnwrqWPlbyWx7cGuhrnfHcazeGdQQruzE2R03cUAfnt4nOL4OTl9xOQa3rSRb/SsOWbywAcEnJql4itZHvpDNGiKD2PJ9OKveGI4o5nilLp5q5UZzuPr7UAdX8HtMDeJejMAwwQMHn1Nfa2lRCGwhQDBA5r5u+AWlA6tfPKIztdGAJwcc4r6Zh/1aj0FAD6KKKACqcpxqlv0x5bf0q5VOX/AJCtv/1zf+lAFyiiigAqG5XMLgYGRzU1MmGYzQB8TfGvS2g8S3LuHRnY7eO3rWR8M7byb0MUZecg4GSc9c17H8eNBUXxvNrHGCAv+ea4TwPp7tG3lMEcfKAcjr6j1oA6y1TdrRMqglWGM9BjoeOte2+CXEmlqFb7revFeLWsXkaluddzZwNx3YH+Ne1+DNraco2qjL1A+lAHVxdMVLUcXQfKBUlADH9f0xVLVRiymPA+XvV5wcZHUVm6sM2Ey56qcUAeC6/bK93O5LryfkB6g+lc14qtFuPD7xockLjGSPx+tdnqyM14VYKGHOBnJrO1u2D23kBThxtyOck0AeUeB9Bll1qNBEyFSMue/NfY/hC1Ftp8SbeiA/SvEPAOgv8AbjJL8rEgAemP/wBVfQmmJstwOCfWgC5RQDkZooAKKKKACiiigAoPIooNAHLeOdOW70yaQLlkQ5wOcV8/65oixRBQNxcchU5X3r6Y1WFZrWSKQZUg157quhRnaqpvBz32n6UAeZeBfD8bagsqKjup+Rhznrk/nX0N4WhEOnKApBNcf4R8PQWxGIgvzEAAH869Et41ijVIwEAHQUATAYooooAKyfE9u1xol5Gv3mjIBHWtao51DxMp7jFAHw/418PvBrSsgZhIeOM846motI0rbPDviON+Pm5474r3bxn4WSfVRCqfdJYEjgH0qlpvhofbI/MXBX5d20DHvxQB1nwi0WOzs5pkixuYAtjv7V6mowMVz3hC1+y2XkkEbTwT1I9TXRCgAooooAKpyf8AIUg/65t/MVcNU5f+QrB/1zf+YoAuUUUUAFI/3T0/GlpGGQQaAPOfinpC3+kOxjD+XyvPcV5N4U0eS3d1kQl2bl8Yx7Yr6A8SwmXTZo1AwR2NefLpQiZWKyAE7ic9CaAOatbEtqrog2knJyehx617B4WtDb2ScjBH1ri7fTc3/wAwIUnHPBr0bTokhtVRRkGgDSjHyjinU1Pu8ZA96dQA18EYaqV6m63YYwcd6vMAeCM1DKoI6YFAHlWu6Wq3ZfaAfcZwc1nXunlo9oZl7gr6V6JrNjHI6s446c/55rDex/fDapbjCigCPwTpUcEYlkRSRxkc16JboFTI6HtXOaBCsasgU4zyB0zXSxAhBnr7UAPooooAKKKKACiiigAooooA5LxP4ittHuSJnAXGSBziuKTxpaatcObZ1CqcuAKp/HzQbm5hF7abzkhZAvcCvOPDWmT2enXkkkUhXaTtU53Y78UAe9aR4jtY7sJK6rG+NrNx1FdvC4dAysCvtXztoE0GoRC4iRyVG3DjO2vXfh/LdyRTrdSM6rwhPp7UAdhRRRQAUx3VVbJxgU+ue8ZyzxaePsxYZ4YjsKAMPxVfWRuY3RldgfnAbkVzkutW0NzuXIiQ7j0z9Kwb+BMOfOkWThiN2a5LxF9oFjKIIZWLNtG0HJ98jpQB9B+FdatdXZzaOModrL+Ga6ivGfgXYXQmubm4V4wcZUnvivZqACiiigAqlL/yF7fGf9U/8xV2qUuP7Wt+efKfj8RQBdooooAKD0oooA57X72G1h3SuAB29q89XxBBLdyKjoyY/I+9bPxUtbp4fNi3CMA7sGvJreJY1jSYFgRngEc+9AHsemXlvNMjOV55HI5Ndpbsm1TnIxXlmiWatbJuHIx1bke1dv4ZuZJMrMWIBwufSgDpx0paBzRQAHpUDbVPI5PrU56VjeIJntLRWi9cdaAKPiS8ii2ZcAqecHk1xd54nghmHmkABtu4HmjVPPmEss55cYy3THqK851e1Tz5W2lZG42g9OOv/wBegD2fQtbhu5YfLK5fkc4P5V3KnKgnrivCPhLZzPf7zJuVcbCSf517umdoz1xQAtFFFABRQKKACiiigApFXauMk+5paKAMDxfMLXSpJ2AIUdG6V4Y/iZJJpoFlVUbIUL3H9K9g+LjOnw+1h4kLOsDEAD2rxLwV4YlvYraWYvtZUYn0oA2dEmJ+zJbwI3IJIGN1e6aFEY7CPcpVu4Ncponha1W6hmYktEc9MA/Wu7QYVQBgAYxQA6iiigArN11W+wyuqqwVScEe1aVRuqyqyNyvQigDwDWJftEjPEIhKnJKrtFQ6L4hkiky5jZckduORXouq+Dre3mlZVDxzMWC9xk8/WvIviRYTaNBJe2kKrFGNgXBzg+3rQB9DeE5YrnS454QoVvRcc1t1xvwkkkm8C6bLN954weev412VABRRRQAVSlx/a8GevlPj8xV2qUv/IWtz/0yf+YoAu0UUUAFFFFAGZrsaCwnkkXeqqSR+FfP2o6xNFqX7t4zCHxtC8kHPXHIr6H1rJ0u5C8kocCvn/TPD3n3Elx5QYvJtdR0zmgDqPDl5PIVd4gQ/OWGCM16ToSN9nVwgGTxx0rB07SoljCdxgfdrrLKPyoUWMfdGORgUAXVOQDS0i9O1LQAGs/VY42gYMM9z3rQqCYY+982ccUAeXeIskIoAVlOSPX0Fefa5rrLcrCWRgG53KDgV7jrWkQybpGQFWPJryTxl4V36k7REsG6nA6D60Ad98LriG/sS8CAlACGXAGPY16LXA/CKzWz0QoiAAEjPc131ABRRRQAUUUUAFFFFABRRRQBV1S3W60+4gcAiRCvIz1rh/DWlLZxSQqBGVYjHQkiu/ZRyTk8dK5bTy39q3IY4jD4xjvQB0FhEI05A3HmrlQWnEQGcmp6ACikGe9LQAHpxzSAYzzS0UAUdQhWQqGGe4+tcT4h0VdbkitZkjCBxyRznPp+FdzdnLBSPlxms6BN+pgccc9KANPTbOKwsoraBQsca4AFWaQUA5oAWiiigAqlJ/yFrcf9Mn/mKu1Tk/5CsHH/ACyf+YoAuUUUUAFFFFADJ13RMPauKfShYFkjQKBL5i4AGM967g9OaxdURZFBxtXryaAJNOiKjcQCcZbP8q0UwApAI9s1RsOv3iTjnFXlLEbeoH5mgB65yeMU6mhcNTqAEfG07ulQsmWB3ZBPWpzzURLFsAYHagCC5jEkTA5x6muYvrNWlEZXJfueoFdawO0k4/Csa/RlnTbg59aALWhWsdnbJFGmPlwSK1arWvKhTgYAPFWaACiiigAooooAKKKKACiiigBMc5rkYd8XiGUYwOvI9a68nAya5XUSV8RIXztK+vp2xQB0lv3HYcCpqq2R+Uj8+as7htznigBR78UUUUAFFB9qa27AIHPcUAUbpiLndnK4x9DUGnhG1GQqOVTH61LesPNOSemMVU0CQy3t4xXbjC4oA3aKKCQDyetABRRRQAVSlJ/taD08p/5irtU5B/xNoOn+qf8AmKALlFFFABRRRQAjAlSAcGqGpgKmQB9MVoHpWfqfy2xJ4IGMDmgCvZMpKtkgqea1SQF4OCelYemuGTghfm5B65rajJxkJjP60ASDnp2paYuGAIJODT6AGsOO/XtTS3BweRxT3+6ece9RP98Afe9aABgMHuPWsvUUHnxknHPP0rSduoyD6VlyyBr8IQu5RmgDWgZeApGMcCpqZEuAPT0p9ABRRRmgAooooAKKKKACiiigAPSuY1zCaxC+0EqN2N2M109YHiOBHlhlbG5SB7igDS0xy0R/OruKytGUISgOdvWtWgAooooAKKQ59vekZwo5PXpQBkalhfObII9qTwwp8iZ2zktgZ9Kg1WQmNg33nOPwrV0lDHaKpBDd80AXKKKKACiiigAqlJ/yF4On+pf+a1dqnJ/yFoP+uT/zFAFyiiigAooooAQ8c9qp37B7ZgBnjpV2oJwvlsNq4/rQBg6c/wC8zz9M5H1rfRjtC5XPfnvXO2xMN4yMAQeAAOldEshbOBkD2oAkRskj9KdTU+72/CnUAB6VWkIVgmMLx+BqzVeQqJCXzjGKAIrjqWP6VlW2JNXdemFBJP6Vqz8x/wCeKytPQ/2hPkjAAJb0oA3068fdxx6U+mqP4sk5FOoASilpKAAUtIKWgAooooAAc0UlL2oADWT4hTdaEHp2z61rZrP1kgWT7jjtQBFpiOpU5DHbyR3NainJPGMVm6WcqoY8gdh7VpKABxQAtFFFAAelMk+WMnbnA6U+o5yPIc9RigDAv1Lso2kqxwSOo9637dPLhRc5wOtYb5a/twCCAec1vjHagBaKKKACijNBoAKoyH/ib2/P/LJ+PxFXqoyHGs249YX/AJrQBeopCaRjQA6imZbzByNmPxzTiaAF4qKdQV569uakpjgMhyMgc0Ac9KAmoEOdueADW5GxZEK8AcGsXU3MV/bHYrBiM5PIHvWrHKzQ5TGMAkDqKALifdGDninU1PujjHtinUAFRShcgE/MegzUtV7ksNpGfwoAhnPyYHXv9az9MG29uXAbDDnmrkxwpJx0zVbSiDJLuJG5sdKANpDlRwR9aU0meRSmgApM0m7mgkUAKKWmp3p1ABRRRQAUUUUAFUdYANhICAcjvV6sjxNcJa6ZNLJztXIAoAk01sQJjAGM5FaKYIyO/WuJ8GeIYLzy4BIpfGMA8/Q12yHIyMY7YoAdRRRQAGopTtif5eAO1S1j63qsVhGrSnHJHWgBljEDfNIfmUDOMetbdcX4S1231bUJhGScg4YHIIB/Su0FABQaKKACiiigBCKpSAf2xBnr5L/zWr1UpP8AkMQf9cX/AJrQBdxSbRS0UAJgUYpRRQAYpGAKkEcYpaRvunPFAHP6vnzYHxgFuntWpZ7Y4BtAy1cp8QL5bCGAxNiQOCFFbHh/UY7+0RwdpOMoetAG8mSoJ/SnU2M9s5NOoAKrXgyq4znPGPWrNQ3BAK5ByehzQBRmJVDuyducj2qpoUplXKp/y0PJPOKo+JdYSwspmYrvC8DOKi8AaiLzShJNGFlEhXg5+lAHYnrRS0UAM6mlK0uOc0GgAUYzS0CigAooooAKKKKACuR+IkLy6RIEYjONw9hXXVy/jfdJY+VsXa/ylmOMCgDxPRIbzTfEFpLaRhrNX3FixJPp37V9C2V8rxRF8LuUZOe9ePWdkWumhtmBjRsLgcGurFxNbWkMO11kBxuPPWgD0UUEgDmqOmXCyxIu4Fgo4zVm5BMDhfvEcUAQS3qrKET5j04rzb4nTXdxPDDbjcCMsV7c11MLyrcyRtEdinOfWsbW4G+2lpBiIDhiMgjvmgCr8NbPyr6OTptVgBn19fWvT64bwdNbR3Wy2ZWDjA7EYNdyKACiiigAooooADVGTH9swf8AXF/5rV6qUgH9rwnv5L/zWgC7SHp1xS4ooAQUtFFABQelFB6GgDyn4q27N5Do5UOSOOoI5FUfhpezpcBbjJCcbmPPP4103jmC3uhGLn5QrZGDXKQRKku2zRniyFJXjBHegD1yK8jDgF1+bAzmrtebQ6jcy3KxpbtkOFJ6Feeteg2YYQgP1459aALBIAyeBWRfalbn5PMAPUD19ak1u4EVsyLIqyEcA15Tc6rFc3DrclvM5Axn9KAMX4h3dzqd9II8iFDwVPPFdD8BTcy2140rAwBwseevv1rJmtYbkeVJjK/eZz0B713HwztvsAltlx5Q+ZWByGz1oA9AooooADRRR3oABRSCloAKKKKACiiigAPSvNPFut/2lJJZWzKSrbHJ7c16TIwVCT0xXmlz4UuJfETSxNIIpH3MD9cnFAGl4S0NYo98mAOuAf1ra1Cy3SReXbh+eQ1a1lbLDCkYH3B1PereKAMLRNBFhfS3jTyu7rtEZPyqPp61u0UUARGFSxOBk9+5rM1LS1urV42IA65UVsUhGQQaAPLILiPQrpZHlUQI3PHPoTXpWmXcd9Yw3EJyjrkGuT8ReGluZS+d8Zzkf3T2rp9Ct/sumQw/3RjpigC/RRRQAUUUUAFU3BOrRH/pi/8A6EtXKqPn+1YvTyW/9CWgC3QOlFFABRRRQAVDdzLb20krdFBNTGqmpIJLORCM7gRigDzXU7pNbuwkZCLjcCf0ro/DeiQLYh3Vt/3s55+tYGn+FJPt7EyMIQcsQeefevRLG1EMKpk7AMAe1ADYrGLamEUEc5xzV2NAigClUADAGKWgDifGXhSS/wBatNatr24jlt1KNApyjg+ormvChuNX1fUrLWNJNnJFzDNgr5gzjNetnmo2iRjkjkd6APNfEfhwW/72Jgq7QpJyc/hTvBd6unSCCYt5jNt3N/n1rudUtFmtmjI6jgivNzod1aaw0kzSNErgqWGeM0AetKcgE0tQ2bbraI8/dHWpqAA0dqKTPNAC0UgpaACiiigAooqrqP2o27CzCmQjjccUAUfEmqR6dYl2cKSdo+prm9A1+SbxCtjKV2zKWjOeScc1dbw5eX16JdSkR4DgvDnIJrobPSrS1aJ44EEkYIRscqD1AoAuqMACloooAKCcdaKKAChs4OOtFFAGbfztDa5mwpJwfes7w3ra3l7c2chAkjOVGQcj1rU1qxe+tDHE4jlByrEZFYY8L/ZpVu7DEV9gB2U/K34dqAOroqlpQvBEwvwofPG054q7QAUUUUAFU3/5C0XPPkvx/wACWrlV2ic6hHKPuCNlP1JB/pQBYooooAKKKKACuc8U63Dp8KHcpfcFAPc9K1NXN79nxpyK0p7swAFc9L4auNRdZdTAd1yVXcMKfWgC/DdItuPIXdIQDjGea3os+Wu4YbHP1qjo1gbOEiRV3n0rRoAB70UUUAFFFFADJU3oQDisDVyqk+avzLyp9K6KqV/YrdKegb3oAzfC2sxakkkcbcxfLg1v1xQ8M3enXv2rSvvHJZCwAJPeuo0tr1osX8So46bWBzQBdphHNPpu3mgBVBFLRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal bone scan for comparison.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_52_6977=[""].join("\n");
var outline_f6_52_6977=null;
var title_f6_52_6978="Contact dermatitis berloque 2";
var content_f6_52_6978=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Berloque dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 576px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJAAYMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxdqjjH7zrUj02IfPWRBYWp7O2nvbpbayt5rm5PIigjLtj1wOce9a/hTw//bU1zPdzta6PYgPeXSrlhn7scYPBdsHrwoBY8Dn0qWWw0fR50D22kaIN0GyGXA3FPm3yD555uhyMgZOQBg0rDPOv+EK8TGMudFuFAGcPJGrY+hbNZF/p97psqR6lZ3No7/cE8ZUN/unofwr0PwzpRsrJ5dK07xVfQTMlx9sm0xArABgoQSMGdcNnA5OAelaFpd2l5BPHDOj20QC31lc27hY1zy0tsw3KSQuGHTJO4UWGeTrQa6fxb4cGmwrqWnxyx6dJJ5UkEr73s5TyE3fxo2Dtb1BU8jnmCcc0gENKKKBSGL3p60wU8HmgB4paQUopDFpRyaB7Uo60gLOnOI72Fu27BrsLc/vgCa4lW2sCOxBrt9O2ySq/UYBrjxC2Z24V6NHRWi/ICe3QVoJgAADJIqhao7YIU4rQiifIBU49RXnyO1EqZ6k1PuBxk8e1Mjt13ZwTVhIVxyMCsmMar5OAM08bx0AA/Op44QMY/lUoi47ikMqFHJ96QxPjjPXsaviId+1P8rkEdPSiwXM4pMP4sj3NNO8dVH0rS8kg84574pjQ88CnYLmc5JHORUDg44INackQHUVUkh6laAuZlwQqMX4AGayb6E4LL1HIrdlhIyQTzWdcK2CGHFXHQTOF8UHMMZPXfzXNPjFdf4rtHNoZEUkI+TjsK5F/u162HacDzMSvfIX6VRm6Grz9KpS9DXQjmI7fk1ejqjb9avR0MCdeue9PHSmJT6QB70fhRRQAtJ2oFA6UAJzngYHv3/wpT2pTQccZoGNA+ag9aUd6RuvFACYopQOKKAMR+nNIrBCWbgAZNOaopAXikUDkqQPyrYzPcPDdjFpuk6Xpr3AtpIbYX07IrZaacZdicbGVI9qkNyOgBzXG6XfR+KfGRvbi0+1RWcLz6dpHzbJo4vn8jI5BKgtnBLPgHiuoubu5udbfT7fTVez1Cwhube/Tfjc1ptVCfuDJBAHByOc1x3gLR/tJ/ty7nNvp+lTwmRVcpLJJkEIpH3QB8zH0GO9BR2mmpqF/rumWtpZ6wJ47d725nuJZpYIoJW3wgRt9x15XLAAbc9K0/jFpkz+MLXW9DmtrA2VsRNf3soj+0yk7xHjqwKllJI2nJTtii/uNZaD+z9Tv1lS9vPtoUSHatu/CyHPMpOenX5MKOpGjf+LW1jTfF1prWkaZql9pEeLW2iX5ZbZVG6QyMCGaNju2qc5DAZwTTA5O0mfUriztYNJceH9atdrzLkmFphhY3OMJslRcMecKo+vmJV0LJLjzEJR8dNwOD+or07wjaSDw7ocDsxy0VyZtoZUV5MqrEkFSRyCAcHNea3RD3dyyEMrTSMpHcFiQaljCO1upIGmhtLuSBc5ljgdkGOuWAxSWdvcXsvl2VtcXUpXfst4mlbb64UE4969b8GxeK5fh54OfwfdTW622s3MmoMl0kUaw+YDmUMw3JgNxg/rTrg3eq6P4mg+E87R6g3iKWe4isJlt55rYpiNo2JXMQfccA++MdSwHkKK7IzrHIUQ4dghwh6YY/wAJzxzTijoqM8ciq4yjMpAceqk9R7ivZvEMK61YeM9M0+e3k1m7h0GzvpY5F2S33msJXBHBxlSxHoab8Sv7E1rwvf2Ghatp95J4TeP7JbwxOskdoqLDMrMQFkO9d+Vz0+lJoDxwZp9NHrmrdnZXN44W1heQnuo4/Os20tykm9EVx+lORSzAAEsegHJNdTpvg64lKtezCNT1ROT+ddfpGg2dgMwQjd3duT+dc88TCO2p0Qw0pb6HE6P4Uvb0q9yPs0H+198/Qdq9A0zSILGJY0XO0Yy3JNaEcW3pgDrT9p6jp61wVa0qm53U6MYbDkRRgDrU6gHpUaJx6mpo1J9/SsGzWw/GAMYqWNCeSOPenRxlfvYNTomWyM5pCBAACF/GpShIPY0saKOg4zUuwnANFhXIgv6U9l46U8x4Ix+NBAHtiiwDD0+VSajZR3/Kpx3wAD0qN14BHWgCuwzyOh9agljBHXn0FWpYTsO0gE9+tQeWRyTlu/akMoSxjOCpz61TuYM9jjvWu6Njdziq7oc9896aYzmrq0BDEjOeK4jXvD7wlp7Jd0fVox1H0r0+5iwfmDY61mXFvliQCCK3pVnB3RlUpKorM8afvxVGbrXpOveHYrwtLBiK4PVgOG+o/rXAarZT2M3l3MZQ9j2P0NepSqxnsebUoyg9SjAOaux8Zqpbj5sCrkfYVqzEmSpB0pqdKcOlIYvNHailoATFLgUlA6CgApTyBRQaAEFIetL1prAH6UAOB9/0opB06UUDMQ02M/OKc1MT79bGZ6n4D1eW/wDDzaTFlr6xjJWH7R5Pn2wferhjkAwsSWwC2zHoa6Ox1K40fT7qTw7Zxanp2psbwwqq207sw2loS6nEb4yyDDqT8uQwx4vZ3M9pdQXVnNJb3UDiSKaJtrRsOhB9a9B0zx5a3UZTW4GtLl2zJc20IlgckYLNAfuk55CfKeuBQmM66X4kaGbY2cnh3VbBYrZYxFHpwkVJOrhQ2GQhslWyRltxGeuTqGqa34thgttWsodC0uYK97p8DBHv33cNg/NDERgMeM+hJFYlzqJfXDeWPjSytdP80PHZM1xsRB/AVK5P496l1XxdpFsbiPTUk1LzGz5bRmC2PX/WE/vJCAccbQ2Bmi4zQ8VaiumWa6gViW/eOW308ooB3sNskg44jjX5R2LEY5UmvLURYwAucAYGewq5qV/d6pfPeahN5tw4C5wFVVH3UVRwqjoFHAqsahsCN4kc5dA31GaVkViCVBK8A+lPxW3o/hnUNSKt5ZhhP8cg5I9hUSko6sqMHLRGEsaAAbQFAwABW3pXh69vtjCLyYhyHkGOPYV3ekeFbTT9rhPOm/vyDJH0HQV0MNl0JxmuSpiraROynhesjlNL8J2VvgzKbiT1fp+ArpbezSNAqKqqOyrgVpRW2BjGfY1OsO05C1xTqOW7OyEIx2RUitieg4qURFCA3NXokzxgfXFSNAduQRms2WUxFkAdB61KIMEZHAqwkJxyPz71L5YweKkGyqiDpjirCR7WGBgH1owflwMipwPl4BFAhqR+34VOqntSQo4A349zUyihEsUJjqBT1j5zT0Q4xmnqAeKoRAQSw60EYBJ6VYdeP8ajCcnj86TQEIHzcCkZeeB9KnZQvBz+FBTnsaQyDZuAOPeoZIgCfWrwQ5pjR7h2p2C5mshI6EZ9O1QmMIBgE+9X5kZc4H5VA6ng9CKgq5QmTPQcDrVKW2yOnFasi8Hg4BqAhfQnPrTAwrm0A5Gay7/TYrmJo54VkjP8LCusMIfr0qOS3AzgD0rSMmthPXRnkmp+DPLZpNOcqP8AnlJ0/A1zc9rNaTCO5iaJ/Rh1r3Ke0Dj37ZrLv9LinjMc8SOh7MM1108U1pI5amHi9Y6HkaDg04V1WqeFDHuewfjr5b/0P+Nc1NDLbyGOeNo3HZhiuyFSM9jjnTlDcZ60fjQKPX1qyAPQUY4oxzS9KYhBQe1L/Og0AJjjr+FN9KdTT60DCinAcUUAYbdK09I0G61C0a8WW2t7fzfIja4faJZP7q/yz6nFZjdK6DwuNbazddIu7OKGS4MUcNyy7nn8vd+73AgNt7kjnHetkQV7LRby6hhePYDLFczLGxw2ICA6kf3snAHerM/hnWbeORp9PlRo5FjZMqSN3AOQSOvHXg9cVPpkXii003yrXT7tIDE0qu1uDIkchBfax5AcqMr1PpzWtpGneNriWGGysZ0Db5kM0aJGRKrqzEnjBDuPYkdwKltIpK+xhv4U8QJIqPo92rMu4BgBkbgvGTycsox1+YcU8eF9XW2uZzZkG2JWaIuu8EE5wM/NjBJxnFdQvh7xpqMcAuGdgBHIuYw5bYV2MfUjag/CtvT9D8QDULe7vxNdtDcI6oIFRRIpDKAw5HIGT3GQTzWbqwRoqMmee2vh68ltdQmmK2wsJFhmjZHdw5QuBhAcDCnk8Vrad8PfEF2sbS2TW4ZDIyMwMiIADkqD3BBA6+1d9pfh6fTYjbfYoyb6ZpikqB2aQZDNz90/MfbBrprSPVYJIsukUl0XI8wDI28MTxx0/GueWIWyTNo4e2rZx2i+AWsNr/YXll2eYHkKn5euQM/p1rqYtCvVTJs5VAUOcgDj+vQ8Vq2gvolyIEu4yBJG6cqpcYDDA6447Yqb/ibBd8qSgJzvKjg8jP15Nc0nzau50x93RWMFYMAE9DU0cGcEjFag026YFvszLltoQY4OM9PTHeg2c4dY/IkbcgcMqkqAegJ7H2rDkl2NeZGeIz6d6kWPnHXmrklpNFnzYnTA7j6f4j86YBt+brUNW3KTI4kAqVgOgx7U5R6daQr6EDFSMQglcUAZOealH8+cUu3nJH40CIGBBPYVNFliDjmlaNSQxGSOntTYkcTgq2EHUYpbMNybb61LGCHwRkYyD705RkADvzUgX8aqxNwXP1/pT1U/jSqoKg4pyk5xVWJI3X86QehH51L09zVYIRMXywBGNp6fWkxkjNjtmk6j0oft60cUgFBHANKV5PSmoCH5AINSsO5NNAynKvBqs4HpzVycZOMZxzVduOpHNQykVnH41FKgPAq0+B1zUboGOKQyuiBUwcn1pjw554x6Vc8vCjqaiKtuORVElGWLPIAPpVWWEEHitVhwdvJ9Kruo3YxTAxbi1yCcCsbU9Lguoyk8YkXtxyD9a6uVcVWnh3jGcY6HHWrjJrYTSe55Xq3h2e03SWu6WIdV/iH+NYR/yK9juLbIOOlcxrPh+G6LSIPLm/vqOv19a7aeI6SOSpQ6xOCPWl5xVq+sZ7KTbOhA7OOhqviupNPVHK1bRje9HpSnFHSmIae9NbgfjT8cU0jNAC5xRRRTAx44pJnWOJGkkboqjJNd94Q8Oa5BZNmOGKB5DMrm2Es0MmzYWRuiHawHfBIPWul0LQLTTIAttGN5+9I3LMfrXUabe3OnW80VsyKkpy4Zck/KRx+f5gelc08VraJ1ww1leRTsYb62hZPsHmTt5YSZ4SzqyNgOAeN+eMjoR0q4sur6hNDH5MRaEeYFEIVVAy2T7HBqY61qCtCUkjUxqVQhegKbDn8s/wC9zSR6pciWWby7fzJG3n5OFbBUMBnggEgduawdS+7ZuoW2SGLda1MIkjtgFj2Oix22AP7v8untVpH1gwLbvEwRVwqGLB2Yxgdscc0xtWu3kUny8jB4XqQGGevfcasW2pXMTKV8o4IOCvoAPX2FLnXdj5fISJrqdvO8lZBDuRsRZGGGCreox2q3K16rx3dxGo8pzGu9BjJGcEdxioYLyaJ90Plq28yEqv8AERyasXN5LeKyzLGF3hwFHQ4xxz09qjmVtx2d9iSDULmNQEMaqNu1VTAQDGAo9OOlKLudSgXZhcY+QcYyB/6EagUccVMgHyjvU8z7jsuxaa/uH/1ghbJHymPI46cVJFfXBdC5R9oK5Iw209Vz2BxzVXGM96cBj/8AVRzy7hyolvLppYHhSNY43dXKr0wq7QB6etVAMjBqSRucYpETPXsazk23qWlZDVXB65qRlBHSkYsHUINxJ79h3NSSH5gOakY3bjGM80pGOg4qQc80pUE0CI8ZAIPboKaEOSP50TwPK0ZjkaMKctjvVgDIApARWjmVeVKYypBGCD6VdRAcDPTtTIVJHPWrCjJxjkCrSIbAjAyAOKb24p4XjpQykv1A9abEJ0HHXFRTN06596lUgnHbHJ96jkxzwAKTGiBicDH0oySv9AKUDBPTn3of0HHvWZQ9QNy808nPAPSmLyoOBUgAI7VSJZXnwExnNUyrHAU/LV2cArggAVBt24A6VL3LWxA/HfJpqrzuPWpG45qTYAAMY4pIbIT6560wg5I9qseX7UxgTnvVklVwPT8qhZD0zt78VaK85xTHRSMjrmgCm8ZB4/Womjz7VdMZHJ+amFPlweTVIRmyRe2apTwBh93Fbbx8c96rzQkr700I5i+sElRlkQMp6giuP1Tw6YyXs+n/ADzP9DXpbxZ6jP1qjc2e/JA4H5VtCq47GcqanueQyxtG5WRCrDsRUea73VdGjmZ2kBbIGP8AZ+lcnqGlzWpJUGSP1A5H1rthVUjknRcTO9ab3NO/Wk75rUxE59KKD17UUxnuKxBU6AfShxv7jPp6VPjqKQqBhVFeQeqiIRjr1zSqgBx3PIqwq8e9LsGOKAuRKuMYHSpUXnNJt7VNGvzZxQA9V6HOKlL7AoCkk0ImTjtU4XkZxQFx0XIOelSqP1pB0AHSpUTGOOKAFQc+gqTH0xR0wKXbtHSgCJ1BbkdqRVKjqealkBCg0wqcAA1DRSYg6+9DZyPb9aXBx7j1pjkkDnk1Nxkiv0BPJ/WnA5UmoUyRx1Hf0qVfmOKVwY9WyO/4UvmLuYZG4daE4UZpVAPH40ySS2bLYq0Ac9TVaLJcYHFW14Oen1q4kyHDnocn1poAHXjFO7+lNcMTwRTZJD5IjklkVnYykEqzZVcDHyjtUcxAU7u3WrWABg8/1qvKmQcg/U9KmRSIwMqGUjGOtKcZHSkBwMd6aSpyagoVSu/p36VYYjbj161UgVlfB4NXCueTyacRMgnAI54qBwQcgZFSyqd2T09D2pAe2OKl7jRWK8nJ/wAKn25AzxxjFK68dcAdKfGMqPWhIGyHDKMDH41GVOScVYdDjjPHemc5xwe+ParsIrsvPTmo2TPIqyyZ7f8A1qYVAPpRYLlYDGPegrg8c09gQ2dpxSkZGapCKzLnPHFQuoPUVbI6+lRSLn1+lNCKRiHOOhqrNArbSRkg5Hsa0mjz2qBwQT7daHoNGFeRKGCsME9PQ1k3dnkEEfhXV3NujptYDaefpWdPbEEkj/8AVQnYrRnn+p6KrEuo2t6r/UVzt1ay27fvFO3P3h0r1Ce1RmLccjk+tYt5YDkFQQe3qK6qddrRmFSgpao4PB/yaK3pNFQyNtLgZ4A6UV0e2ic3sJnrJP8A9YUKA3POc9aULkZPSpY046cV553CxpnGTinlQBx17ZpyKctkDHG319804Jkjt7GmkBFt5zjmpFTjHOKcR8xxUiDjrmiwrjkXaBtGAOKmUEdOp/SkUY69KlX6UgHIv6VIgKn60KOc9qenHJ6GgAA+bnpUqjPbHvTQB+NSAZU5PFAxkvA/GmhcofXrUki4AA6ZoiPHHXNS9x9CtsHJyc9TVeYhHAXoOh9KlnJXK5yaqs2SMc9uaxZoiRSjsrY+ZQQD/Op7VibkqcEY6VTxiQHp2q1aEG44OCOAKSeoNF515x260yRegX8xT5B83U5NO2kAYAzWjICPhlq2ozzniqmMEHFXY+VB6cVUSZB+VAXI5NP780Y6VViRmPmOcYpsi7kJA96lAOBTWGB7UNBczWIYdcGhVYlcjIzSScOTgkA9KehLHK9TWCNR6glzgc9RUyglvmJyKjjx5nB9uKtEYPFaRM2U5FBfkZ+tM8oLx2qeU/MefbFNUcAE1LKIWHUHuaWHB46mnumfwFNh5bGOR3oW4D26HmmsMD0qbbx0qMhiPm61ZJE3HHtmomGeMCrGOenFMZRkUwK7DA+lMIPJ4xUjDcpBBGRyAaY36GgCIjHWonHp61YYY461E55pgQsOPWopAccKWPAxVgjg4ppGOtDQIqupwemKqXEe5f61fkAz71XbBUcEZ7EdKgpGRcQjrgcdKzp4gVNblwoKkDt0zWfNHkA9DTTKMJrcbjwPzorSaI7jgHH0orS4jo0/+tUy579vSooxgZPepQeKCCRR6Hn0pzHcRxk+vpUYYZ2/pT16+1NAKR0p6KAaZ0I61KnTimyUSqKkH/6qjTIJ/SpV4X1qWUSKcjrj3p6nI+lMGCOOKUZBpDJV9e1SDjvUa89AKkXnntQAr8jg8jvQgGw9hSLxx2zUnAPXikBlakdlwo4ywzVdcK5J9an1f5pYwOtVjhYwu7r0PfNc8tzZbEzjJyWye4FPtwBcREH60yK3IUfLxnnPWrEYUSpuwGLcD1oQGg+CisuDS9DSueAB607GfvcelasyGnOOaswnIHNQOvWrFuuB2xTjuJ7EmCeBSgcUq57U7PBArQzGk8Ugz7U4jP4UH5Bux/8AXpAZcyFZWPQHqKI+Bx1FT3g/ejjqKr7SrkfpWD0ZsndCxEecAMgZyT6Ve7cfnWcG3MpA6HBHrWgDVwZMkU24kI96ecHgdaa5/fMOxpw6ckcVKGRhmErAr8o6H1pYhiQjPFKxznHJNNjP77Iz0oAnIxyTxTW54p/0FNIPIFaEkZOPpUbjNSmom4x+lAETenf+dQnBqR25wQc0wjjjrmgBpIJxtOAM5qJgeemBUuDz0AqNwSOKoBucD3qMjH196fjIHNB7n9KTAqzERgMSRkgdM5NQydSO9W3HANV3Gc45qCinN1weKoyrluR+PpWlKvTJFUZRySOlNDKu30Iop7IM0VQzVUgrxyKU5HHGajTGTjPHpTwwGB2zTMxccg88VJuI6cVG3JHTignjpTQEytzkGp4j6dapggcdqsRHj3707iLaEEHJxUgPqagQ+vWpUORUjJ14HApy5J6dajQ5H071LyF464oGPA96cM9DUMRO1d4AcjnFTjgZ7d6QxQcLk9/Wng8Ypg4x1P15oJwP6UCM+9YG4wPvetQ+Xl/k+ZwcjPaif5rqTdxnpzUq4ALRANXO9WbLYfEhLHJyfTNTLF8wJycUiKR83RqcjExEHIJoQmaW0bV+mabj07etIeEQDtRnkAHvWzMhSMHk5NTxHI9Kq5O7BB+tWoB0OM0R3B7Ewp2SRg0g5GAKMEkZNamYHOeetJjnA9c0rDPUUvBGDSAp6iRsFZzMWPpir+onGwD1qiMDkHjPSuep8RtDYWE5ZQoOc5NaYxtwayUO2Zdh4zWnuO057CnTYpoqrxI56YPSn8AdOKiDE7hnvUgPzHoaSGJ1479qYRhwTxQr5LZzTHYFTzyDg+1AWLgJz7UYAz/KmwkMm5DkDg/Wnbea1RDGN3xVeQseF4PqR0qwRzUbKScdqbEVyoAwW3HuajfAbrgCrDAHtUDDseakoZnJqOU4HPTNOYAqVYYH86Y7EgZGaq4rDdpJHrTTnIPbvSnkZz0NGcrQBG59etRSdM1M5xwevaoXPY8dqkoqyjB6CqcwB6evars33cnOB6VUk6kdqEMr8+lFK27cfmx7UVQi2uducVJ6fnUYJ6Ajk08En8KZIjtjHGc9adgE+1IfvdAB/Og9yPyoBiH2NWYjyMVWTk+wqeLoRmgC0CKmTkZzUCnjnHSpVbjH6UDLCH8u9TBugqvHyM/pUgZgVCjIJ5NK4WJRyfmHFShsZqIDjipF6c4xTAM9DjnvTm5z6Unf0pzDjPtUsDEKGS5lIbgHqau2yFV2leB0PrVe2GTJ0DZ5q5AQEUDIzWCNmSq6MSm4bwKCmF4piQBZzKWOD6VKh3Mofge1UvMgsEnaopwUZGfzpXxjjoKIwGGe4rQkRyBy2AByTmrVuBxzmq56MCOPfnNTQHkYxjHFEdxPYse/rSkcY7+tC9+tK3UVqZDCcZ9aOvWlPvSfypDKGpKCoPOe1ZZJDE9Qe3vWrqeQg29KoTshVVHDA44rmqLU3hsRK2ZMjHBAODWseIjzmsXIMiYAXmtokbcdMiin1CfQz9x2nb1HpVhQWX0qqjdc9QeanL/Lkcf1pIGKwIYqOfXFRldgOB948mnqP4h1PrSsOnP0piJrckRgdRUxFVYCyEbFZ9zYbBHyj1PtVog9a2jsRLcjYY+lRt0qd17du1MYelUK5A4PGB9ahkXIqy/TFQHP40rDK0gwBnvUTcA1YlXiqzdKQDU4Hc+9BOM8U1QQxO7g/wAOOlOPzHHegY1uB7VCx+T5uMVK5znAxUbDjPT60hleReOelUWTZwp7mtCTng9apyLjI7UIZX2/5NFLt9OlFUBYVQOMUDIyPfinHg8UgGM57etMkX+GmBueaTd8pxTM8ZpCHrkNg9O9TRHJBGar7sj6VPCeBTAtqcjtU8WPyquhGP8APFWIiB1PFIZYX2HeiIybnDKFG75SDyy+p9+tMTg1MpyMmgB65p6+hpuTnPvRvCkZ79KQEhznHUU5iQjZ9KapIHWnv/q27nFAFCDAGRyDz9asjbwD0bt6VWijLQJ2749Kmi+Zcn9RWKNWSxlig3D2p8Q3zqP7tM3EHG0kfWprRt0rBe1NauxL7liRcEUvGBjrRJyPel3bQN1aECOyhcucD1qaAcjOKaBjHSnxjAGOapbiexYHekFDZ2/L1IpuSVBxnjpVsgXnfnsKYc4x69fanjr/AI00579akCjqI/dqSScd6z+oBxtHatLUQGVd3ArNb/VHnHWuep8RvDYj2ENnGDx1rUXG0fSsuViMKCWXA/GtVfuL34pQCZTYKsjY4I60Y3YANMvNwlKqQuRxnvT0PHTkdfrS6j6EoU7fQ0xhkbfzpyNkYPB9KCQTyKoklsxhiOMdKtYxVa2jyzHdkE1a9ea2hsRLcaw49BUTfSpjyMZqMk85qySu47VG3AOanfgcVA2R9KQxjjn3rHvLxLe5iiYH942Aa13OQT2qhc26SOrMASDke1SyotdRcgrk0ehAzSgcUAjnGMdPpTAZJnA2AFs9zjion6Y981YbGBUD4weeKkZC3fHXpVSXl8cjHPTirM2QhKgFvrVduOuTQhlVs5OAfyoqQ9e1FUIlPqKiQFVwzZPPWpj7dahk+6cYzQCEyBUTNgmnHO0ZxnFRO3PHXGKBDw3Sp4nzgVTBOBirKMFAwOaALkb/ADDPSrSN6fjVCN889DVlW/KkMvJyevFTxHknFUkl4wPvAfdq0hO09qYiZjn3IpenXpTVOQCaVvunmkwRImCCe1K7bY2I64qK3l3odoPBxTp2CoSR260m9B21KdvMNmT3NT+Yq4Cc59e1VIAWQHb07VLnIAA5z1FYGrRYMmFB4GelWNN5R255PX1qqwJUAHAFW9O/1PI6ntVQ3JlsWmOU46VHNH5gUgng5qVwMAA0oIxxWr1MxUBwCW59KmyF5qA/LzmpFbPIppiZZ3c456UwAZLKOT1pc8Z60vTpVkCnimv1pfXPSgjjPpQBnajuI55HcVQkyoUgce9aGotsAJPWs595Ktj8Aa5p7m8NiME7sE8dBWtEMRLx0HNZbDPDL9TmtC1bMKrnOOKUNwnsU73/AFyHHA70sZBw4XGe1SXYB5wMj1qNR0IOM+tJ7jWxMD37g8U/qpP9OtVIJ5JJpEkhaMo2Nx+6/uO9WxkgcH61aJH2bEuy9queveqdv/rG5/Krg5+oraGxnLcaAdpyajZccn8KlOMgVE5zVCImqInmnycE+tQudoJJ4pFIY2d3b3qvLxU7k1Xk55oAZmgkBR6E0Y+Xpke9BJIztHWkCGPwOahkP0FSPyee9QyqCByRg5471BRE2B0qu/NSueT6VHjHUmmhkBAz98D8aKk2g9h+VFWSKwwKgkYdcfjTpH461WllwOaQxzP0qNz71E0nWkVsnGc0ITFH3zk/SrSuCRVPG0k9qmX0psC4h59qtxtlc5qhGck1ajYY4qRl2PBIJ4NWlJx+NUYs5yT9RVyMg96QFhcsemKeRgH0xTA3VhgU8fMAaYCxDaO1Mu2/0d81IcA5qG/OLR8AZqJbFLcpo0gjGWAJ4zUylQVVsZ9qpJIpZcdR/nFTBwSxDAN0JrE1aLMkuxeO/Ga0rT5UAJ7ZrEZg5Vcgk1sWYZYwD6c1cHqTNaFqQjBI60kfTk8inY+Qgd6jjJzzWrMiQjjnp706I5Ye1RElvY5qWFhwTwc0luJ7Fvp05/pSg84zg/WgHA46mlCgnPGR+lamYhPHQn2obnj9KU8dcCmMSBnGCe1AGfqHzbVI/GqHOSM59K1LwARljzWUH+YkevNc1Tc3hsDArJyfpVqxJCP1HOar5y4H+RVq1P3h6VMdxy2FnXdGwPOaz4pODu7d/WtJ8kHOayZARK46AdBRMIllJAcHv0/+tVkMcew9Kz4uVyCOOCtWN2WUAcHkUJg0WrL55GbHXtV8YA96oab0c56nmr5AA9q6KexlPcYeKjbHapXxmoWPPFWSR54O4YNQtyDnpUjn0qM+2M0iiI9Kgk9MVMwHJ5561DJxQBGpz70mQRgU7Ixjnmmd/brSY0RvkZ759aic/p61LIcmoHHPHNQUQvzjFRE4471I5zx2FMPpmmgItxFFBxnmirEVrhgAazJ5wH56VoXfK5/CuW1O4Mcu3POcc0RVwNdZcjrUkb5xjrWTbz5A5q7C2CDn8KdhF/d6HmnR5B61Du44609B8wyaTBFosQCQeRViB9wUjoaqKeaswnA47VJRfib/AOvVlHwAOvvVCF1PPPpVmCVW6c1IF+JugFTrwo96qRMcjH41YHTimBMACOahvxm2ZW54zipgcf41DcDMbdeR1pPYFuc/5hkU7ep61cjjdYiMqQePpVREKOc/eHYd60rUk4Y5x3XHesDoY6KNfMUAZYVp2rNtAaqMS4bcvU8k+lXbfP4daqO5nLU0E4UYIqKUYIHrUq7dg4xVd87vmxk9cdK1lsZIcBgZDYFPiwGHPeombjHWnWzMGycE5qU9R9DRXvmnKeaYDngGlXBHBrcxHsA2Nyg85wRTHJxkdPehj2Jx7imkjafSk2NIrzqWBAIx6EVkFSsjDt6etbL/AHcDisq4TEp49xisKhrAi+XBIPPQ1YsGy7A8DGRVUDP3x7A+tT2bFZlzk9qzW5b2LpPPNZtyCLhh1B55rSfP49s9Kp3eNynB9M+lXLYmJB8qqSevanq3ykg5GOg61HKAUAIOKVMBD/d7Edqgo0dMx9n3AYOelXs/L61n6aT5GR0Jq7n5Rxn6V0wfumE9xGHNRPyetSHr70xufr1qhEBHXA6dqYeBUjfe9qic4bAIyR0z29aBkTZ9KhYZ69KnNQyGgZXhEojxctG75PKKQCO3B7+tLxt47UrZOfQ0hBIxSY0QzZKgDGfWoH5Oank4AHaoWHvxUFERB470xgRyfrStjADHJHSo3z5i8/KBgimgGk89qKYxXJ4z+FFWBBOoCkHoa4HxfN5ZaRPvrz+Neg3gAjbjNeW+NZ9pI9TV0ldkyehr6bcrc2kM6dHUH8e9a0EnQZriPA175sF1at1iYOv0PX9a66Fu9XOPK7Ep3RrRtz0q1F+tZ8LdquxNnFZNFIsrxjPWpl+Uj0NQKOnP4VIMn8KkZbRug7VaiIA4FVIsDFWFOKljLkD4PHpU6OetU4OT1q1GcnA5NICyHzjPAHapCcg4HOKjVQRUikYoA5yXcl04PTOK0Y23EDOMDoKp6koF/jscbqs2QABOc56Vh1N3qrlyIhTgcnvVyBhgEdaqDHlntzT4WyQoPA6U0yGrmopGevSmOBvHFKp4HamSsAR61q3oZIR+AcDp+tMtGfzGzjBPAp5IwAaSBds2VyBUdSuhpL6+tOzkY/Oo88UqN7VvcyHn171GzenWnE5J54qLPY0mwQjdOO9Zd9xJgcD6VpMc5HGe1Z+pptVXOeuDWU9jSG5UAYrjt0qW0BFwO/HeoE4TOSeehqa0ZfPUdyODWK3NGamc9McVWvF/cEj61MOvBpJBlSAMjGDWz1M1ozIbLfIOh9acMFPmJAHHFEqYDZ4AP40kYyMM3HrjmsjU09OXEHXgnOKuZHb0rO05zt2sOM4B9avLyOPzrog9DCS1HOcjnp6iq8u852thu1TPzn0qI9eOvSrJGFsnIBHqCMVG2N2eM9M/0qRjknrUbcdKBjHHoahfj0zUzHjnmoXPPHemIiftxTCCCBUhBAJqMtk4I5xnNJlIZKc1A3T2qaTpULsMVAyGUA49qhk6HmpXIYcVBK2B0poZHn1bmioiTmiqFYNRkCwnsAOfevHPGMwa5IHTrXqmuykQvknAFeMeI5vMupD2zgCunDq8iJuyK/hS+Fp4hhDHCTAxN9T0/WvTlwB74rxNmZZQynDKdwI9a9ls5BPZwSj+ONW/MVviY2aZlRle6NK2Y8EmtOElgO1ZFucMPStK2POO9cbNkXEOKsRMPXiqwPYVYjAyM1myi1G2easRkM2M84qCMc8dBUkaqGBqGMuRgD2FW0GOneqaNyO9WELYFAFpByBUg68YqBT6dKlRhg4PSkBT1GEyAlRkjmoNPBEYLAZ9q0s5BGOlZVo6rcSoM53ZxWclrc0i7qxcPAyx4A5p1sxEh4+U9KbIw6KPaoUcCfCduvPAqSlqbsRyuT3qOU/OCeaSF8r71FPIBKB3rRvQyS1JWJ2ntS27M0oGeRyaYMkZFJbP/pBBbkdBU9R20NXOTQDUaYCkLnkk80oJJxW1zIkY5wKjYelOx3P501846/lQwGZx2qrqOfJGCOatHIbHrVDVB+6B7g1nLYuO6M8bVBzz9KfZtmQDoTzVfeABxUto2JVyc5NYmzRsDIJPekPr09qTdjBPp0pS2T0ODWpiZ0sgLtnB9AKbuwQAvDdabOQJmBGOeuKeSpULxmszSxY02QfMjDB61fUj14rHtHIuB0A71qAjPy1rTehE1qSknJ9qbmkbkqe9NfNamYjYHpzUTDBOO9JKimRXYkbeOvFIx7UANY4z61C5zz09qkk/OoH+76UwAnK5BNREjIGeTT8gCo3xuB70MaGuRt6/Sq8vIwO/WpnORVd+hNQNET/Kg9arTNg4FTSt+lULiTvTQyNpvmNFUnlO89etFWFhviZtlu+MV4xrTEzOT616t4wn2wNzXkGpPukbHrXZhomFV2RmhcjPrzXrXhxhJoNi5/55CvLAOc16d4PO7w9a+wK/rW2K+FGGHleTNuIYPWtS247cmsyIDd0/CtKA8CuFnUXFB4PerEanHPWoF5HFWIc9/wAqyZSJoeMg81ZTPAPWoo1596sIoyM1LGTRDkc896tJjb6+uagiHrUq+opASoecU/HBx1NImMZNPGDikxiA44zWZCoFxKxzndWmwwc9sVkz5S9+QnLdfSs5GkC98uOe/QVVJ2yL25/I1KHypx81RbQZUY9u1Qy0bUD5QHGKgkO66xk5A4zUkLZjGKi3K85PAA4BHerexmtyXdsHJ+lNsG3XTEjj1pJDkHjHY1NpyAMTuyD14pLcHsaQAA6mnL1pOD7CgZPFbmIo6U05zTiOMn9KRiBjAoAjI3MfWqOpLmFh39av5z+VU74gQEms5bFx3MCQ/KRxn9acjiORccEgHPrRIRI5HRvWohkFlcfp0rA6DoIzuUEg4NPPA4zUFuxNuhb0qYn5elaowe5mXifvizc85FRq2SOP/r067ci5yW46YqMMAcnt+lQarYkclJg5OB1rWU5UMD2rGlLbd3buK1LY7oQRkcdDVw3InsTqcUpNNHT3prk/hWyZkBPUVGxJXOCO2DTi2SPSo2OTQIjkOOlQSNU7Hk9M1XkPPrTGNeoieR3FOZuKZuwcYpMED4x/Kq7njryKmk4YHt6VXl4BIHOKQyrO20Gsq9fAOD0q/cPxz171kTfvpNg7nmmhlYRyyDcFJB70VppEQoAAxRVXA4fxxeDYyA8E15pdPlsfia6XxXfeddOM/In61yJbdlj1PNerh4WVzgrz6FhccA16V4IbPh+IZ6Mw/WvM17etej+BjnQVAPSVqMSvdFhviOlQ4PFaFuenrWWrDP1q/bt6157Os0U68VciGTkVSj7elXIy2QABjvWbKRcTAAHerCjnjmqsZ+b6datx9KhlE0Y5qZRjOeKji4PHOalw23PvSAeOmKegbqRxTU6HPFTA4XnikMa2SDmsljjUW56D61rPgZPbvWIjtJO79MkgH0FZzNKZNJkDdH83t0qFGeQAEYGeaWcnYm4nAPGKrmYH5UGEU8moNUjoI22227GOOKhjYKwOODTmkAsQRnBHFJECIgG7DtTZmh0jsS23p61d05Qqkg5zWTNI4IUAfga1dNx5OBzt64px3FJaGgnvnHanZyfb1qNWJP0qRDzitjAcT1yOKYx9RinnkYHQ1DISOgzjtQwGkk1R1FsRhScZNXHI59aydVbJQdTnmspGkFqZ8x5/dnn0pN3CnqxPejkdQTz0p0a/vMFQcnIrI3Na0wsCI55PIqwDjvzTI+EOOlKcAc1qjB7mXdlftTBkwxHfpUIzjrirGq7lA24x64qpCC2MnP06VD3NVsSu6GI8YbH4GrmmS/JtySO9Zu0u5ViQPXFT6cWWduu0+nY009RNaG10PXihiCMd6jHY559aXrya3RgN6Z9KjYjdgZ56HFPbrUZOKAInz3xnoagc/n0qWQnPTIP6VCSCARnB5GaYDSckfrSDOM8UuMDmmt93igBshyOlVJOBzVmVsKMdaqXDenWkBm3rYGR1FUbZcsz9yeKmvmJB+tFumIgBVFIsBTjrRTguRnBopjPnnV5i0hUnJY5NZ4+6cUs7mSVnPemj7te7GNlY8icuZ3J04wa9C8BOTpEi/wB2U/yrz1furXc/D982t2no6n9KxxC9w0w79868feq7Bnv0xVIYzVmA5wM15x2mrbtkVoRc/Ss62OB1FX4j09KzkUi1F1q7HjAqnEQx+lXIj7VDGTxjBqcHjvUA4HNSjJxz+FSMl5zgipAdvpUS8c5yc8U7I9aQyK+lEdu7Z7YFZUA2wgKQ/GeT0qzrLfu40z1OT71WUHbnIHaspbm0NEMuJGACt909ahXcWGEABPA9aku0ZShC8N2pLfLXSKFJORnmpNEat4cWyRtwTgcU5CQNq4woxUepZDw/3s8CnZfySxwW9B0pvcz6EEitvBcY5wBW5p4KQ7SMVz6OwmCsxY571v2pLRgnFOG4qmxbHHT9KkU981GDnqKeRxntWqMB+/rzTHPHNJUcrHaQpI96GwsNLD+lYuqP++RV9Oua1pG49BWDqEv+lMwX7vFZSNqa1EOP4RkAVGMhV2k5B49hTcq+3YTnrT7dHMqgjI6j3rM02N1dxiXJ5x1FKoBBznNJGuFA7CpGAAHvWqMGUNWG23GeazFZUTgle/HSte6G6FlxWImBuVxgA/pUvc0hsWpSrRgj5ffPWlsJD54AOcjqarRsVJUMNp74p9gSJhnHXjFIdtDcU4HOafu4P8qhBzj+VSfQ4rZMwYjDjpTGHykdKcVwxb1601hwcdfeqEQHPOTmom561K7AA81C5GaYEb5BAHrn601mwOhFOZxjr+tRs3QdaQDZfu+9Upjgkn0qxM1UbphjJ7UAZs5DTAe9WoBuHP5VURd8xx0WrsIwAe9UWtiysfyjBGKKkVcgdaKoVz5YJ607tTD3p+eK948YnT7orsvh8fnvVz2U1xqYKius+Hz4vrtexjB/Wsa/wM1o/Gju+nNWYMZ96qjGOangJBrzTvNSA5Pqa0IWJxk/KOoxWZbnGK0IjnFZyKRehwv1NWoyRwMmqcZAUenrVqNsdOlZspFtWOB3qaNvWqyNgcfhU6nC5I5z0qRkwPPWncDv71FwVOQCDSLwSrEkdQT1qWMz9YYZjJbHOBTLXLLlh8ueuetN1Zh9oXGTx0pqsXQCE+2PSsmbLYW5YlgOozxnuKdpY/00ndwOajkbBG07nI+7VnSVBdmIAGOaEU9i1cYe5BJ4A4560iqdu1G+c8moblA14OT06elWVdUiOSFY+lLqT0KiKRIM+vWugsj+5HNYcS72GDgd63rQAIuDx71UNyaj0LK4BNSjgc5qMcHtk1KoI61sjnI2G05xUUpx1PXpUjtz0OBUUnPNSykV5yAuT2Fc/ecXDjPJOa35GyO9YGpf8fRwOaykbUyGNvbrWlpkZY5IyB0NZ4UhF9CetbtmoSFVwN3WktWVN2RYwVGRSZ98Z5qQdM5/CkfAGQMVoYFa5wYWwawHI345P41uznEbgjcMcH1HoawcgHbgDnv3qJbmtMaQUHyZ6+tSW8hWdSexFRyHGfXvmkjYZDZ5FI0OlT1zmgMc02GQGNSO4zTmNao5mHbJ5pjsAck1FcK0iDy5HiIdWJXGWAPKnPY9KcWGRxVk2GsMH3qtOcA7Rk56VO/I5NQSYP8AOgCJsHPNRs3HBwRTiePeoX69fegCOVsde/6VnXL7R61clfg9qyrtsimhha9z6mtCMcgflVOBSFHY4q1ExwM9qZRaDkDFFNXkDINFUKx8sGnA/LimnvSg/LXvnjFleEFdR4BP/E0mHfyv61y6/dFdH4FfbrZH96JqxrfAzSl8aPQ8+tSxMQetV89KkRiGHrXmHoGpCQQMmr8LDAFZcBOBV+FhxUSGjShJ3c1aRhjFUo3z9atRngE1ky0W1OEPbFOijEZ3RBsHquSfxGe9RKeMEHAqeMtjj7tSMlWZem4D13cUGQZJDfIo60gIPWqWp3GyPykPzN3qWVFXZQd2kuy4bryCe1SjKIzRkAnniqSkF8E9eM1aLrhskYUYB9KyZux5mRUDL1B/GtTSebfe2Mk1ipMm0IFz/tGti1DR6bggAkE8UIUtiESD7XJu6nof6Ul1IxZV4z6iq6PlUUHB6Zx1p84XZgc9+KQ7ElrhLhnQYZyAxz1rpbXIiQ5zXO2gO5eMc8V0kA+RfpVw3M6mhYXBPWpB15NRqCPapSO5rVGBHLgj/Cq0h9CeasEDkL361WkGCeORzUSGiCQ7RzwPWsfUIt86kEKOmTWtIVxnpn0rL1M4iQH1rNmsHqVCrJ8oO8D3rctHDwISD0rGU7lYFBtx2rS0jcYijcjPB9qUdyp7GgjE5UHAoch1ycj2NJjacYwKe4xyTxVmJBcALA30Nc4zKXx/Fmugv3C2r7+VI4PpXO7SAGOCQcfSpka09hThlKg8n+dRqxHGD7VMcBgG4b68moQuXU5xg0jRG5p7brVDnJxirEpJX39aqacQbcEZyCatgZ61cTnluMjBVMMcn1oH60pIFNckcDpWiJYwng1BLwMjqalkbHQ896rueMUxEUm7+HGPeoXyAATz7VM7YFV5WG3mmIqXLEZNZkjbpFH4mrV2/UVSi+ZyetNFIvwkYHrVtF+UAVTtye47VdiY7OfqKEUx53Z6LRSbx3Jz7GiqEfLPfNKvOaTtSocD3r6A8YsLjaK3fBuf7eix/cb+VYSH5RW54OOPEEHurD9Kxq/Cy6fxI9GAyc5P0qQH1qIewpytXmHol23PPr9a0oTleOtZVv1HNaULYI4qJDRfhNXFbBOapxtyKsKeRjJ+tZMtFyEngk8VaTpk/jVOLJIyeKtx4AArNlEvReTn0rH1Jh9o5OeO3QVquwAxn8a5+5k33BI6E44qWaU0IhDqTjBHSnks+STu45FMiKxrk/MD3x0qQsx+4W29Cahmo6JcsqEAZPFb1wu21I/hC4wKxrCMNdJkEru4rb1PAtHPOTQTLdIyLWPfJ2AHX1xVi5CRoTtIVuKZYxMS3zjJHAq1cfLGwcBsdB6e9SNvUisN0kwU5x6V08I2oARg+lc9pij7SuDz1+ldJGMnJq4GVV6kyncMjIPvTmbIwetNjJBNLjJzzzWpiMcelRSdcHrip36VDJt+tSwRny/eyOlUr1PMiOe3OavyEAn+76VUuQxidUIDY4NZmiZlrOFQbRn1NX9JnbzGRhw3NYamRLgudoXoVYVes5AbhGzjBqdjaS0OjPQHoRTt3GACaag34xT87DWhzlW/bbaMQtc+yOoVhtwT8oxW7qb4tXKjPt6Vhb2Y8Djr06VEjWGxFKcvmRirg9MVLG3GePXmkZt/LA78dMU2Nv4MYPTFIs1dLDeUWPG45FX27ehpIEAiVQuOKDnJDLx2OatKyMJO7GkYz70xmwPWlZuuCSRULtnFWSMlxj1NVmckVPJVeQjFUhETyAgdarXDbl24yCOalfPYVUnbaSB1pgZ92SqBIsKAABkcAf8A6qZb9cY5pLth3xmnQnDKRwc1RUUXoR6jp0q0jcZGPoKrxkAE9zUkRIQZPekMlbk5C0VEGIHDcUVQHy/SqaT1pRX0B4pYT7oFbXhQ7dftM9yR+lYifdrU8Pts1qyOf+WgrKovdZUNJI9QA9qUdRRgA5p2CRxXlnpE0R+b0rQhbPXvVG3U9cdOtXrcEsD+NQxo0bZccA/LVvA29PpVS3JyG455C4q+uCM8isZFokiwQCcZqynHfmq6JjG3irGcLwKhlEN9Ksdu244yMCsJSDhD17Grmp3G5/LGCo/nWfEjA7nPAPX0pG8FZF4pI0XyjCDkgU5JGKrGQAoPOetNjbenyAkk8E0ZKOpbG4dcnrWZSNTS4w9yW3HC9BV7VMGDJ6H9faodJ2/Z+B35NLrDgxqvOT0xR0M38RFp5HlkqoyTwaZcyM7HjGDUtuDFEWPoM1XnkDSAg8HrxUl9S7pkZ+0Kw4B5rokxnA+tYWiEPMepwOprfiGxzWsDGq9SVOp9KeOQf0puBxzgU4DI9PStDEicYTj16VA5HJqd8857dqqy8Ln1qJDRWkAJJ7niq0mNpHtU5J56imH5gSRzWZZzTRmRiCcEsetSbWRuME4wT6U+7RkuWXbyTx75qP5hKQ4+YfyqToOltGzBGQe3Oas5BB5qhpkqyQL7cYq8BkkDirRzyWpT1LCQMST+Fc6CPOddxCkZArf1YZRcdjWDOCxAAzj26VL3Naew9GxIvK4PSo8lmZlXJzUu1FHzCmN8rFRyPWpKR0FuW8pGPBxzUrcgYqvZSrLAjKT06e9THg8dK1ic73IpOT9KrvknOasyYHeoTwKoRXdsZzVZyGGc1NJgnB/Gq0pAPqPWqQEc5wAc1n3DdcnoM1ZlYjmqNy/XOKpCKFw3zqp7mp7f5gmeT296pSkPOR3Xmr1meQTzgGqZa2Li8AEnkcVIScZ5x6UxSPTPepAwxlecYpIYvyrx/OigsM8EYoqhWPmId8UDvQKRT161754hZT7oq5psmy/tm9JF/nVJPuCp7M4uoTno6/zqJbFR3PYFPPPTNSLxwKjHODTkPze1eSz0y1AeeelaFuQDntWZGT9av2xHGQKhjRoQZVzjBX0Pb6VfHK/WqEZ+UHqexq3CS2M4rJlosRZyAae7dRzim7OASeacRlDnt1qCjnZ5D50gTgE9DSRsWyOCKkvgi3T7AahgP73c2VXPT1pdDpWxoxtsj3IRxwSP5UHa8ilTuZu3cUBdrHn930FNswhulwcDPSs2COktI1it0X061UmHmX2H5A6DPSrgdY48segrNSZGuWkOTuOKTIj1ZZkaTdhVwPeqjEqfmAye4qwWneRxt/dsOG7Cq8a/Oy4OR1b/AOtSKRtaHkbz8uD6VtoMnpk1j6Ip2OMYGetbWCjD9a0hsc9T4h0Y55qQ8KM0zuSozntSqW2/PjPtVmYw9STVWYZXPvmrUvTgcVXI2k9ahlIpNwc5xkUmQFINPcAggjjNNHpn6VJRlasu11ODkis+OThsk5P3gen4VpaqzeYhI+XGOfWs8hhGGAGyoNo7GzpIBt+OQD+VaHQZ/WszR/8AVsOCCa1ApyR071aMpbmbq4G1N2cE9RWVGwjYuvzDpWnrkm1UGSCTWQQdhZWxx0qHuaQ2JWKmPfjO0cqODmqgcvECy7X/AIkJ+77U9mIToQp6j39aiKkqG5x0NCKR0Wn82qZxnHWrLEjHoaztIJ+yAcEDOKv7iUBOR6g9quOxhLcawHUA5qu561Yc/L8tVpD3FWSVpfvDPpVaXv0wO9WXOSciqkrEDBHHWqQFSbG3qPrWbOSWPTAPFXpT6VQuD+FWhGWc/aGYDktWlbnkYPFZsBLsCD1NX4jwSo5BwKpmiNGE5Y9ef0qQEduh4qCDdv8Amb5j/KnbMKNzDOegNSMmGw9hRUJk2nGVopisfNVIDSnrTSRzjrX0J4ZZT7oqa1H+lQ/76/zqCPhRVmxGb63HrIv86iWxUdz2FVpyrzSD72O1OFeQz0yWMEE9/ertsMdaqRnPfirkBGec1DGjQi5AB49KuxY9uKowkYGcDPvV2MAnnrWTLRZU8Zp7c5Paok6GpUZfLHHNQUc/fxFLlv8Aa5+lQQAluRwp61c1hm+0JggDrVSAltxJwDxS6HQtUXg6uPlAHGBn1p9qQ12mF5J/KqbL8/Pb9Kt6WP8AS0Yn2qGgNu+I+zEHjI6VmQsVkXABGcGtDUhutmYdqylMgBypII79qlihsaySIq8k7QfzNRllefcgzH059apqHaPLSEHOfY+30qzZgu4UYGe3vSHax0ulxlYM8c81pAccjmq1suyJEBxgc1Z6DgZNbRVkcsndirjJxmnDBPtSY+XtTgMCqJInJB6cVBJ0z3HNWHHNQyr+lQxopEbicEY9aaAuBnk08rtY46daQLnPQioKMzXAT5eQOaqov7rLr8mOlXdXOyNP4trA4JqtGzTscKqL1ANQ9zWOxJo77Z2GR9K2gcYzWFYYS7wMMO2OtbynI55qokT3MXXBudCR8vrWdujjQ/Lu9/WtHU3dpNgA45x61mhwXB/iHPtUvc0jsQncSCeg/SmksysC2Qe2amY5G7Bx0OKiARYyQefpQWaej48k9Rz17GtE9OpzWbo+Ra/MRjJwKvkZ+tXEwnuNkYgdKgdvTrU0vSqsgAGaoghnJyCD9apzkkEdu5NTzk4xVSdgVHOKtAytJyue3Ss+6OFY54ANXpOmT6VnX3ywOQccYFaISM+2OOSPyrQt3AVcnrk1nQgrgA+lacahsNnp6VUjRF1F3EEjpT8AD1NMicY5+lK/CE+lQMbvPcfnRTC2DgE4oqhnziaZ/FT2PXmo19T+VfQHgluP7oq5oyb9Ws1x1lX+dUo/uCtjwpH5niGzHoxb8hWU3aLLgryR6kDzn3qxGAw9sc1XTNXLfkYNeSz0RsaEHpVyFcHIORTdnTFSxqRx2qWUi3Bt2jI5z1q4gweDxVK2zvwQNvY1ejCjrzWTLJ0wMHpTogXiBGTSKQVP06U2W4W3t93PA6epqCkYuqZa8boSBj6Uy3OFOR9KhmJldzn5mOTUo3bVTOG70mdFrKxMfmHz55qayKLPGSOh5qvJKwIUD5fX1qW2YBlfHGetSxo1NSm5VQfqKhhOcDG3HODzS6hhplK8NjmmwrnOOvoe9SC2JiijIwDjvVmyjxKu0kZPWqo+U/eyOn/1qvWK5lj9c+tSJ7HTxZIXHXHWpl3A+/eoYwcDrVjPFbo5GSJ3P5CgHI60ozjPFMYk9OlMkaSc8VGy5qTByaaW4GfSoKKkijcetRhTyamkOSc9ajU9dufpUjMrV5AhVSATVaFT5O48gDI5qfVhmaMlcjvUYChc7Qc+9Zvc1jsR2B8u+UjjJ710BUVz6KRdqyZChhXQoMjI6+tVEUzG1kYmXAxkdao+WY3D/eUjB46VqaqMsrc8ce1UYZvLRo2GQRUvcqOxXZWEQTaA2ck+lU5gPMK9xVxndocp2ODVZyBFk8v14oRaNTSY/wDRgylsnPGeD71eckdRWXoUpKMmeQcj6GtUjKnI+lXHYxnuQycjg1Vk4BxVplXoarzJhD7VRJRmXI6ZNUplJJzitGTO0YqjcdenNWhFOTrnJ2gY246+9Z9+P9EkJ9M1quoPHQ1TvVBgkX1Bq09QRj2mPvHk1etSVBGTxVCIlRkegq1HklT+HFWzRIuKwRtp4zzVgMFyc8471WUbskn5jx0pxDBzkgg1I7D/ADFf5vWimfJ3zRTA+dHPWo0PanvUcfJNfQHgluL7orqfAMW/WJJMcRxH9TiuWi+7XcfDuMbL6XHOVQH9a567tBm1FXmjtNtWYBg57VAnzVbhX8RXmM7y3Dll9PSrCoMdMjrUESkMKvRr8pIxWbGhEjOPlq3BG2w561GEOODzVqEccnHtUMtDljIX2NZWsSZuI4umOa1wW7DFY+pbftWed2MH0qDSG5RALuNv3qtqAoAK5bGDTIkAyQcY6mpDznyznj86TNhCAVI2856elJACpyMDnrilG1EBz26UR/MxIJHGeTipGi0xLNuzz61JHlyNozz175qup3sqjr0OKuQqFDKeex9RUsbGI6nC4IPc1saQgeZd2RjkVkuq7xg+34V0GiIHJYHO3jFJLUibsjaXpx1p6n0601cgDgU5MnOK2OQmUjimE8mgjAyelBPBOOaAGMcA89ajZuOOtObnp261Gy5B7E1LGVpmyaYr+lLKuTnvimKNrZ7ioKMzVWc3CKDgE9ajmIQK6jIHXnipdZ3GSNwAQD19Kr5/d7CQxBySB1qHuarZBC6tMMD5M5+tdNHjAB6kVysLDzF2n3/CulRAyoxHP0qoE1Clq7BAoweTwaxXYHocHsa1tWA3gb88dKyiQGOACTz0pPcqGwwvsBDDh+n0qDzlBKscqDg4HU1LJls7gCfSqhQkH5cHPT0pFo0dEdVkcE/MfXtW4SD6VgaRFvutwI2qM/WuiKiriZVNys4B74qGTkHFWnUA9PxqFwMdKszM6XkYqnNg4A61oTIRkr1qnMvQ4qkBVcAr0yaoXAzn0rQYjBB4PoKpyjjmqQzBUFJHXOMGrSgGQFTgGmXabbjcBnIpyAmPk5qy0TZKElTx/KpDKq9Ru9B61GQMKGPGKcQgIYnp0zSKFOCeWFFNwD/9aimI+eH4OKijPz09utNi+8a+gPBLcX3a9E8AxbdHkfH35j+gxXncfK816n4Rh8nw/aDGNwLn8TXJinaJ0Yde8bMRINXoSCM9M1TC9h3q5AMYHWvPZ2l23+Ykk8+lXI+nJxVSIAD0q2nJ55FZsosxkAYBzVuMjA6HNVkUZGMH3qxGMYqGUTgcYxWZq9qwImBwF4IrWj4A7AetJeIr2zDrkVDLi7M5iMgzYJIGKtxRsWyg79SKs21ouxTGB64PWrfkHgYxUNm1zLlh2qQVOScg9qjjQsGBxwO9atwgEYDcgVWtYSbW4ZQCuKVx3K1oFDHJ5PTNaMaqBznPc1StUDEbuvQCryqSpBPPqe/tUsJEUibW9CT+ddFohIiLE4HSudmLCRRIPpz2rpNF3fZlzg+lOO5FT4TVDE9qfyOhqOPJ5NSHrWpzDgcqR0PpSEUo6knNA5bpwaAGgEH2prD16VIevJqOQ8cdaTAryqADjHFV+HZlU8jr7VO5H0PpUZBxmpGZ+qQ+ZbHIJA54rKtRGV+Zicnr3xXRSAFTz0HFc4oUXbHA255rORtB3Q9osStg7mA4ArX0ucmMxsSccis0wqVOGyR0wadYMRcR4IXnk5oTsweqHXhYSuWI5PGagjiLLkjA9T3qbUTuunwRg8U+0iBJBOSKQ76FURA7ssNy8jHOaglTEnzbiDznHWtXbEmBHjcDg1mDfJcct1baB6UDTuaekWflr5r/AHiOCPStLABJHenImFUDjFK464HStkrIwcrshk6dM1XcEnpVog4281DJ6GmIz54+MAnmqco6ZBrSlAx1wRVKVRyRTQXKEifMTnrVWQZyAOlaTqSuDjNVGUbunPpVDMa+j6EjOKgQqCNpP41o3aDFZgVVY5HQ8ZqkVF9B+VwCepOOtMZixwT+NI6pjdzg8jNV2BDk55p2LLAY4++KKomY5+7RVWA8MkpsX36dJ1pIvv17x4BbiBIwO/Few6TA9vaRxM+9VVQoxjaMdPevKNKhM9/bRdmkUfrXsUY7CuHFvZHZhluyeIE8e9WoVww4xVeEetXYx6CuFnWi0gAwe1WYhkdKjjHAHapo1+YEngVDGWI+nA5qzF+fvUMPp1qymcgetQxkqY9c1KyYiP6U2Mc49OalfBjIPFQykyrbRlQCBtParirkEsM1HGuAAM1YCcdT+dSU2V5ok8rOKhnVY7Erbqu5+KvuqmPnn0qtHGzMVA+QdDUspMz7S0ZBmUZY/pVgwEPlcY+layxEDGAcd6Qofm+XqKVgc7nPagvKkA9etb+j/LbIACB6GoLm2EiHdjH0qTRxgFeSAeKFowk7xNhDyO9TKPxqNQSOOtOBYD5hitjAcuMkUpIHQU1cjpSHJJPFIAJ64pjZCmnkHHpTW4X1qRlNz82DTQcD9KfNyeDmoguTUDEnAWJieh71iJEElYuByc+ua6BkzERgnisiKEM7EjBzUyLixqDbnK5I5x6ioXkiSXeilcDB9vcVqrATtLY9KgubTcpwoB7Eiiw00UAwkbBJye+KvWykIEI5Hv1qCCzY8PnJ7VfECjBycgYwKEgbRRu4wqkjIx1IqnYFftcZc/LuxWjcQMykcis9l2XS7iF5ByOgoKi9Dp1PHt2NI3PalQkhc8ilcZNbnORP0HrVdx2PXtVlge9RsODmmFylIv8A9aqsgxkmr7pzVWQAnI5HSgLlNgccVVmXaD3NX2GKrugIJB5oGjKmQlTx0rHuQEfnmugmHDdu1Ymox4Ge3XNXEd7MrsQfvelV5WYk4HFTbQw6896qXTYOA3SqRqNYnPSiqhkbPT9aKuwjxaTrSxY302U8+1Oi5kr3TwDoPCib9fsx2D5/IV6xD0ry7wSpbxDFj+FWP6V6hC3pxXnYr4jvw/wluLGRg1egxnmqEXXHatCAAsAeeK5GdCLsAGKmjOD057VAIyy/LKyY/u45q0ifKATn3PU1mykTx9QQOtWI25yTxVaNSKsLzjGKhjLUIySSetJcsscJdzhRyTjtTYAwXGScep5omyNpHPPIqWUiaIZQNg89zVlOhzVeNsjHSpw20YGagY91GzPFLDHsGCeKUAbfmNPX5hxwOlIAVuSD0xS5ByO1PwApz+FIAOhNAiNsqORxUVsP3+R930qeUEL61SBKXIAHz9frUspG+oGynEEtzUcLEhd3XvUzHn29a36GDALgHOKQjOQcfWncnnOaXbnknHtSC5GRng800gYIqUnB4603naTjrSsO5SkTDZ/Wo4iS3PFW5gCODzVdFOTUWKuSZ+Xj8qz5ExcNtHzevatGID8KgmQCT0NEloEXYjROuT9KjlLEgKePerUaFuTk4pHjDsCOMVNh3IYkIJ4+U9+9WDGMDbk07jOODRzzjiqSE2V2iGQT26VTu4ItoygyTzmrjyBT82SeuaoTo11IEAbGeSKllRNKBVEKhG47VJn6ZPT3ot4tkIHt0ps670VQSNrhgR7VtEze4HJ/GomGevapifwqCTnNMRE+McdaqGNEBCKqjk4UY59asyHHWopMYoGVSueKhkXqBwatHkccVFKuDmlYaM+4U7cAcVjX4yrDGOOtblwPlPrWNeAHIqojMF5GH8qpzsWOW6dhUt2cTOucCqFzNHGPnKge5xWyRaegF1yetFUDcDPABHrmirsRzHlEw2tjtT7fG85okUM2M4IHWiPKNg9a9q+h47Wp1XgLB1wk9omr0qLjrXmfgTjXF94m5r0qPqP6152J+M7aHwlyI5xnrWlAcYBxWZGSWHrWlan5NrDr0rkZ0IvxEMOe/PFW4yAo2j8KqwgBMjmrEbAVmykWI/fvUgI3HHIpiDK5BBFSINo4FQUWY+R3qUpuByarocHg1OD8vpUsCKFtjYY9auRsM5B49qoZ+bGB7VPE2Mds1Bdi4XCAkjiljffgqcDvVWX5gcEikikVcZOfYVI7GkewJ6U3IBz2qKNznrStlwQvHvmmSSbychaqhm+1DuBznFTIPkANNjG2bjaAKlgjXjbK4PX1qUY7GoYyWA9KmQdsVsYjhx9TSngmgd/agAdyAaYCEZBpC2Bg8Ypc8+1LIqtg0gKzjcfaoT34qdxg8CouOR3qGUIhIBIB+lEvIzxS7tvTpTLhg0ZyCB7UdA6kkZDKMdacwwvqKrQNkHnmpwx44pIGMdCy8YOKbkqvcf1p0u3bgZzTJCQow1AIhlJ2sXwMdql0zHls5HDHINU7hmK7WGQTzg1o26Kluqoe1EdWVLRD3HOAcCkbAI9aXoOufc0NtYDr9a1RmRORnoKiZfWppByMVHL78GgCtKADgc1A/QZBxU4VgSWYFSeMDGB6e9QuQDznNAyIjqB3qNwcY7VLwMnNQSEHPPTigaKdwMjPoax7wE5IAB6fWtqYYjJHOaybocEkAc9KcRnF61aLPdbnLD5cYDEVkzaTbkZdAcZ+9k10GqkJOATjiqExzCAeAa64vQ55PWxhXEXlTMigYXGPyoqa8lAupAAcA4orVGLv3PPVsgrbpWLH0XgVOkKj7qDPuKswoZGJxV1LdQBXY5mKRJ4WzHrcBPQhl/SvQoj0rhNOCxajanplwK7aNsEd65K2rudNJ6GjAcspPGO9aULY69ay4jwD3rRhJJx61zM3RoRZAGDx6Vcibdx+tVLcEjr71ZXhgQM96yZZZ5AwDj6U9XPAKn8KhJbg54FSxv03DHuKkpFhOXyCMdx61YQ8c1VUKZMgnNTISDy2RUMYYPmknnP6VLkscYwD3p8ezPy1MqrjJ61Nh3IkIcbU5I61WcGOQYHOK04415bt2xVG7QeeDg8frUtFRepaXO0ZHWnk4GM81FAcYBPPr2qUEHjDfj1FBIZwM9TUMXFwDJ345qb5FHOSM1HcDe6lT83apY0bMXzAYPFTx9sn86r2+di7utWOnPWtkYMecEH2o4GPekQ9RSk8kD86oQAAg9OtAGPqaOmMDn0oPTnmkAyQZ57VXZNpyBzVphnnOKhk+8MfjSaGiJVznjpTmTjmnhck4zzTmXC9unWlYLlDJ80gAe9SpjvVaWVY5zjmniTI4qEWx8jA8U1nUden8qY7YB4z7YocZwcdRypoArz4CkkgDtV6yU+SNwOazJTvuVROuc4PStmMAAAU4asJbAwwuDg5ppPIA7VI2SO1Q/U1qQI7cDnmopTkdeT2p7jHNRPzx3pDImzioHwRk/SppM+tQuOQKAICcMRTCN3b2JqcjGc9O1RsPw+lA7lSVML71mXSfKfrWvKMg/pWXcqQGA7nNCA4zxDlZUb0NZBlDtCPU9vrmtjxZ8lrvXs3865dZGWGWY5yq4X/AHj/APWrshqjnqaMglJkldweGYkUUxT8oyzZx60VsYmRbxBVGRzUzkKvJxinZwKz72faDjnFbJXZmOS43alaBeT5q/zr0Fc7uBXn3hiL7RrCuekeCPqe/wDOvRF/yayr6NI3o7Fy1O4gn/8AVWtbYwAeayrdCCCAPpWrBjAyK5ZHQi/FnkCrKZyKqRjJGKvREKFB6Vmy0Sg8cipRkYGPxqOM9we/NWO3sahlAi5OcH8KnXbjjr0qLGBx1NWI1woYioYyWMjjIP5VImSTjOPzpmSByAalQcZHFICdHJwMD6iqV26pMB39MVbUHoaqahH8yHBwe/pSlsOO5Yj2kg9qlEW6Qn+HH61Vt1YnB5wOatqMEBM5qUDEMeMZ5ApjLmVSAAAamYkZzuPFUJ5GjYPzxzj1oYkb8fykHrUo568VXs5RNErc/j2qzk7ie1bLYxY4jH3aUgZpF+bPNOXnqPxpiGEGmqxyd30qRu/pTQvPrmkMRmGOgqMnNOkBxxUeOByQaTAcBnOOvvStnBH86O49ac3UkdaAMbUo38xSo79+BUqAhQMgk+1JrHVM8g9qZbplAWPJ7egrF7mvQlwADyMk96ZK5yHxg4pHwGOep56VBI2FOTwP5UXBIqF83KkHDZ5roIWyo47VzlnEbm83A4RT3FdEi7RgHpVUwqDjz2qJ/ve1SHoeDTdpIBFamYwnJqGQ4IBFTOcHFQvliOOaBogcEg4GB05FMfipmU8gGoWBJHrQAwjjI/WomznH51O46etQsDlhk/hQwRBMAwNZ84yMda0pFO0gCqMy5470kM5DxPbmawnTBPHGOua4K/l2gQxt/qzhiO7HrXp2rx5tpFPGQRmvJnhlt5isgJVSefWuyjqjmrFrZnkA49qKfET5a4x+dFamdjEWQlCp4YD86qw2b38zgOURASTjPPYVMqlSCvJ7j+ladkgjgB6byWI710XsZEPgyDy7hmbqW/kK7hB0+tclo2IL9E6EMV/McV18Liueq7yudFLYt24JPBrTgXIDDrVC35GQOa1IB8g9a55G6LcIyeefarKgnFQW4JGScelWlJ3YxzismWiVcKwJ6elT556ZzUSjlQRzU0eM4PWpGSKCTnuami5Y8cUi8HpUy56dc1LHccFBPtUirg8800LnBBqVTz0yaQh6DBz+VUdQmYSrHj5TxmtFefwrP1IYkQ4GR3qZbFQ3C1dkY4PGOatQy5c5GB61VVs465NTHIbrjPWpQ2TSSAHrxiq1wVbGBlsdelPkG1Qcg4NVbgEjchzzwDx+NJgkbWlMBbqK0UYevNZ2msDAABx3OMc1dTpxwfWto7GUlqTjoelKoGPm796h4dSuSMgjIOCKeuFjCrnAGOaogecEUoIxzxTVYMDTup5oAZkY7HNMKgk1Jt9M00jPWiwDQvpTSCc98VLgA0jfdz0FKwXMXVmG9AqndnrTolZgGb8ecUl8m6YsDyKEY7c4wB2rB7m3QRl9Tj0qrPn5hhelWjnaWOCPT0qtcAhTtADEdvSkxor6Moect+mcVvqcHpxWLosarK+G49uhrbC5BPI7c1pTWhNR6gwPPWkPQ8dKcoI6mlx6kfhWpmVnyTim8An1qcr1wKaVHNA7lc4/+vULpnkDpVmRcfSon9hQBXbOOnNN287iKlYFuKQDCmgCvKCw4NULn7mCoIPGa0pVJUg//qrKuLVFuGnDS72G0rvOw/8AAemfekMx9UXMRGPavOr60EkzNvRSexHWvSNUOInHeuDnwJMMeCSM+ldFHRGVQxvsE38E0YXsM0Vpta8n5l/Kit+ZmPKjklXn0xWhn5UFYenXb3Mr21xlblOeB8rr61tJl2QJjrxmuiSs7MxRDJPHFOZlI3ROjH6A12cTjIxyD0rn5dKt1tplTLTOMs56sfYVd0W6a5sI2b765jcdORWU7NXRtT0Ontj6Vp25G0YrGsnA4Hete3YBa5pI6EaEJ56YNXYyOSapQMOM1cjG7gDj2rJlosw5PQZFSeWpwfTmmwDHH86nGccjmoZSJI9xA3YxUijHQkVCu48Hke1TjbipYDw+eoqVCM5poQHgCpQOBwDilYCRRn0x9aoal8oBx1OM1dVR6YpLiASoBj3GKGroE7Mz4x3ByKlUtjAPB/SnxWzxHBp3lEv2A/nWdi7kUik7ckCqtwDhW3YBbHSrsltuI7H0qOSBnbGCQOMUNAmaOm4EOFyQKvhgTxyKoW0ZgVVyTV0H5T2rSOxlLcdkA4xwakU5OO1RDnBHSlVjnAFMkmB5wOmeacByevFRE5HvT0Yjk1SEOzg9KMZPtS/eBpAeBxxQIaevHFKenShuAe9IMEZANAGVfKPMzjBzyRTR90+tXLlPmJ9RVEkqSO30rCSszZaoTOEGzueaiK5Q9eDUg45HAPJphYkMec9akoTT1EEnyZwT3rXHU461kwIVuQecnr/jWqD8vXitaZExT70oAxnFC8KDSnnpnFaIzI26Eg1Gec84qYqA3t6VG1MZC444qHt3qywyORx3qF8c0AQlc89DTWHtT2HAweaYzZxnINIZBMc8DrVObhT0Jq7NjFUZzndj0zmkMwNYYrC+eMDNcDdMFlQHPzE/jXZ+K7jyNPlbPIAH1ycVxeqt5aIcjKSgV00loY1GAkZRjOcUUhB9BRWpmclo9mYIPMl5ncZY+g7CrMBKs5OOvrViMgK3c+lUpX2kkD1rovcx2Na0uy0kbg5KnaB6irKAWuolkGILvp7SDqPxFYlvJtK4HAArftjHeWZhmJGWDI46o46GokrFRZr2cm5hnpW9buMD+dcraSMshWUBZFO1h2/D2retJOMA9q55o6Ys3IiCPpWjCfQEVkWxyARya04XG0HOcdawZqXovUVOg3Ec/N2FV1ZSM9KmiUOu1s4PocEVBRajAbpgkcHBqZI1zjHNQRKFQIo2qBwAOlWY8KvPakBIow3HH41IrckYxTUxgkjr3p6Dv2oEOABX61Iq4HcmlXoCRUgI7UxEbLxSBBghgKmPXrzSHG0cYxSsBC0YJ3H9aVVAyRgH0p464NNYDPP1pAPwMAZp4ZcHJ7VEvbP41MoUjtQJgTlMKce/pTlJP19aaFyQSzfL1A6N9akU4JxQAKeOaVnIPAz9KOhBFPwO3SmIM9+aDyMZIz3HUUYOScg9MDFOHB9jTEMwTjNKRkccUjg9FzmnBgBhqQFS8yE6Gs5sgjJyc8GtW4G4HHC1SaMBzgA1lNamkXoRCMlSWPtx2qN18tSc8nueamkyRxzjr9ahk4jXnIY/lUlolsIjzI+Qc4+taCqAAO2OKihwF29MDpUinnHetYqyM5O7H9sUuKb5iqwB6mpMrgfnWiIZG5VBkg49hmopAM8/jUxIHI4qFmxTGRsQB3qJkx9akY+/FROfmBLAY9qQEbA9KjZsD8KezDPNRStmgaIZ29QazLqTapx171buZcAnoO9ZF7OqhstgKDn2pIZzHiaUTTRox+VD5jD6dP1rkdeY/wBn7hyfMQ/rWrJdfbZrqY9GmKgZ/hA4rJ8RjbZxovBMi/zrrpq2hzTd2XV+6OCfeinxEeWucZxRTuB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperpigmention stage of berloque dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Dermatology Online Atlas,",
"     <a href=\"file://www.dermis.net\" target=\"_blank\">",
"      www.dermis.net",
"     </a>",
"     . Copyright &copy; 2011. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_52_6978=[""].join("\n");
var outline_f6_52_6978=null;
var title_f6_52_6979="Brain aneurysm PI";
var content_f6_52_6979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F54428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F54428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Brain aneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 590px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A brain aneurysm is a swollen bulge or &ldquo;ballooning&rdquo; in the wall of a blood vessel in the brain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_52_6979=[""].join("\n");
var outline_f6_52_6979=null;
var title_f6_52_6980="Cyclosporine (ophthalmic): Patient drug information";
var content_f6_52_6980=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cyclosporine (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/26/14756?source=see_link\">",
"     see \"Cyclosporine (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/42/23202?source=see_link\">",
"     see \"Cyclosporine (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8012533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Restasis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14959798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Restasis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691836",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701875",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cyclosporine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699642",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use right after opening.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part of opened vial not used after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11643 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-118.97.94.19-6E5BBB852B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_52_6980=[""].join("\n");
var outline_f6_52_6980=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012533\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14959798\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030358\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030357\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030362\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030363\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030365\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030360\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030361\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030366\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030367\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/26/14756?source=related_link\">",
"      Cyclosporine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/42/23202?source=related_link\">",
"      Cyclosporine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/8/30858?source=related_link\">",
"      Cyclosporine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/28/40390?source=related_link\">",
"      Cyclosporine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/55/36729?source=related_link\">",
"      Cyclosporine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_52_6981="Multiple sclerosis PI";
var content_f6_52_6981=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F63006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F63006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Multiple sclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 648px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In multiple sclerosis, the immune system attacks nerve cells in the brain and spinal cord. These nerve cells work kind of like electrical wires. They carry electrical signals and are wrapped in insulation that helps the electrical signal move quickly down the nerve. This \"insulation\" is made of a material called myelin. Multiple sclerosis damages this myelin, so the nerve cells cannot carry signals very well.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_52_6981=[""].join("\n");
var outline_f6_52_6981=null;
var title_f6_52_6982="Aprotinin: Drug information";
var content_f6_52_6982=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aprotinin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/0/40963?source=see_link\">",
"    see \"Aprotinin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F136410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Trasylol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F136450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Blood Product Derivative;",
"     </li>",
"     <li>",
"      Hemostatic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F136414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Test dose:",
"     <b>",
"      All",
"     </b>",
"     patients should receive a 1 mL (1.4 mg) I.V. test dose at least 10 minutes prior to the loading dose to assess the potential for allergic reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Notes:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     The loading dose should be given after induction of anesthesia but prior to sternotomy. In patients with previous exposure to aprotinin, administer loading dose just prior to cannulation. A constant infusion is continued until surgery is complete.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     To avoid physical incompatibility with heparin when adding to pump-prime solution, each agent should be added during recirculation to assure adequate dilution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regimen A (standard dose):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 million KIU (280 mg; 200 mL) loading dose I.V. over 20-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 million KIU (280 mg; 200 mL) into pump prime volume",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500,000 KIU/hour (70 mg/hour; 50 mL/hour) I.V. during operation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Regimen B (low dose):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 million KIU (140 mg; 100 mL) loading dose I.V. over 20-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 million KIU (140 mg; 100 mL) into pump prime volume",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250,000 KIU/hour (35 mg/hour; 25 mL/hour) I.V. during operation",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F136415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2550580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment required, but increased risk of worsening renal dysfunction with use; monitor closely",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F2550581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No information available.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Trasylol&reg;: 1.4 mg/mL [10,000 KIU/mL] (100 mL, 200 mL) [bovine derived]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11217104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Available in U.S. under an investigational new drug (IND) process. The program will provide aprotinin for the treatment of adult patients undergoing coronary artery bypass graft (CABG) surgery requiring cardiopulmonary bypass (CPB) who are at increased risk of bleeding and transfusion during CABG surgery with no acceptable therapeutic alternative. Healthcare providers using aprotinin for this situation must also ensure that the benefits outweigh the risks for their patient. Healthcare providers with patients who may qualify can access information and forms for enrollment at file://www.trasylol.com/main.htm or contact Bayer Medical Communications at (888) 842-2937.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F136396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer through a central line. Infuse loading dose over 20-30 minutes, then continuous infusion at 50 mL/hour (regimen A) or 25 mL/hour (regimen B). Rapid infusion (&lt;20 minutes) can cause transient blood pressure decrease; to avoid incompatibility with heparin, add while recirculating the prime fluid of the cardiac bypass circuit.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F136395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of perioperative blood loss in patients who are at increased risk for blood loss and blood transfusions in association with cardiopulmonary bypass in coronary artery bypass graft (CABG) surgery",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Aprotinin has been withdrawn from the worldwide market due to evidence demonstrating an increased risk of renal dysfunction, myocardial infarction, and mortality in patients undergoing cardiac surgery (Canada has lifted this suspension); use limited to investigational use in the U.S. only according to a special treatment protocol allowing for treatment in select patients at increased risk of blood loss and transfusion during CABG surgery when alternative therapies are unacceptable.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F136448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Atrial flutter (6%), ventricular extrasystoles (6%), ventricular tachycardia (1% to 5%), heart failure (1% to 5%), arrhythmia (4%), supraventricular tachycardia (4%), bradycardia (1% to 2%), thrombosis (1% to 2%), bundle branch block (1% to 2%), cardiac arrest (1% to 2%), heart block (1% to 2%), hemorrhage (1% to 2%), myocardial ischemia (1% to 2%), pericardial effusion (1% to 2%), ventricular fibrillation (1% to 2%), shock (&lt;1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation (1% to 2%), anxiety (1% to 2%), dizziness (1% to 2%), seizure (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Creatine phosphokinase increase (2%), acidosis (1% to 2%), hyperglycemia (1% to 2%), hypervolemia (1% to 2%), hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (3%), dyspepsia (1% to 2%), gastrointestinal hemorrhage (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Disseminated intravascular coagulation (DIC), leukocytosis (1% to 2%), prothrombin decreased (1% to 2%), thrombocytopenia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Jaundice (1% to 2%), hepatic failure (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increase of &gt;0.5 mg/dL above baseline (high dose: 9%), oliguria (1% to 2%), tubular necrosis (1% to 2%), kidney failure (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Hypoxia (2%), pulmonary hypertension (1% to 2%), pneumonia (1% to 2%), apnea (1% to 2%), cough increased (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Sepsis (1% to 2%), multisystem organ failure (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactic reaction/hypersensitivity (no prior exposure: &lt;0.1%; re-exposure within 6 months 5%; re-exposure &gt;6 months &lt;1%), hemoperitoneum, skin discoloration",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F136399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to aprotinin or any component of the formulation; known or suspected exposure (including through fibrin sealant products that contain aprotinin) within the past 12 months",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F136381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Death: Has been linked to an increased risk of death in observational studies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Has been linked to an increased heart failure in observational studies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactoid reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Anaphylactic reactions are possible.",
"     </b>",
"     Hypersensitivity reactions are more common with repeated use; the risk of fatal reactions appears to be greater upon re-exposure within 12 months of previous use. Patients with a history of allergic reactions may also be more likely to develop a reaction. All patients should receive a test dose at least 10 minutes before the loading dose, although the test dose does not fully predict a patient&rsquo;s risk. Fatal hypersensitivity reactions have occurred in patients who tolerated the test dose. Epinephrine, steroids, and facilities for cardiopulmonary resuscitation should be available in case such a reaction occurs.  In order to administer in a more controlled setting, patients should be in the OR, intubated and ready for rapid cannulation and initiation of cardiopulmonary bypass before the test dose is administered.  Delay adding aprotinin to the pump prime solution until after the loading dose has been safely administered. Hypotension is the most frequently reported sign of the hypersensitivity reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal dysfunction: Has been linked to serious kidney damage in observational studies. Renal dysfunction (elevations of &gt;0.5 mg/dL over baseline serum creatinine) may occur with use and may increase the need for dialysis in the perioperative period. Patients at greatest risk are those with pre-existing renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute) or those receiving potential nephrotoxins (eg, aminoglycosides). Monitor renal function closely following administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F136386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Aprotinin may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Aprotinin may diminish the therapeutic effect of Thrombolytic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F136389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2540558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F136419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Trasylol Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000 kiu/mL (100 mL): $325.94",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F136391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bleeding times, prothrombin time, activated clotting time, platelet count, red blood cell counts, hematocrit, hemoglobin and fibrinogen degradation products; for toxicity also include renal function tests and blood pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Because aPTT and ACT are difficult to interpret with aprotinin use, the manufacturer recommends two different ways to administer heparin:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     1). Fixed heparin dosing where a standard loading dose of heparin plus the quantity of heparin added to the prime volume of the CPB circuit should total at least 350 units/kg. Additional heparin should be administered based on patient's weight and duration of CPB.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     2). Heparin dosing based upon a protamine titration method. A heparin dose response, assessed by protamine titration, should be performed prior to administration of aprotinin to determine the heparin loading dose.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F136394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antiplasmin effects occur when plasma aprotinin concentrations are 125 KIU/mL and antikallikrein effects occur when plasma levels are 250-500 KIU/mL; it remains unknown if these plasma concentrations are required for clinical benefits to occur during cardiopulmonary bypass;",
"     <b>",
"      Note:",
"     </b>",
"     KIU = Kallikrein inhibitor unit",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     While institutional protocols may vary, a minimal celite ACT of 750 seconds or kaolin-ACT of 480 seconds is recommended in the presence of aprotinin. Consult the manufacturer&rsquo;s information on specific ACT test interpretation in the presence of aprotinin.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F136401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Antagosan (DE, HR);",
"     </li>",
"     <li>",
"      Antikrein (JP);",
"     </li>",
"     <li>",
"      Aprotimbin (HR, KP);",
"     </li>",
"     <li>",
"      Contrycal (EE);",
"     </li>",
"     <li>",
"      Contrykal (DE);",
"     </li>",
"     <li>",
"      Fase (IT);",
"     </li>",
"     <li>",
"      Gordox (HU);",
"     </li>",
"     <li>",
"      Haemoprot (IN);",
"     </li>",
"     <li>",
"      Hetailin (CL);",
"     </li>",
"     <li>",
"      Iniprol (BE, FR, IT, LU);",
"     </li>",
"     <li>",
"      Onquinin (JP);",
"     </li>",
"     <li>",
"      Pantinol (AT);",
"     </li>",
"     <li>",
"      Protosol (IL);",
"     </li>",
"     <li>",
"      Repulson (JP);",
"     </li>",
"     <li>",
"      Rivilina (AR, PE);",
"     </li>",
"     <li>",
"      Traskolan (PL);",
"     </li>",
"     <li>",
"      Trasylol (AE, AT, AU, BE, BG, BH, BR, CH, CN, CO, CY, CZ, DE, DK, EG, FI, FR, GB, GR, HK, HN, HR, ID, IE, IL, IQ, IR, IT, JO, KW, LB, LU, LY, MX, MY, NL, NO, OM, PE, PH, PL, QA, SA, SE, SY, TW, UY, VE, YE, ZA);",
"     </li>",
"     <li>",
"      Trazinine (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F136380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bleeding from CABG surgery is thought to result from a systemic inflammatory response induced by the procedure. Contact of blood cells with the cardiopulmonary bypass (CPB) equipment leads to deregulated activation of the coagulation and fibrinolysis systems, with concurrent upregulation of proinflammatory cytokines. Aprotinin is a broad spectrum serine protease inhibitor that attenuates the coagulation, fibrinolytic and inflammatory pathways by interfering with the chemical mediators (thrombin, plasmin, kallikrein). Additionally, it protects platelet-expressed glycoproteins from mechanical shear forces. This preserves normal hemostatic activity through protease receptor-independent mechanisms (eg, via ADP, IIb/IIIa), while blocking CPB-induced thrombin-mediated aggregation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F136398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Extracellular space; renal phagolysosomes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Aprotinin is slowly degraded by lysosomal enzymes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2.5 hours (plasma); terminal: 10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (25% to 40%; &lt;10% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bidstrup BP, Royston D, Sapsford RN, et al, &ldquo;Reduction in Blood Loss and Blood Use After Cardiovascular Bypass With High Dose Aprotinin,&rdquo;",
"      <i>",
"       J Thorac Cardiovasc Surg",
"      </i>",
"      , 1989, 97(3):364-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/52/6982/abstract-text/2465457/pubmed\" id=\"2465457\" target=\"_blank\">",
"        2465457",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boldt J, &ldquo;Endothelial-Related Coagulation in Pediatric Surgery,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 1998, 65(6 Suppl):56-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carrel TP, Schwanda M, Vogt P, et al, &ldquo;Aprotinin in Pediatric Cardiac Operations: A Benefit in Complex Malformations and With High-Dose Regimen Only,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 1998, 66(1):153-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/52/6982/abstract-text/9692456/pubmed\" id=\"9692456\" target=\"_blank\">",
"        9692456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cosgrove DM 3d, Heric B, Lytle BW, et al, &ldquo;Aprotinin Therapy for Reoperative Myocardial Revascularization: A Placebo-Controlled Study,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 1992, 54(6):1031-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/52/6982/abstract-text/1280411/pubmed\" id=\"1280411\" target=\"_blank\">",
"        1280411",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Engles L, &ldquo;Review and Application of Serine Protease Inhibition in Coronary Artery Bypass Graft Surgery,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2005, 62(18 Suppl 4):9-14.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fergusson DA, Hebert PC, Mazer CD, et al, &ldquo;A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(22):2319-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/52/6982/abstract-text/18480196/pubmed\" id=\"18480196\" target=\"_blank\">",
"        18480196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hess PJ Jr, &ldquo;Systemic Inflammatory Response to Coronary Artery Bypass Graft Surgery,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2005, 62(18 Suppl 4):6-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Huang H, Ding W, Su Z, et al, &ldquo;Mechanism of the Preserving Effect of Aprotinin on Platelet Function and Its Use in Cardiac Surgery,&rdquo;",
"      <i>",
"       J Thorac Cardiovasc Surg",
"      </i>",
"      , 1993, 106(1):11-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/52/6982/abstract-text/7686594/pubmed\" id=\"7686594\" target=\"_blank\">",
"        7686594",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karkouti K, Cohen MM, McCluskey SA, et al, &ldquo;A Multivariable Model For Predicting The Need For Blood Transfusion In Patients Undergoing First-Time Elective Coronary Bypass Graft Surgery,&rdquo;",
"      <i>",
"       Transfusion",
"      </i>",
"      , 2001, 41(10):1193-1203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/52/6982/abstract-text/11606816/pubmed\" id=\"11606816\" target=\"_blank\">",
"        11606816",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mangano DT, Tudor IC, and Dietzel C (for the Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation), &ldquo;The Risk Associated With Aprotinin in Cardiac Surgery,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(4):353-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/52/6982/abstract-text/16436767/pubmed\" id=\"16436767\" target=\"_blank\">",
"        16436767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mangano DT, Miao Y, Vuylsteke A, et al, &ldquo;Mortality Associated With Aprotinin During 5 Years Following Coronary Artery Bypass Graft Surgery,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2007, 297(5):471-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/52/6982/abstract-text/17284697/pubmed\" id=\"17284697\" target=\"_blank\">",
"        17284697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller BE, Tosone SR, Tam VK, et al, &ldquo;Hematologic and Economic Impact of Aprotinin in Reoperative Pediatric Cardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 1998, 66(2):535-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/52/6982/abstract-text/9725399/pubmed\" id=\"9725399\" target=\"_blank\">",
"        9725399",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Penkoske P, Entwistle LM, Marchak BE, et al, &ldquo;Aprotinin in Children Undergoing Repair of Congenital Heart Defects,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 1995, 60(6 Suppl):529-32.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schulze K, Graeter T, Schaps D, et al, &ldquo;Severe Anaphylactic Shock Due to Repeated Application of Aprotinin in Patients Following Intrathoracic Aortic Replacement,&rdquo;",
"      <i>",
"       Eur J Cardiothorac Surg",
"      </i>",
"      , 1993, 7(9):495-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/52/6982/abstract-text/7692900/pubmed\" id=\"7692900\" target=\"_blank\">",
"        7692900",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spray TL, &ldquo;Use of Aprotinin in Pediatric Organ Transplantation,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 1998, 65(6 Suppl):71-3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verstraete M, &ldquo;Clinical Application of Inhibitors of Fibrinolysis,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1985, 29(3):236-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/52/6982/abstract-text/2580684/pubmed\" id=\"2580684\" target=\"_blank\">",
"        2580684",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Viby-Mogensen J, &ldquo;Interaction of Other Drugs With Muscle Relaxants,&rdquo;",
"      <i>",
"       Semin Anesth",
"      </i>",
"      , 1985, 4:52-64.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Woodman RC and Harker LA, &ldquo;Bleeding Complications Associated With Cardiopulmonary Bypass,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1990, 76(9):1680-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/52/6982/abstract-text/2224118/pubmed\" id=\"2224118\" target=\"_blank\">",
"        2224118",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8875 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-36135ECCB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_52_6982=[""].join("\n");
var outline_f6_52_6982=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708629\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136410\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136450\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136414\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136415\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2550580\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2550581\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136393\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136377\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217104\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136396\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136395\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136448\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136399\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136381\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298768\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136386\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136389\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2540558\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136419\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322997\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136391\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136394\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136401\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136380\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136398\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8875\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8875|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/0/40963?source=related_link\">",
"      Aprotinin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_52_6983="Screening and prevention of gastric cancer";
var content_f6_52_6983=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening and prevention of gastric cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/52/6983/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/52/6983/contributors\">",
"     Annie On On Chan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/52/6983/contributors\">",
"     Benjamin C Y Wong, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/52/6983/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/52/6983/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/52/6983/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/52/6983/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/52/6983/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/52/6983/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/52/6983/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric cancer remains one of the most important malignant diseases with significant geographical, ethnic, and socioeconomic differences in distribution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4661?source=see_link\">",
"     \"Epidemiology of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The value of screening asymptomatic individuals for gastric cancer remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/1\">",
"     1",
"    </a>",
"    ]. Mass screening programs have been implemented in some countries (eg, Japan, Venezuela, and Chile) where there continues to be a high incidence of gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/2\">",
"     2",
"    </a>",
"    ]. By contrast, the relatively low incidence of gastric cancer in other regions (including the United States) makes this strategy costly and unwarranted. Proponents of gastric cancer screening in low risk regions agree that case-finding rather than mass screening is the most appropriate approach for early detection. Case-finding is the testing of patients who have sought health care for disorders that may be unrelated to the chief complaint [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SCREENING PROGRAMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Annual mass screening for gastric cancer has been provided in some countries with a high incidence of gastric cancer (such as Japan, Venezuela, and Chile), with the aim of detecting gastric cancer in its earliest stages when the prognosis is better [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=see_link\">",
"     \"Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening methods and intervals vary in different settings. Population screening for gastric cancer in Japan, for example, is recommended for individuals older than 40 years. Screening has traditionally involved a simple risk interview and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies. The barium studies include the conventional double contrast barium x-ray with photofluorography or the new double contrast barium x-ray with digital radiography. An upper endoscopy is performed if any abnormality is detected. In contrast, gastric cancer screening every two years via either upper gastrointestinal series or upper endoscopy has been recommended in Korea for individuals aged 40 years and older [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective cohort study of 2485 patients with gastric adenocarcinoma in Korea, compared to individuals who underwent annual screening for gastric cancer, the risk of advanced cancer was higher in individuals who underwent screening at four- or five-year intervals (four-year interval OR 2.5, 95% CI 1.4-4.5, five-year interval OR 2.2, 95% CI 1.3-3.7) but not in individuals who underwent screening at two- or three-year intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/8\">",
"     8",
"    </a>",
"    ]. In subgroup analysis, individuals with a family history of gastric cancer and individuals in their 60s were more likely to be diagnosed with a higher stage of gastric cancer if upper endoscopies were performed every three years as compared to annually (family history of gastric cancer OR 2.68, 95% CI 1.3-5.7, gastric cancer in 60s OR 2.09, 95% CI 1.0-4.3). These data suggest that in areas with high incidence of gastric cancer, screening every two years is appropriate for individuals over the age of 60 and for those with a family history of gastric cancer, while screening every three years may be an acceptable alternative to annual screening for other individuals. However, more studies are needed to confirm these findings.",
"   </p>",
"   <p>",
"    Serum pepsinogen tests were introduced for mass screening to identify individuals with atrophic gastritis who are at high risk for gastric cancer. Inflammation from gastritis leads to elevated serum concentrations of pepsinogen I and pepsinogen II. However, as the severity of atrophy advances, chief cells are replaced by pyloric glands and the concentration of pepsinogen II remains elevated, while the concentration of pepsinogen I decreases. Patients with extensive atrophic gastritis, as suggested by low serum pepsinogen I concentrations and low serum pepsinogen",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    ratios, can then be offered screening with upper endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31205?source=see_link&amp;anchor=H7#H7\">",
"     \"Classification and diagnosis of gastritis and gastropathy\", section on 'Serum pepsinogen isoenzymes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relatively few studies have compared the efficacy of the various screening methods. A systematic review evaluated four screening methods (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    x-ray study, endoscopy, serum pepsinogen testing, and H. pylori antibody testing) for detecting patients at increased risk of gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The study was commissioned by the Japanese Ministry of Health for creating guidelines for gastric cancer screening. The study focused on a total of 59 studies, only 10 of which were considered to have directly addressed the key questions. The authors found the highest level of evidence for detection of cancer and reduction of mortality for screening programs involving barium x-ray study. Sensitivity ranged from 60 to 80 percent and specificity from 80 to 90 percent. The five-year survival rates were 74 to 80 percent in the screened group versus 46 to 56 percent for the non-screened group.",
"   </p>",
"   <p>",
"    The sensitivity of endoscopy was 78 percent, but no data on specificity were available. In addition, the details of the adverse effects associated with endoscopic screening programs were unclear. The sensitivity of the serum pepsinogen test ranged from 40 to 80 percent, but the specificity was below 80 percent. The sensitivity of H. pylori antibody testing was 88 percent but specificity was only 41 percent. The authors concluded that gastric cancer screening in Japan should be performed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    x-ray study. Importantly, the extent to which the improved survival with screening could have been due to lead time bias is uncertain.",
"   </p>",
"   <p>",
"    Serum trefoil factor 3 (TFF3), a small stable molecule expressed in the goblet cells of the small and large intestine and in gastric intestinal metaplasia, may be a better marker for gastric cancer than serum pepsinogen. In one study, the sensitivity and specificity for detection of gastric cancer were both 81 percent with TFF3 compared to 45 and 88 percent for pepsinogen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/12\">",
"     12",
"    </a>",
"    ]. The combination of pepsinogen and TFF3 may provide even higher sensitivity for gastric cancer. However, prospective studies are needed to compare the performance of TFF3 with endoscopy and to confirm its diagnostic utility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative effectiveness of various screening programs is unsettled [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. An effective screening program should have the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The disease should be common in the population, otherwise the individual benefit will not offset the risk, cost, and inconvenience of screening the rest of the population",
"     </li>",
"     <li>",
"      The diagnostic test(s) used should be safe, simple, inexpensive, and reliable",
"     </li>",
"     <li>",
"      Effective treatment should be available",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most data on the effectiveness of screening come from the experience in Japan. The mass screening in Japan fulfilled the first two criteria and is generally considered to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/13\">",
"     13",
"    </a>",
"    ]. However, whether the third criterion is fulfilled remains unclear. That is, does the detection of early gastric cancer indeed provide survival benefits for these patients? There are no definitive data from large controlled trials, although uncontrolled studies suggest that the screening system has contributed to detection of cancer in early stages and an overall decline in gastric cancer mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/4,14-18\">",
"     4,14-18",
"    </a>",
"    ]. However, lead time bias, length bias, and selection bias must be considered when appraising the overall effectiveness of the screening program.",
"   </p>",
"   <p>",
"    Observational studies evaluating the effectiveness of screening may in particular suffer from selection bias. Individuals taking part in screening programs are generally healthier than those who do not. A prospective study of the Japanese screening program demonstrated that a large reduction in risk of gastric cancer mortality was observed in men who underwent screening when no consideration was taken for potential health selection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the benefit of screening accounted for only 8 percent of the benefit on gastric cancer mortality after adjusting for known confounding factors (particularly the overall general health of participants). In women, the mortality benefit could be explained entirely be selection of relatively healthy women for screening.",
"   </p>",
"   <p>",
"    There are also reports from Japan suggesting that the screening program is having only a limited benefit. A report from the Japanese Ministry of Health estimated that 40 percent of gastric cancers remain undetected [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/19\">",
"     19",
"    </a>",
"    ]. A decrease in gastric cancer mortality was not demonstrated in a cohort study, although the sample size may have been too small to detect a benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost-effectiveness of gastric cancer screening depends mainly upon the incidence of gastric cancer and the cost of screening endoscopy. A cost-effectiveness analysis found that in a high-risk group of Chinese men ages 50 to 70 years (in whom the age standardized incidence of gastric cancer is 25.9 per 100,000 population), screening was highly cost-effective ($28,836 per quality-adjusted life years saved) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/21\">",
"     21",
"    </a>",
"    ]. By contrast, averting one gastric cancer death in men in the United States would cost approximately $247,600 (assuming an incidence of gastric cancer of &lt;10 per 100,000 population). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=see_link\">",
"     \"A short primer on cost-effectiveness analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Primary prevention with H. pylori eradication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recognition of H. pylori as a gastric carcinogen has provided the opportunity to institute strategies aimed at primary prevention through its eradication. Emerging data point toward the effectiveness of such approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Some of the most direct evidence was provided in a controlled trial from China in which 1630 healthy carriers of H. pylori infection were randomly assigned to H. pylori eradication or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/24\">",
"     24",
"    </a>",
"    ]. Prior to randomization, patients were evaluated for precancerous lesions such as gastric atrophy, intestinal metaplasia, or gastric dysplasia. These features were absent in 988 of study participants. Eighteen cancers were observed during follow-up of approximately 7.5 years. While there was no significant difference in cancer incidence overall, the risk was significantly reduced in patients without precancerous lesions at baseline.",
"   </p>",
"   <p>",
"    The greater benefit observed in the population without a precursor lesions suggests that the magnitude of benefit from H. pylori eradication may not be sufficient to overcome the increased risk from injury that has already occurred or that the initial steps toward development of cancer that could be mitigated by H. pylori eradication are irreversible. Whether H. pylori eradication therapy can reverse or reduce the risk that precursor lesions will progress is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/25-32\">",
"     25-32",
"    </a>",
"    ]. It is also possible that a benefit would have been detected with longer follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Screening recommendations for specific groups of patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus has not been achieved on screening recommendations for many conditions that predispose to gastric cancer. However, some form of screening has been proposed in several subgroups of patients in whom the risk of gastric cancer is particularly increased [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/33\">",
"     33",
"    </a>",
"    ]. These include elderly patients with atrophic gastritis or pernicious anemia, those who have undergone partial gastrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], those with a sporadic gastric adenoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/36\">",
"     36",
"    </a>",
"    ], immigrant ethnic populations from countries with high rates of gastric cancer (",
"    <a class=\"graphic graphic_table graphicRef60151 \" href=\"UTD.htm?34/54/35692\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/34-43\">",
"     34-43",
"    </a>",
"    ], and patients with familial adenomatous polyposis or hereditary nonpolyposis colorectal cancer (particularly if gastric cancer has occurred in the kindred) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=see_link\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optimal methods and intervals for screening and the risks and benefits of screening in these populations have not been clearly established and recommendations from various groups differ (eg, some groups recommend screening patients with partial gastrectomies, whereas others do not). One set of guidelines issued in 2006 by the American Society for Gastrointestinal Endoscopy suggests the following [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6983/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2859228\">",
"    <span class=\"h3\">",
"     Gastric epithelial polyps",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adenomatous gastric polyps are at increased risk for malignant transformation and should be resected completely. Hyperplastic polyps have a rare malignant potential. Endoscopic polyp appearance cannot differentiate histologic subtypes; therefore, biopsy or polypectomy is recommended when a polyp is encountered.",
"     </li>",
"     <li>",
"      Polypoid defects of any size detected radiographically should be evaluated endoscopically, with biopsy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      removal of the lesions.",
"     </li>",
"     <li>",
"      Polyps should be endoscopically excised whenever feasible and clinically appropriate. If endoscopic polypectomy is not possible, a biopsy of the polyps should be performed, and if adenomatous or dysplastic tissue is detected, referral for surgical resection should be considered. If representative biopsy samples are obtained and the polyp is nondysplastic, no further intervention is necessary. If it is felt that endoscopic biopsy cannot sufficiently exclude the presence of dysplastic elements, referral for surgical resection is reasonable in polyps that cannot be removed endoscopically.",
"     </li>",
"     <li>",
"      When multiple gastric polyps are encountered, a biopsy of the largest polyps should be performed or they should be excised, and representative biopsy specimens should be taken from some others. Further management should be based on histologic results.",
"     </li>",
"     <li>",
"      Surveillance endoscopy one year after removing adenomatous gastric polyps is reasonable to assess recurrence at the prior excision site, new or previously missed polyps,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      supervening early carcinoma. If the results of this examination are negative, repeat surveillance endoscopy should be repeated no more frequently than at three- to five-year intervals. Follow-up after resection of polyps with high-grade dysplasia and early gastric cancer should be individualized.",
"     </li>",
"     <li>",
"      No surveillance endoscopy is necessary after adequate sampling or removal of nondysplastic gastric polyps.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2859236\">",
"    <span class=\"h3\">",
"     Gastric metaplasia and dysplasia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopic surveillance for gastric intestinal metaplasia has not been extensively studied in the United States and therefore cannot be uniformly recommended.",
"     </li>",
"     <li>",
"      Patients (with gastric metaplasia or dysplasia who are) at increased risk for gastric cancer due to ethnic background or family history may benefit from surveillance.",
"     </li>",
"     <li>",
"      Endoscopic surveillance should incorporate a topographic mapping of the entire stomach.",
"     </li>",
"     <li>",
"      Patients with confirmed high-grade dysplasia are at significant risk for progressing to cancer and should be considered for gastrectomy or local (eg, endoscopic) resection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2859243\">",
"    <span class=\"h3\">",
"     Pernicious anemia and gastric carcinoid tumors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single endoscopy should be considered to identify prevalent lesions (gastric cancer, carcinoid tumors) in patients with pernicious anemia, but there are insufficient data to support routine subsequent endoscopic surveillance for these patients.",
"     </li>",
"     <li>",
"      Surveillance of carcinoid tumors is controversial and should be individualized to the patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2859250\">",
"    <span class=\"h3\">",
"     Postgastric surgery",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are insufficient data to support routine endoscopic surveillance for patients with previous partial gastrectomy for peptic ulcer disease.",
"     </li>",
"     <li>",
"      Because gastric surgeries are performed for peptic ulcer disease, an index endoscopy should be performed to establish the presence of H. pylori infection, chronic gastritis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intestinal metaplasia.",
"     </li>",
"     <li>",
"      If surveillance is considered, it should be initiated after an interval of 15 to 20 years. Multiple biopsies from the anastomosis and gastric remnant should be taken. The threshold should be low to endoscopically evaluate upper gastrointestinal symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2859257\">",
"    <span class=\"h3\">",
"     Familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer (Lynch syndrome)",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with familial adenomatous polyposis (FAP) should undergo upper endoscopy with both end-viewing and side-viewing instruments. The optimal timing of initial upper endoscopy is unknown, but could be performed around the time the patient is considered for colectomy, or early in the third decade of life. If no adenomas are detected, another exam should be performed in five years because adenomatous change may occur later in the course of disease.",
"     </li>",
"     <li>",
"      Biopsies of gastric polyps in patients with FAP may be performed to confirm they are fundic gland polyps and to assess for dysplasia. Antral polyps are usually adenomas and should be resected.",
"     </li>",
"     <li>",
"      Patients with hereditary nonpolyposis colorectal cancer (HNPCC) are at increased risk for the development of gastric and small-bowel cancer. Although there are insufficient data to show a benefit for upper endoscopic surveillance in patients with HNPCC, endoscopic surveillance should be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine screening for gastric cancer is not recommended outside of a few countries with a high gastric cancer burden that have already implemented screening programs. The effectiveness of these programs is unclear. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Screening programs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Eradication of H. pylori has the potential to reduce the burden of gastric cancer, but the ideal means to implement a screening and prevention program and settings in which it would be appropriate remain unclear. Large scale studies are urgently needed to clarify the targeted population and cost effectiveness of mass screening of H. pylori and the subsequent eradication strategy in different populations with different gastric cancer incidences. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Primary prevention with H. pylori eradication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In populations with a low gastric cancer burden, the decision to recommend a screening program should be made on an individual patient basis. Periodic upper endoscopy (possibly with specialized techniques such as chromoendoscopy or magnification endoscopy) can be offered to patients who are considered to be at increased risk (",
"      <a class=\"graphic graphic_table graphicRef60151 \" href=\"UTD.htm?34/54/35692\">",
"       table 1",
"      </a>",
"      ), although the benefits and risks of such an approach are unclear. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Screening recommendations for specific groups of patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The intensity of screening should be based upon an appraisal of the magnitude of risk in each patient, their suitability for treatment should a lesion be detected, and their willingness to accept the uncertain benefits and risks of a screening program. Patients should be counseled appropriately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/38/618?source=see_link\">",
"       \"Risk factors for gastric cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/1\">",
"      Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008; 9:279.",
"     </a>",
"    </li>",
"    <li>",
"     Journal of health and welfare statistic. Tokyo: Statistics and Information Department, Minister Secretariat, Ministry of Health and Welfare, 1996; 43:51 (in Japanese).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/3\">",
"      Sackett DL, Holland WW. Controversy in the detection of disease. Lancet 1975; 2:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/4\">",
"      Mizoue T, Yoshimura T, Tokui N, et al. Prospective study of screening for stomach cancer in Japan. Int J Cancer 2003; 106:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/5\">",
"      Llorens P. Gastric cancer mass survey in Chile. Semin Surg Oncol 1991; 7:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/6\">",
"      Pisani P, Oliver WE, Parkin DM, et al. Case-control study of gastric cancer screening in Venezuela. Br J Cancer 1994; 69:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/7\">",
"      Yoo KY. Cancer control activities in the Republic of Korea. Jpn J Clin Oncol 2008; 38:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/8\">",
"      Nam JH, Choi IJ, Cho SJ, et al. Association of the interval between endoscopies with gastric cancer stage at diagnosis in a region of high prevalence. Cancer 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/9\">",
"      Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006; 9:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/10\">",
"      Hamashima C, Shibuya D, Yamazaki H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008; 38:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/11\">",
"      Hamashima C, Saito H, Nakayama T, et al. The standardized development method of the Japanese guidelines for cancer screening. Jpn J Clin Oncol 2008; 38:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/12\">",
"      Aikou S, Ohmoto Y, Gunji T, et al. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening. Gastroenterology 2011; 141:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/13\">",
"      Murakami R, Tsukuma H, Ubukata T, et al. Estimation of validity of mass screening program for gastric cancer in Osaka, Japan. Cancer 1990; 65:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/14\">",
"      Hisamichi S, Sugawara N, Fukao A. Effectiveness of gastric mass screening in Japan. Cancer Detect Prev 1988; 11:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/15\">",
"      Fukao A, Tsubono Y, Tsuji I, et al. The evaluation of screening for gastric cancer in Miyagi Prefecture, Japan: a population-based case-control study. Int J Cancer 1995; 60:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/16\">",
"      Oshima A, Hirata N, Ubukata T, et al. Evaluation of a mass screening program for stomach cancer with a case-control study design. Int J Cancer 1986; 38:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/17\">",
"      Tsuji I, Fukao A, Sugawara N, et al. Cost-effectiveness analysis of screening for gastric cancer in Japan. Tohoku J Exp Med 1991; 164:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/18\">",
"      Kunisaki C, Ishino J, Nakajima S, et al. Outcomes of mass screening for gastric carcinoma. Ann Surg Oncol 2006; 13:221.",
"     </a>",
"    </li>",
"    <li>",
"     Report of the Research Group for Evaluation of Effectiveness of Cancer Screening in Japan. Tokyo: Japan Public Health Association 1998 (in Japanese).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/20\">",
"      Inaba S, Hirayama H, Nagata C, et al. Evaluation of a screening program on reduction of gastric cancer mortality in Japan: preliminary results from a cohort study. Prev Med 1999; 29:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/21\">",
"      Dan YY, So JB, Yeoh KG. Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol 2006; 4:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/22\">",
"      Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997; 6:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/23\">",
"      Saito K, Arai K, Mori M, et al. Effect of Helicobacter pylori eradication on malignant transformation of gastric adenoma. Gastrointest Endosc 2000; 52:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/24\">",
"      Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/25\">",
"      de Jong D, van Dijk WC, van der Hulst RW, et al. CagA+ H. pylori strains and gastric lymphoma. Gastroenterology 1997; 113:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/26\">",
"      Forbes GM, Warren JR, Glaser ME, et al. Long-term follow-up of gastric histology after Helicobacter pylori eradication. J Gastroenterol Hepatol 1996; 11:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/27\">",
"      Annibale B, Aprile MR, D'ambra G, et al. Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia. Aliment Pharmacol Ther 2000; 14:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/28\">",
"      Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst 2000; 92:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/29\">",
"      Ohkusa T, Fujiki K, Takashimizu I, et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med 2001; 134:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/30\">",
"      Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000; 119:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/31\">",
"      Kokkola A, Sipponen P, Rautelin H, et al. The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia. Aliment Pharmacol Ther 2002; 16:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/32\">",
"      Ito M, Haruma K, Kamada T, et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 2002; 16:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/33\">",
"      Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006; 63:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/34\">",
"      Lundeg&aring;rdh G, Adami HO, Helmick C, et al. Stomach cancer after partial gastrectomy for benign ulcer disease. N Engl J Med 1988; 319:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/35\">",
"      Tersmette AC, Goodman SN, Offerhaus GJ, et al. Multivariate analysis of the risk of stomach cancer after ulcer surgery in an Amsterdam cohort of postgastrectomy patients. Am J Epidemiol 1991; 134:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/36\">",
"      MING SC, GOLDMAN H. GASTRIC POLYPS; A HISTOGENETIC CLASSIFICATION AND ITS RELATION TO CARCINOMA. Cancer 1965; 18:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/37\">",
"      Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998; 114:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/38\">",
"      Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004; 109:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/39\">",
"      Kokkola A, Sj&ouml;blom SM, Haapiainen R, et al. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol 1998; 33:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/40\">",
"      Alexander JR, Andrews JM, Buchi KN, et al. High prevalence of adenomatous polyps of the duodenal papilla in familial adenomatous polyposis. Dig Dis Sci 1989; 34:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/41\">",
"      Aarnio M, Salovaara R, Aaltonen LA, et al. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer 1997; 74:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/42\">",
"      Yatsuya H, Toyoshima H, Tamakoshi A, et al. Individual and joint impact of family history and Helicobacter pylori infection on the risk of stomach cancer: a nested case-control study. Br J Cancer 2004; 91:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/43\">",
"      Chen MJ, Wu DC, Ko YC, Chiou YY. Personal history and family history as a predictor of gastric cardiac adenocarcinoma risk: a case-control study in Taiwan. Am J Gastroenterol 2004; 99:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6983/abstract/44\">",
"      Boeing H. Epidemiological research in stomach cancer: progress over the last ten years. J Cancer Res Clin Oncol 1991; 117:133.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2618 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-110.137.129.113-C8D6F1E5A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_52_6983=[""].join("\n");
var outline_f6_52_6983=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SCREENING PROGRAMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Primary prevention with H. pylori eradication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Screening recommendations for specific groups of patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2859228\">",
"      - Gastric epithelial polyps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2859236\">",
"      - Gastric metaplasia and dysplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2859243\">",
"      - Pernicious anemia and gastric carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2859250\">",
"      - Postgastric surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2859257\">",
"      - Familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer (Lynch syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2618\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2618|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/54/35692\" title=\"table 1\">",
"      Risk factors and proposed screening recs for gastric cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=related_link\">",
"      A short primer on cost-effectiveness analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31205?source=related_link\">",
"      Classification and diagnosis of gastritis and gastropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=related_link\">",
"      Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4661?source=related_link\">",
"      Epidemiology of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=related_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=related_link\">",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/618?source=related_link\">",
"      Risk factors for gastric cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_52_6984="Management of the child and adolescent with chronic abdominal pain";
var content_f6_52_6984=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of the child and adolescent with chronic abdominal pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/52/6984/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/52/6984/contributors\">",
"     Mariam R Chacko, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/52/6984/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/52/6984/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/52/6984/contributors\">",
"     George D Ferry, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/52/6984/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/52/6984/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/52/6984/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/52/6984/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic and recurrent abdominal pain are common symptoms in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/1\">",
"     1",
"    </a>",
"    ]. The management of children and adolescents with recurrent abdominal pain is reviewed here. An overview of the evaluation of the child with chronic abdominal pain is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=see_link\">",
"     \"Evaluation of the child and adolescent with chronic abdominal pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79257292\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic abdominal pain is defined by pain of at least three months duration, although some clinicians consider pain of more than one to two months duration to be chronic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Recurrent abdominal pain is defined by more than three episodes of pain that are sufficiently severe to affect activity and that occur over the course of at least three months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overlap between chronic and recurrent abdominal pain exists, and the terms are sometimes used synonymously. The 2005 American Academy of Pediatrics (AAP) and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) guidelines for the evaluation and treatment of children with chronic abdominal pain recommend that the term \"recurrent abdominal pain\" should not be used as a synonym for functional, psychological, or stress-related abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/2\">",
"     2",
"    </a>",
"    ]. Functional abdominal pain, which is the most common cause of chronic abdominal pain, is a specific diagnosis that must be distinguished from other causes of abdominal pain (eg, anatomic, infectious, inflammatory, metabolic) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=see_link&amp;anchor=H12#H12\">",
"     \"Evaluation of the child and adolescent with chronic abdominal pain\", section on 'Functional disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79257661\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic abdominal pain is best treated in the context of a biopsychosocial model of care [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/2\">",
"     2",
"    </a>",
"    ]. In a survey, families whose child was seen in an abdominal pain clinic with an integrative treatment approach incorporating a biopsychosocial evaluation into clinical care reported higher rates of satisfaction with the evaluation process and higher receptivity to beginning treatments than families whose child was seen in a traditional gastroenterology clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/4\">",
"     4",
"    </a>",
"    ]. The primary goal is return to normal function [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]; relief of symptoms is a secondary goal. Return to normal function is facilitated by reinforcement of non-pain behaviors (eg, return to school). The avoidance of reinforcement of pain behaviors (eg, by providing attention, rest, special treatment, distraction, or medication) is equally important [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Triggers for pain and reinforcement for pain behavior should be identified, clarified, and eliminated if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Education of the family is an important aspect of the treatment program. Cognitive-behavioral therapy may be useful in improving pain and disability in the short-term [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/3,8,9\">",
"     3,8,9",
"    </a>",
"    ]. Evidence regarding the benefit of treatment with H2 receptor agonists, supplemental fiber, or a lactose-free diet is inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/3\">",
"     3",
"    </a>",
"    ]. Nonetheless, a time-limited trial of such therapies may be warranted in selected patients. The recommendations that follow are generally consistent with those outlined in the 2005 American Academy of Pediatrics (AAP) and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) guidelines for the evaluation and treatment of children with chronic abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/2\">",
"     2",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The management of children and adolescents with chronic, recurrent abdominal pain requires a balanced and efficient approach. As a general rule, empiric treatment should be initiated after the initial evaluation because response to empiric therapy is part of the diagnostic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/1\">",
"     1",
"    </a>",
"    ]. The patient and family should be informed that the evaluation, particularly in cases with a long history of pain, will take at least two to three office visits. In addition, documenting pain in a \"pain diary\" is useful for evaluation and management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Therapeutic relationship",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most important components of treatment is the establishment of a therapeutic clinician-patient (or clinician-family) relationship. The clinician should express his or her confidence that the pain is real and serious enough to have affected important activities in the",
"    <span class=\"nowrap\">",
"     child's/adolescent's",
"    </span>",
"    life. This is also a good time to elicit the parent's perspective of cause(s) for the pain and allay any unfounded fears of a life-threatening disease. The patient and family should be assured that the clinician will search for identifiable causes, initiate a treatment plan, and continue to follow the patient on a regular basis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/10\">",
"     10",
"    </a>",
"    ]. Periodic follow-up validates the clinician's continued support and interest in the",
"    <span class=\"nowrap\">",
"     child/adolescent",
"    </span>",
"    and family.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient and family education is an important part of the management of the child and adolescent with chronic abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/2\">",
"     2",
"    </a>",
"    ]. The differential diagnosis, including functional abdominal pain, should be reviewed with the patient and family after completion of the initial history and physical examination. The possible association between stress and pain should be mentioned, whether or not an organic cause is suspected. Patients who have chronic pain, regardless of the etiology, can be depressed or anxious from the experience [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/11\">",
"     11",
"    </a>",
"    ]. Having a concrete example of how stress can directly cause abdominal discomfort (ie, churning of the stomach or headache before a test) may help them to understand this relationship.",
"   </p>",
"   <p>",
"    Additional evaluation for possible organic etiologies should be discussed and arranged if indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=see_link\">",
"     \"Evaluation of the child and adolescent with chronic abdominal pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, if the clinician is confident that no serious organic cause of pain exists, a positive diagnosis of functional pain should be made and the patient and family should be informed regarding the benign nature of the condition [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/5\">",
"     5",
"    </a>",
"    ]. Discussion of the proposed mechanisms for functional disorders (eg, visceral hyperalgesia, reduced pain threshold, or impaired gastric relaxation response to meals) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/12,13\">",
"     12,13",
"    </a>",
"    ] helps to validate the patient's pain and sets the basis for therapeutic interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients and families are more willing than are others to accept the role of psychologic factors or negative life events in the pathogenesis of pain. The family's ability to accept such a biopsychosocial model of pain may be an important factor in the child's recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Families who are less willing to accept a biopsychosocial model may continue to focus on the search for an organic etiology despite a thorough evaluation with normal results. Pediatric health care providers may feel pressured to pursue further or conduct invasive laboratory testing in these children and adolescents. However, the performance of continued and repeated laboratory procedures to seek an organic etiology does not alleviate the child's or adolescent's pain.",
"   </p>",
"   <p>",
"    Families that seem reluctant to accept a psychologic role for the pain can be helped if the provider is able to foster an alliance with them. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Therapeutic relationship'",
"    </a>",
"    above.) The provider must make clear to the parents that he or she understands their desire to relieve their child's or adolescent's pain; any discussion that suggests to the family that the provider believes \"nothing is wrong\" with their child may alienate the family. Asking how the child's or adolescent's illness affects the family is helpful. The child's or adolescent's pain may have become a focal point of the family's life, creating stress for other members. The pediatric care provider can address these effects by prescribing a return to structured activities of daily living, including school attendance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Return to school",
"    </span>",
"    &nbsp;&mdash;&nbsp;A plan for return to school must be included in the management. Only 1 in 10 children with recurrent abdominal pain attends school regularly, and approximately one-fourth of patients miss more than 1 day in 10 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/6\">",
"     6",
"    </a>",
"    ]. School absenteeism is an added stress for the family (particularly when they are confronted by the school's judicial system) and can interfere with the child or adolescent's school performance and social functioning.",
"   </p>",
"   <p>",
"    Parents who are concerned about their child's emotional reaction to returning to school may need assistance in implementing the plan for return to school. These parents should be encouraged to work with the school to develop a part-time schedule to facilitate the transition. The process of transition back to school may help to disclose previously unknown school or family problems. Home-bound schooling is strongly discouraged unless a rationale involving health and academic performance and needs has been justified between the clinician and the school counselor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RELAXATION TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older children and adolescents can be taught brief muscle relaxation techniques such as deep breathing exercises to be performed at least twice a day [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/15\">",
"     15",
"    </a>",
"    ]. A family member can act as \"coach\" if necessary. The goal is to use nonpharmacologic therapy to help the child or adolescent relax when in pain. In the author's experience, few families are opposed to this recommendation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIETARY CHANGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary changes that have been suggested for children and adolescents with chronic abdominal pain include removing lactose or increasing fiber. High-quality evidence regarding the effectiveness of these interventions is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. However, the following interventions may be helpful in selected children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lactose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence regarding whether a lactose-free diet decreases the frequency of pain attacks for children and adolescents with recurrent abdominal pain is inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. Nonetheless, a trial of a lactose-free diet should be attempted if symptoms are consistent with lactose intolerance (eg, cramping pain, bloating, or gas related to meals and milk). It can be achieved by eliminating milk and milk products or by using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/62/14306?source=see_link\">",
"     lactase",
"    </a>",
"    enzyme replacements (eg, Lactaid",
"    <sup>",
"     &reg;",
"    </sup>",
"    milk or Lactaid",
"    <sup>",
"     &reg;",
"    </sup>",
"    drops). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link&amp;anchor=H17#H17\">",
"     \"Lactose intolerance\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Fiber",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence regarding whether additional fiber intake decreases the frequency of pain attacks for children and adolescents with recurrent abdominal pain is inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/3\">",
"     3",
"    </a>",
"    ]. Nonetheless, a trial of a high-fiber diet may result in improvement of symptoms in some children who have constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/6,19\">",
"     6,19",
"    </a>",
"    ], particularly those who have hard stools or who have constipation as a component of irritable bowel syndrome (IBS). The proposed mechanisms of action include enhancement of water-holding properties of the stool, formation of gels to provide lubrication, bulking of the stool, and binding of agents such as bile [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, a high-fiber diet may aggravate pain in children who have long-standing constipation as a result of withholding stools (most children), which leads to decreased contractile tone and a dilated rectum. The addition of fiber to the diets of these children increases stool bulk, causing greater distension of the rectum and colon. In addition, some children may experience increased bloating and gaseousness caused by colonic metabolism of nondigestible fiber.",
"   </p>",
"   <p>",
"    High-fiber foods include fruit juices (prune, apple, or pear), high-fiber cereals, raw vegetables, salads, and bran-containing breads. High-fiber cookies, granola bars, crackers, homemade trail mix (raisin bran cereal, dried fruit, and nuts), and fruit salad may be more acceptable to children and adolescents. Metamucil can be mixed with a flavored milkshake [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/21\">",
"     21",
"    </a>",
"    ]. Young children should drink at least two to four glasses of water per day, and adolescents should drink at least six glasses of water per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoidance of foods, beverages, and medications that can aggravate dyspepsia symptoms (eg, high-fat foods, caffeinated beverages, and nonsteroidal antiinflammatory drugs [NSAIDs]) may be helpful in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exclusion of foods that increase flatulence (beans, onions, celery, carrots, raisins, bananas, apricots, prunes, Brussels sprouts, wheat germ, pretzels, and bagels) should be considered in patients who complain of gas [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/22\">",
"     22",
"    </a>",
"    ]. Underlying visceral hyperalgesia in children and adolescents with functional abdominal pain may explain the exaggerated discomfort experienced with consumption of gas-producing foods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12697?source=see_link\">",
"     \"Pathophysiology of irritable bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with dietary interventions, the use of medications in children and adolescents with recurrent abdominal pain have not been well studied [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/3,16,23\">",
"     3,16,23",
"    </a>",
"    ]. Thus, medications should be used as part of an overall treatment plan and should be directed at triggers for pain (eg, gastric acidity, constipation, altered motility) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An enema or suppository may be the first step in the treatment of children and adolescents with severe constipation. It then can be followed by a stool softener (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/24/39299?source=see_link\">",
"       lactulose",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/28/20931?source=see_link\">",
"       mineral oil",
"      </a>",
"      ) and a stimulant medication (eg, milk of Magnesia or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/1/42003?source=see_link\">",
"       senna",
"      </a>",
"      ) to evacuate the bowel completely [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36298?source=see_link\">",
"       \"Treatment of chronic functional constipation and fecal incontinence in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A trial of an H2-blocker (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/58/43943?source=see_link\">",
"       cimetidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/1/33815?source=see_link\">",
"       ranitidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38885?source=see_link\">",
"       nizatidine",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/61/29655?source=see_link\">",
"       famotidine",
"      </a>",
"      ) or a proton pump inhibitor (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/53/2904?source=see_link\">",
"       lansoprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/38/21095?source=see_link\">",
"       esomeprazole",
"      </a>",
"      ) for four to six weeks is recommended if peptic ulcer disease is suspected.",
"     </li>",
"     <li>",
"      Antispasmodic medications typically are not recommended as first-line treatment in children and adolescents with chronic abdominal pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84830021\">",
"    <span class=\"h1\">",
"     PSYCHOSOCIAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A referral to a behavioral pediatrician for younger children or an adolescent medicine specialist for a teenager can be helpful in the management of chronic abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/3,15\">",
"     3,15",
"    </a>",
"    ]. These specialists can provide strategies for empathy, encouragement, and return to activities of daily living without allowing ongoing pain-induced disability [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=see_link\">",
"     \"Overview of psychotherapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In randomized and observational studies, cognitive-behavioral treatment and relaxation therapy help to reduce pain and improve function [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/8,24-31\">",
"     8,24-31",
"    </a>",
"    ]. As an example, in one prospective study, 64 children and adolescents with functional abdominal pain were randomly assigned to four groups: fiber only (control); fiber and biofeedback; fiber, biofeedback, and cognitive-behavioral interventions; and biofeedback, cognitive-behavioral interventions, and parental support [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/24\">",
"     24",
"    </a>",
"    ]. All groups had reduction in self-reported pain after intervention. However, pain reduction was greatest among the active treatment groups (79 versus 93 to 100 percent).",
"   </p>",
"   <p>",
"    Behavioral treatments may be considered for motivated patients who associate symptoms with stressors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/32\">",
"     32",
"    </a>",
"    ]. In randomized and observational studies, hypnosis, guided imagery, biofeedback, and psychotherapy help to reduce anxiety levels, encourage health-promoting behavior, increase patient responsibility and involvement in the treatment, and improve tolerance of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/15,33-38\">",
"     15,33-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients and families, particularly those who continue to focus on the search for an organic etiology, may be resistant to referral to a therapist or counselor. The pediatric care provider can facilitate referral by explaining to the family his or her own limitations in management without further assistance from a therapist. The provider should discuss the potential benefit to the family from counseling sessions with a therapist who can help the child to cope with the pain and can support the necessary changes in the child's life (eg, return to school).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;A follow-up visit should occur two to four weeks after the initial visit to review laboratory test results, determine patient response to dietary changes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medications, review the pain diary, and glean more information about potential psychosocial triggers. Continued medical follow-up may be necessary for management of constipation, irritable bowel, or peptic ulcer disease. During these visits, the diagnosis may become clear. Further evaluation and therapy can be directed toward continued medical follow-up or referral to a behavioralist, adolescent medicine specialist, gynecologist, gastroenterologist, or other therapist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     REFERRAL INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to an adolescent medicine specialist or a gynecologist is indicated if a gynecological cause is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of endometriosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31125?source=see_link\">",
"     \"Primary dysmenorrhea in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Referral to a gastroenterologist is indicated in several situations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If suspicion of a serious organic condition such as inflammatory bowel disease or an abnormal test result needs clarification. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3288?source=see_link\">",
"       \"Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4650?source=see_link\">",
"       \"Treatment of ulcerative colitis in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If peptic ulcer disease is suspected, preliminary test results are negative, and the pain continues despite treatment with H2-blockers or proton pump inhibitors for at least four to six weeks.",
"     </li>",
"     <li>",
"      If the initial evaluation and treatment approach has not been helpful, obtaining a second opinion from a gastroenterologist may be effective. As an example, if lactose intolerance is suspected, but the pain is not responsive to the initial lactose-free diet, performing a hydrogen breath test may be helpful. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link\">",
"       \"Lactose intolerance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the patient has active or persistent bleeding, weight loss, early satiety with peptic symptoms, loss of appetite, chest pain, or vomiting, endoscopic investigation may be necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients diagnosed with functional pain should be informed of the benign nature of the condition. Progression to organic disease rarely occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/6\">",
"     6",
"    </a>",
"    ]. Pain resolves in 30 to 70 percent of patients by two to eight weeks after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/6,39\">",
"     6,39",
"    </a>",
"    ]. Factors that have been suggested to be associated with worse prognosis include \"painful family,\" male gender, age younger than six years at diagnosis, more than six months' duration of pain before seeking treatment, and high levels of depression and anxiety symptoms and negative life events [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/6,39,40\">",
"     6,39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcome data from long-term follow-up studies of children with recurrent abdominal pain is contradictory. Some case-control studies demonstrate that gastrointestinal symptoms, somatic symptoms, and functional disability (school or work absence) occur more commonly among cases than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. In other studies, psychiatric symptoms and disorders occurred more commonly among cases than controls, but persistent abdominal pain, irritable bowel syndrome, and other somatic complaints did not [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. These studies are limited by the lack of analysis according to etiologic classification because of the lack of availability of necessary diagnostic tests at the time of case identification [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6984/abstract/41,47,48\">",
"     41,47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/40/29315?source=see_link\">",
"       \"Patient information: Chronic abdominal pain in children and adolescents (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic abdominal pain is defined by constant or intermittent pain of at least three months' duration. Recurrent abdominal pain is defined by more than three episodes of pain that are sufficiently severe to affect activity and that occur over the course of at least three months. Most children with chronic abdominal pain have functional disorders (conditions in which the patient has a variable combination of symptoms without any readily identifiable structural or biochemical abnormality). (See",
"      <a class=\"local\" href=\"#H79257292\">",
"       'Terminology'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Chronic abdominal pain is best treated in the context of a biopsychosocial model of care. The primary goal is return to normal function, rather than complete elimination of pain. Education of the family is an important aspect of the treatment program. Establishing a therapeutic relationship, patient and family education, and a plan for return to school are important components of the treatment of chronic abdominal pain in children. (See",
"      <a class=\"local\" href=\"#H79257661\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment for children and adolescents with chronic abdominal pain may include relaxation techniques,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dietary changes. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Relaxation techniques'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Dietary changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medications should be used as part of an overall treatment plan and should be directed at triggers for pain (eg, gastric acidity, constipation, altered motility). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cognitive behavioral therapy and other behavioral therapies may be helpful for motivated patients. (See",
"      <a class=\"local\" href=\"#H84830021\">",
"       'Psychosocial therapies'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Indications for referral to a gastroenterologist include suspicion of a serious organic condition (eg, active or persistent bleeding, weight loss, early satiety with peptic symptoms, loss of appetite, persistent chest pain or vomiting) and failure to improve with medical therapy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Referral indications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/1\">",
"      Lake AM. Chronic abdominal pain in childhood: diagnosis and management. Am Fam Physician 1999; 59:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/2\">",
"      American Academy of Pediatrics Subcommittee on Chronic Abdominal Pain. Chronic abdominal pain in children. Pediatrics 2005; 115:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/3\">",
"      American Academy of Pediatrics Subcommittee on Chronic Abdominal Pain, North American Society for Pediatric Gastroenterology Hepatology, and Nutrition. Chronic abdominal pain in children. Pediatrics 2005; 115:e370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/4\">",
"      Schurman JV, Friesen CA. Integrative treatment approaches: family satisfaction with a multidisciplinary paediatric Abdominal Pain Clinic. Int J Integr Care 2010; 10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/5\">",
"      Boyle JT, Hamel-Lambert J. Biopsychosocial issues in functional abdominal pain. Pediatr Ann 2001; 30:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/6\">",
"      Boyle JT. Recurrent abdominal pain: an update. Pediatr Rev 1997; 18:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/7\">",
"      Walker LS, Williams SE, Smith CA, et al. Parent attention versus distraction: impact on symptom complaints by children with and without chronic functional abdominal pain. Pain 2006; 122:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/8\">",
"      Sanders MR, Shepherd RW, Cleghorn G, Woolford H. The treatment of recurrent abdominal pain in children: a controlled comparison of cognitive-behavioral family intervention and standard pediatric care. J Consult Clin Psychol 1994; 62:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/9\">",
"      Sanders MR, Rebgetz M, Morrison M, et al. Cognitive-behavioral treatment of recurrent nonspecific abdominal pain in children: an analysis of generalization, maintenance, and side effects. J Consult Clin Psychol 1989; 57:294.",
"     </a>",
"    </li>",
"    <li>",
"     Palermo TM, Zeltzer LK. Recurrent and chronic pain. In: Developmental-Behavioral Pediatrics, 4th ed, Carey WB, Crocker AC, Coleman WL, et al (Eds), Saunders Elsevier, Philadelphia 2009. p.547.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/11\">",
"      Hyams JS, Hyman PE. Recurrent abdominal pain and the biopsychosocial model of medical practice. J Pediatr 1998; 133:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/12\">",
"      Olafsdottir E, Gilja OH, Aslaksen A, et al. Impaired accommodation of the proximal stomach in children with recurrent abdominal pain. J Pediatr Gastroenterol Nutr 2000; 30:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/13\">",
"      Alfv&eacute;n G. The pressure pain threshold (PPT) of certain muscles in children suffering from recurrent abdominal pain of non-organic origin. An algometric study. Acta Paediatr 1993; 82:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/14\">",
"      Crushell E, Rowland M, Doherty M, et al. Importance of parental conceptual model of illness in severe recurrent abdominal pain. Pediatrics 2003; 112:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/15\">",
"      Banez GA. Chronic abdominal pain in children: what to do following the medical evaluation. Curr Opin Pediatr 2008; 20:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/16\">",
"      Weydert JA, Ball TM, Davis MF. Systematic review of treatments for recurrent abdominal pain. Pediatrics 2003; 111:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/17\">",
"      Huertas-Ceballos AA, Logan S, Bennett C, Macarthur C. Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database Syst Rev 2009; :CD003019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/18\">",
"      Lebenthal E, Rossi TM, Nord KS, Branski D. Recurrent abdominal pain and lactose absorption in children. Pediatrics 1981; 67:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/19\">",
"      Feldman W, McGrath P, Hodgson C, et al. The use of dietary fiber in the management of simple, childhood, idiopathic, recurrent, abdominal pain. Results in a prospective, double-blind, randomized, controlled trial. Am J Dis Child 1985; 139:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/20\">",
"      Friedman G. Diet and the irritable bowel syndrome. Gastroenterol Clin North Am 1991; 20:313.",
"     </a>",
"    </li>",
"    <li>",
"     Dietary Help for Constipation. In: Caring for Your Child's Health, Office of Educational Resources, Texas Children's Hospital, Houston 1992.",
"    </li>",
"    <li>",
"     Hasler WL, Owyang C. Irritable bowel syndrome. In: Textbook of Gastroenterology, 4th ed, Yamada T (Ed), JB Lippincott, Philadelphia 2003. p.1817.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/23\">",
"      Huertas-Ceballos A, Logan S, Bennett C, Macarthur C. Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database Syst Rev 2008; :CD003017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/24\">",
"      Humphreys PA, Gevirtz RN. Treatment of recurrent abdominal pain: components analysis of four treatment protocols. J Pediatr Gastroenterol Nutr 2000; 31:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/25\">",
"      Youssef NN, Rosh JR, Loughran M, et al. Treatment of functional abdominal pain in childhood with cognitive behavioral strategies. J Pediatr Gastroenterol Nutr 2004; 39:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/26\">",
"      Huertas-Ceballos A, Logan S, Bennett C, Macarthur C. Psychosocial interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database Syst Rev 2008; :CD003014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/27\">",
"      Robins PM, Smith SM, Glutting JJ, Bishop CT. A randomized controlled trial of a cognitive-behavioral family intervention for pediatric recurrent abdominal pain. J Pediatr Psychol 2005; 30:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/28\">",
"      Sprenger L, Gerhards F, Goldbeck L. Effects of psychological treatment on recurrent abdominal pain in children - a meta-analysis. Clin Psychol Rev 2011; 31:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/29\">",
"      Palermo TM, Eccleston C, Lewandowski AS, et al. Randomized controlled trials of psychological therapies for management of chronic pain in children and adolescents: an updated meta-analytic review. Pain 2010; 148:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/30\">",
"      Eccleston C, Palermo TM, de C Williams AC, et al. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev 2012; 12:CD003968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/31\">",
"      Levy RL, Langer SL, Walker LS, et al. Twelve-month follow-up of cognitive behavioral therapy for children with functional abdominal pain. JAMA Pediatr 2013; 167:178.",
"     </a>",
"    </li>",
"    <li>",
"     Novey DM, Nelson DV. Psychology of chronic pain. In: Pain Management for the Practicing Physician, Irving GA, Wallace MS (Eds), Churchill Livingstone, New York 1996. p.251.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/33\">",
"      Vlieger AM, Menko-Frankenhuis C, Wolfkamp SC, et al. Hypnotherapy for children with functional abdominal pain or irritable bowel syndrome: a randomized controlled trial. Gastroenterology 2007; 133:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/34\">",
"      Anbar RD. Self-hypnosis for the treatment of functional abdominal pain in childhood. Clin Pediatr (Phila) 2001; 40:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/35\">",
"      Weydert JA, Shapiro DE, Acra SA, et al. Evaluation of guided imagery as treatment for recurrent abdominal pain in children: a randomized controlled trial. BMC Pediatr 2006; 6:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/36\">",
"      van Tilburg MA, Chitkara DK, Palsson OS, et al. Audio-recorded guided imagery treatment reduces functional abdominal pain in children: a pilot study. Pediatrics 2009; 124:e890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/37\">",
"      Vlieger AM, Rutten JM, Govers AM, et al. Long-term follow-up of gut-directed hypnotherapy vs. standard care in children with functional abdominal pain or irritable bowel syndrome. Am J Gastroenterol 2012; 107:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/38\">",
"      Rutten JM, Reitsma JB, Vlieger AM, Benninga MA. Gut-directed hypnotherapy for functional abdominal pain or irritable bowel syndrome in children: a systematic review. Arch Dis Child 2013; 98:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/39\">",
"      Mulvaney S, Lambert EW, Garber J, Walker LS. Trajectories of symptoms and impairment for pediatric patients with functional abdominal pain: a 5-year longitudinal study. J Am Acad Child Adolesc Psychiatry 2006; 45:737.",
"     </a>",
"    </li>",
"    <li>",
"     Apley J. The Child with Abdominal Pains, 2nd, Blackwell Scientific Publications, Oxford 1975.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/41\">",
"      Christensen MF, Mortensen O. Long-term prognosis in children with recurrent abdominal pain. Arch Dis Child 1975; 50:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/42\">",
"      Walker LS, Guite JW, Duke M, et al. Recurrent abdominal pain: a potential precursor of irritable bowel syndrome in adolescents and young adults. J Pediatr 1998; 132:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/43\">",
"      Walker LS, Garber J, Van Slyke DA, Greene JW. Long-term health outcomes in patients with recurrent abdominal pain. J Pediatr Psychol 1995; 20:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/44\">",
"      St&oslash;rdal K, Nygaard EA, Bentsen BS. Recurrent abdominal pain: a five-year follow-up study. Acta Paediatr 2005; 94:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/45\">",
"      Campo JV, Di Lorenzo C, Chiappetta L, et al. Adult outcomes of pediatric recurrent abdominal pain: do they just grow out of it? Pediatrics 2001; 108:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/46\">",
"      Hotopf M, Carr S, Mayou R, et al. Why do children have chronic abdominal pain, and what happens to them when they grow up? Population based cohort study. BMJ 1998; 316:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/47\">",
"      Hyams JS, Hyman PE, Rasquin-Weber A. Childhood recurrent abdominal pain and subsequent adult irritable bowel syndrome. J Dev Behav Pediatr 1999; 20:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6984/abstract/48\">",
"      Apley J, Hale B. Children with recurrent abdominal pain: how do they grow up? Br Med J 1973; 3:7.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 112 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_52_6984=[""].join("\n");
var outline_f6_52_6984=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H79257292\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H79257661\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Therapeutic relationship",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Return to school",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RELAXATION TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIETARY CHANGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lactose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Fiber",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84830021\">",
"      PSYCHOSOCIAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      REFERRAL INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3288?source=related_link\">",
"      Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=related_link\">",
"      Evaluation of the child and adolescent with chronic abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19210?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12697?source=related_link\">",
"      Pathophysiology of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/40/29315?source=related_link\">",
"      Patient information: Chronic abdominal pain in children and adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/25/31125?source=related_link\">",
"      Primary dysmenorrhea in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36298?source=related_link\">",
"      Treatment of chronic functional constipation and fecal incontinence in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4650?source=related_link\">",
"      Treatment of ulcerative colitis in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_52_6985="Criteria for seborrheic keratosis";
var content_f6_52_6985=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    Dermoscopic criteria for seborrheic keratosis: Dermoscopic structures and histopathologic correlation",
"    <sup>",
"     [1-4]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 498px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Argenziano G, Soyer HP, Chimenti S, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679.",
"       </li>",
"       <li>",
"        Braun RP, Rabinovitz HS, Oliviero M, et al. Dermoscopy of pigmented skin lesions. J Am Acad Dermatol 2005; 52:109.",
"       </li>",
"       <li>",
"        Braun RP, Rabinovitz HS, Krischer J, et al. Dermoscopy of pigmented seborrheic keratosis: a morphological study. Arch Dermatol 2002; 138:1556.",
"       </li>",
"       <li>",
"        Scope A, Benvenuto-Andraden C, Agero AL, Marghoob AA. Nonmelanocytic lesions defying the two-step dermoscopy algorithm. Dermatol Surg 2006; 32:1398.",
"       </li>",
"       <li>",
"        Stricklin SM, Stoecker WV, Oliviero MD, et al. Cloudy and starry milia-like cysts: how well do they distinguish seborrheic keratoses from malignant melanomas? J Eur Acad Dermatol Venereol 2011; 25:1222.",
"       </li>",
"      </ol>",
"      <br>",
"       Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_52_6985=[""].join("\n");
var outline_f6_52_6985=null;
var title_f6_52_6986="Age-related macular degeneration: Clinical presentation, etiology, and diagnosis";
var content_f6_52_6986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Age-related macular degeneration: Clinical presentation, etiology, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/52/6986/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/52/6986/contributors\">",
"     Jorge G Arroyo, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/52/6986/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/52/6986/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/52/6986/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/52/6986/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/52/6986/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/52/6986/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual impairment is a major health problem for older adults and has significant impact on functional status and quality of life. Visual impairment limits the ability to safely drive a car and is associated with increased rates for falls and hip fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The growing proportion of older adults in the population underscores the importance of this problem. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3385?source=see_link\">",
"     \"Approach to the evaluation of older drivers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=see_link\">",
"     \"Falls in older persons: Risk factors and patient evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Age-related macular degeneration (AMD) is the leading cause of adult blindness in industrialized countries [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/4\">",
"     4",
"    </a>",
"    ]. Other common causes of visual impairment in older individuals are [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presbyopia",
"     </li>",
"     <li>",
"      Cataract",
"     </li>",
"     <li>",
"      Glaucoma",
"     </li>",
"     <li>",
"      Diabetic retinopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The etiology and diagnosis of AMD will be reviewed here. Treatment for AMD and the other common eye disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26074?source=see_link\">",
"     \"Age-related macular degeneration: Treatment and prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=see_link\">",
"     \"Cataract in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=see_link\">",
"     \"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=see_link\">",
"     \"Prevention and treatment of diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age-related macular degeneration (AMD) is a degenerative disease of the central portion of the retina (the macula) that results primarily in loss of central vision. Central vision is required for activities such as driving, reading, watching television, and performing activities of daily living.",
"   </p>",
"   <p>",
"    AMD is classified as dry (atrophic) or wet (neovascular or exudative) for clinical purposes. Different classifications and grading schemes have been used in epidemiologic and therapeutic studies of AMD. Many epidemiologic studies make a distinction between age-related maculopathy (ARM) and age-related macular degeneration (AMD). All wet lesions are AMD, but early dry lesions that do not reduce vision may be classified as ARM rather than AMD. A further source of confusion is that AMD is often abbreviated as ARMD.",
"   </p>",
"   <p>",
"    Dry AMD progresses to wet AMD in some patients. The risk of developing wet AMD in people with bilateral early dry AMD (bilateral soft drusen) was estimated at 1.0 to 4.7 percent at one year and 13 to 18 percent at three years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dry type AMD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early lesions are more common than later stage disease in dry AMD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/9\">",
"     9",
"    </a>",
"    ]. Findings in dry AMD may include subretinal drusen deposits, focal or more widespread geographic atrophy of the retinal pigment epithelium (RPE), pigment epithelial detachments, and subretinal pigment epithelial clumping (",
"    <a class=\"graphic graphic_picture graphicRef70148 \" href=\"UTD.htm?18/32/18944\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef80193 \" href=\"UTD.htm?13/6/13418\">",
"     figure 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drusen are localized deposits of extracellular material, usually concentrated in the macula, and appear as small, bright yellow objects on ophthalmoscopy (",
"      <a class=\"graphic graphic_picture graphicRef58340 \" href=\"UTD.htm?32/34/33327\">",
"       picture 2",
"      </a>",
"      ). Drusen can be hard, soft, or crystalline and calcific. Larger soft drusen are associated with vision loss. The risk of progression to advanced AMD increases with the size and number of soft drusen.",
"      <br/>",
"      <br/>",
"      A few small, hard drusen are detectable in almost all people over 50 years of age and are a normal consequence of aging [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/10\">",
"       10",
"      </a>",
"      ]. Hard drusen are not associated with significantly increased risk of advanced macular degeneration and its complications [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Focal and geographic areas of retinal pigment epithelium atrophy appear as AMD progresses (",
"      <a class=\"graphic graphic_picture graphicRef79129 \" href=\"UTD.htm?2/36/2625\">",
"       picture 3",
"      </a>",
"      ). These areas represent thinning and loss of tissue in a focal or more geographic pattern in the macula. Depending upon the location of the RPE atrophy, central vision or pericentral vision may be affected.",
"      <br/>",
"      <br/>",
"      Advanced dry type AMD, also referred to as geographic atrophy, is characterized by cell death in adjacent areas of the retinal pigment epithelium and photoreceptors. It accounts for about 10 percent of legal blindness related to AMD [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Wet type AMD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The finding of either large soft drusen or RPE pigmentary clumping increases the risk of wet AMD. Wet AMD is characterized by growth of abnormal vessels into the subretinal space, usually from the choroidal circulation and less frequently from the retinal circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/13\">",
"     13",
"    </a>",
"    ]. These abnormal blood vessels leak, leading to collections of subretinal fluid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood beneath the retina (",
"    <a class=\"graphic graphic_figure graphicRef80193 \" href=\"UTD.htm?13/6/13418\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef68741 \" href=\"UTD.htm?41/19/42303\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef60226 \" href=\"UTD.htm?38/45/39647\">",
"     picture 5",
"    </a>",
"    ). Wet type AMD is also referred to as choroidal neovascularization.",
"   </p>",
"   <p>",
"    Wet AMD is more common than dry AMD among patients with advanced AMD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/14\">",
"     14",
"    </a>",
"    ]. Although wet AMD is found in only 10 to 15 percent of patients with AMD, wet AMD accounts for more than 80 percent of cases with severe visual loss or legal blindness [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast to dry AMD, in which vision loss is slow and gradual, wet AMD is characterized by rapid distortion and loss of central vision over a period of weeks to months. The contralateral eye is at high risk of developing neovascularization, with a cumulative incidence estimated at 10, 28, and 42 percent at one, three, and five years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wet AMD can be subcategorized, based upon the pattern of choroidal neovascularization seen on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography, into classic, occult, or fibrous lesions. Lesions that are predominantly classic typically progress more rapidly [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevalence and forecast data for age-related macular degeneration (AMD) are available from several studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AMD was found in 1.6 percent of 14,752 people (aged 43 to 99) from the United States, the Netherlands, and Australia, but in no one younger than 55 years [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/14\">",
"       14",
"      </a>",
"      ]. Prevalence rates for people aged 55 to 64, 65 to 74, 75 to 84, and &gt;84 were 0.2, 0.9, 4.6, and 13.1 percent, respectively. Dry AMD was found in 0.5 percent and wet AMD in 0.9 percent.",
"     </li>",
"     <li>",
"      In the United Kingdom, a 2012 paper estimates the prevalence of late AMD to be 2.4 percent; prevalence was 4.8 and 12.2 percent for persons &ge;65 years and &ge;80 years respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Eye Diseases Prevalence Research Group (EDPRG) estimated that the prevalence of neovascular AMD",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      geographic atrophy in adults age 40 and over in the United States was 1.47 percent, affecting 1.75 million people, in the year 2000 and projected that by 2020 AMD would affect almost three million people [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study involving model simulation predicted that US cases of choroidal neovascularization and geographic atrophy would increase from 1.7 million in 2010 to 3.8 million in 2050 [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/19\">",
"       19",
"      </a>",
"      ]. Preventive measures (vitamin prophylaxis) might decrease this by 25 percent and aggressive treatment of early AMD could lower the incidence of blindness by about 30 percent. It is also noted that trends for improved blood pressure control and lower rates of smoking might further curtail these predicted number of cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of new cases of AMD was evaluated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prospective Rotterdam Study looked at the incidence of new cases of AMD after 6.5 years of follow-up (27,000 person-years) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/7,9\">",
"       7,9",
"      </a>",
"      ]. There were 1.8 incident cases of AMD per 1000 person-years, with a ratio of wet to dry AMD of 1.4 to 1.0. The incidence of early age-related maculopathy (ARM) was 16.4 per 1000 person-years. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Beaver Dam Eye Study longitudinally followed 4000 people aged 43 to 86 at baseline, with eye examinations every five years for 15 years [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/20\">",
"       20",
"      </a>",
"      ]. The cumulative incidence of early AMD was 14.3 percent and of late AMD was 3.1 percent overall and 7.6 percent in those who were &ge;75 years at baseline. A similar longitudinal study from the Blue Mountains Eye Study in Australia with 10 year follow-up found that early and late AMD developed in 14.1 and 3.7 percent of participants, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one large study in Baltimore, the prevalence of AMD, adjusted for age, sex, and smoking, was greater in whites than blacks (OR 4.4, 95% CI 1.5-12.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/22\">",
"     22",
"    </a>",
"    ]. A systematic review of nine studies found the prevalence of AMD comparable for Asians and whites [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/23\">",
"     23",
"    </a>",
"    ], though Asians are more likely to have a variant of AMD (polypoidal choroidal vasculopathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dry type AMD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of dry AMD is unclear. There is some evidence that abnormalities in components of Bruch's membrane may be important (",
"    <a class=\"graphic graphic_figure graphicRef80193 \" href=\"UTD.htm?13/6/13418\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/25\">",
"     25",
"    </a>",
"    ]. Inflammation and chronic infection may also play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proposed mechanisms for dry AMD include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Photoreceptor and retinal pigmented epithelium (RPE) ischemia due to decreased choroidal or Bruch's membrane perfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/29-32\">",
"       29-32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Primary senescence of the RPE [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/33-35\">",
"       33-35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      RPE cell apoptosis due to activation of components of the inflammatory and immune system [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Genetic abnormalities affecting the photoreceptor outer segments or RPE [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/12,36\">",
"       12,36",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"local\" href=\"#H9\">",
"       'Genetic factors'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Subretinal accumulation of defective microglial cells with impaired chemokine properties [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Decreased scleral elasticity [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The development of drusen may be a common pathway resulting from one or more of these abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Wet type AMD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molecular mechanisms involved in choroidal neovascularization, the sine qua non of wet AMD, are better understood than is the molecular basis for dry AMD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Choroidal neovascularization is controlled by a dynamic balance between membrane-bound and diffusible substances with properties that either promote or inhibit blood vessel development [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/43\">",
"     43",
"    </a>",
"    ]. In 1948, Michaelson hypothesized that a diffusible, hypoxia-induced, angiogenic \"factor X\" was responsible for iris and retinal neovascularization associated with ischemic retinopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/44\">",
"     44",
"    </a>",
"    ]. Animal and human studies strongly suggest that vascular endothelial growth factor (VEGF) represents factor X [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/45-48\">",
"     45-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several isoforms of VEGF, with different binding affinities for the VEGF receptors, have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. VEGF-A is most strongly associated with angiogenesis, and is the target of most current anti-VEGF treatments.",
"   </p>",
"   <p>",
"    Understanding the role of VEGF in the pathogenesis of neovascularization has led to studies demonstrating the efficacy of VEGF inhibitors in the treatment of wet AMD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26074?source=see_link&amp;anchor=H7#H7\">",
"     \"Age-related macular degeneration: Treatment and prevention\", section on 'VEGF inhibitors and inhibitor-like drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age-related macular degeneration (AMD) has become the paradigm for a condition in which specific genotypic polymorphisms predispose to disease, and interact with modifiable and non-modifiable risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/51\">",
"     51",
"    </a>",
"    ]. Genetic polymorphisms in several genes have been identified that could account for more than half of all cases of AMD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/52\">",
"     52",
"    </a>",
"    ]. While the strongest association is with genes involved in complement pathways, other associated genetic factors are involved in immune processes, lipid metabolism, collagen and extracellular matrix mechanisms, and angiogenesis pathways. Genetic factors influence the onset and progression of AMD, as well as differential response to treatment options [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A common polymorphism of the complement factor H (CFH) gene predisposes to the development of AMD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/53-58\">",
"     53-58",
"    </a>",
"    ]. This polymorphism is involved in regulation of the alternate complement pathway that results in increased inflammation. Individuals with one allele with a histamine substitution for tyrosine in position 402 of the CFH gene (CFH Y402H) on chromosome 1 appear to have 2.5 to 4.6 times the risk of AMD, and individuals with both alleles affected appear to have 3.3 to 7.4 times the risk [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/54-56,59\">",
"     54-56,59",
"    </a>",
"    ]. Having at least one allele with this polymorphism appears to explain about 50 percent of the prevalence of AMD in the population (population attributable risk) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/55,56,60\">",
"     55,56,60",
"    </a>",
"    ]. Some [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/56,60\">",
"     56,60",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/61\">",
"     61",
"    </a>",
"    ], studies have found that the increase in risk is greater for wet AMD than for dry AMD.",
"   </p>",
"   <p>",
"    Other polymorphisms of CFH, as well as polymorphisms in other genes regulating components of the complement pathway (such as CFB and SERPING1), may also be associated with an increased risk of AMD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/62-66\">",
"     62-66",
"    </a>",
"    ]. A polymorphism at the rs230199 locus in the C3 gene has been associated with increased risk for AMD, with a population attributable risk of 22 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other candidate genes related to the incidence of AMD have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/67-72\">",
"     67-72",
"    </a>",
"    ]. In addition, two polymorphisms of the CFH and LOC genes are independently associated with progression of AMD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/73\">",
"     73",
"    </a>",
"    ]. A relationship has also been reported for variants of the toll-like receptor 3 gene (TLR3) and geographic atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/12\">",
"     12",
"    </a>",
"    ]. Activation of TLR3 is believed to induce cell death in human retinal pigment epithelial cells.",
"   </p>",
"   <p>",
"    The genetic basis for AMD may have implications for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/74\">",
"     74",
"    </a>",
"    ]. As an example, there is preliminary evidence that treatment response to vitamin and zinc supplementation may be influenced by the presence of a specific CFH genotype, although this will need further confirmation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/75\">",
"     75",
"    </a>",
"    ]. Treatment response to VEGF inhibitors may also be related to the presence of identified polymorphisms in the CFH and other AMD-associated genes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Role of inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the identified genetic polymorphisms support a role for local inflammation and complement activation in the etiology of AMD. An association between biomarkers for inflammation (including highly sensitive C-reactive protein) and AMD risk is suggested by data from the Women's Health Study and the Rotterdam Study [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/78,79\">",
"     78,79",
"    </a>",
"    ], although no association was found between the presence of inflammatory markers and AMD severity in a study of 5887 patients of different ethnicities with AMD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some have postulated that AMD results from impairment in the immune control mechanisms that normally downregulate immune activation in the eye. One model proposes that drusen serve as the antigenic stimulus, stimulating macrophage activity, chemokines, and complement activation in the eye(s) of hosts with underlying immune dysfunction due to age",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    genetic polymorphisms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/81\">",
"     81",
"    </a>",
"    ]. These hypotheses lead to the potential for greater therapeutic success by combining treatment strategies that modulate the immune component and the neovascular component of AMD. Such combination treatment strategies are undergoing Phase I and II clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of clinical risk factors for AMD have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/82\">",
"     82",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &mdash; The prevalence of AMD increases with age, starting after age 50 and becoming more pronounced over age 65 [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/5,7\">",
"       5,7",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Smoking &mdash; Smoking increases the risk of dry and wet AMD, with relative risks ranging from 2 to 4 compared with people who never smoked [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/83-87\">",
"       83-87",
"      </a>",
"      ]. Smoking is also associated with increased risk of progression from early to advanced AMD [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/88,89\">",
"       88,89",
"      </a>",
"      ] and for geographic atrophy and bilateral involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/87,90\">",
"       87,90",
"      </a>",
"      ]. There appears to be a dose-response relationship [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/91\">",
"       91",
"      </a>",
"      ], and risk may persist even after quitting smoking for 15 to 20 years [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/85,92\">",
"       85,92",
"      </a>",
"      ]. The risk may be particularly elevated in smokers who are homozygous for the CFH Y402H polymorphism [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/70,93\">",
"       70,93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Family history &mdash; There appears to be an increased risk in patients with a family history of AMD [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/94\">",
"       94",
"      </a>",
"      ]; the association may be stronger in patients with early onset and more severe disease [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/95,96\">",
"       95,96",
"      </a>",
"      ]. This may be related to a polymorphisms in the CFH gene, as well as a number of other genes. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Genetic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiovascular disease &mdash; A history of stroke or coronary heart disease (CHD) (myocardial infarction or angina) was associated with increased risk for AMD (RR 1.6) in a prospective ten year longitudinal study of over 2000 participants [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/97,98\">",
"       97,98",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Studies conflict, however, on whether AMD increases the risk for cardiovascular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/99-101\">",
"       99-101",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diet &mdash; Studies conflict on the protective role of diet and vitamins [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/102\">",
"       102",
"      </a>",
"      ]. This issue is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26074?source=see_link&amp;anchor=H19#H19\">",
"       \"Age-related macular degeneration: Treatment and prevention\", section on 'Prevention'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cataract surgery &mdash; Concerns have been raised that patients undergoing cataract surgery may be at increased risk for AMD [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/103\">",
"       103",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=see_link&amp;anchor=H27#H27\">",
"       \"Cataract in adults\", section on 'Risk of macular degeneration'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      &mdash; In observational studies, regular aspirin use was associated with increased risk of both dry and wet AMD [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/104-106\">",
"       104-106",
"      </a>",
"      ]. As an example, in one population-based study, regular aspirin use (twice or more a week for at least three months) starting 10 years before retinal examination was associated with a small increase in risk of late but not early AMD (estimated incidence 1.76 and 1.03 percent, in aspirin users and nonusers, respectively, hazard ratio 1.63, 95% CI 1.01-2.63) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/105\">",
"       105",
"      </a>",
"      ]. Aspirin use starting five years before retinal examination was not associated with early or late AMD. These findings are preliminary, and observational studies do not prove causality. Additional studies are needed.",
"     </li>",
"     <li>",
"      Other &mdash; A variety of other potential risk factors have been suggested. Heavy alcohol use (more than three drinks per day) is associated with an increased risk for early AMD [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/107\">",
"       107",
"      </a>",
"      ]. AMD appears to be more prevalent in whites than in blacks with an intermediate prevalence in Hispanics and Chinese [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/10,108,109\">",
"       10,108,109",
"      </a>",
"      ]. Data are conflicting on the role of hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/15,97,110-113\">",
"       15,97,110-113",
"      </a>",
"      ], higher body mass index [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/114,115\">",
"       114,115",
"      </a>",
"      ], and sunlight [",
"      <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/116-120\">",
"       116-120",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors for progression to advanced disease include age, smoking, body mass index, identified gene polymorphisms, the presence of advanced AMD in one eye, and drusen size in both eyes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early AMD is often asymptomatic. Patients with dry AMD may complain of gradual loss of vision in one or both eyes. This is often first noticed as difficulty reading or driving, scotomas, or reliance on brighter light or a magnifying lens for tasks that require fine visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wet AMD may present as acute visual distortion or loss of central vision as a result of subretinal hemorrhage or fluid accumulation. Symptoms of wet AMD usually appear in one eye, although the disease is often present in both eyes. Once advanced AMD develops in one eye, there is a greater than 40 percent risk of development in the other eye within five years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Distortion of straight lines (metamorphopsia) is one of the earliest changes with wet AMD. Patients may perceive straight edges (such as doors or window blinds) as curved or distorted. Line distortion can be evaluated by use of the Amsler grid, a tool for detecting the occurrence of disease progression in patients with dry AMD (",
"    <a class=\"graphic graphic_figure graphicRef56604 \" href=\"UTD.htm?38/36/39497\">",
"     figure 2",
"    </a>",
"    ). The patient is given a copy of the grid and is instructed to focus one eye on the center dot in the grid from a distance of 12 inches with the other eye covered. Patients may also present with complaints of a dark patch in their central vision (scotoma). Patients should test each eye daily and immediately report line distortions or scotomas to their clinician.",
"   </p>",
"   <p>",
"    Most patients with advanced AMD do not become completely blind, though significant visual loss results in disability and clinical depression in over one third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Initial primary care evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the primary care setting, a complaint of visual disturbance should prompt a history that includes the rate of vision loss, whether one or both eyes are involved, and whether the vision loss is for distance vision, near vision, or both. Patients with an acute distortion or loss of central vision may represent wet AMD.",
"   </p>",
"   <p>",
"    Vision loss that occurs acutely (a period of days or weeks) requires urgent ophthalmic evaluation. The evaluation of the patient with acute vision loss is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10666?source=see_link\">",
"     \"Amaurosis fugax (transient monocular or binocular visual loss)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26888?source=see_link\">",
"     \"Approach to the adult with acute persistent visual loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ophthalmologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age-related macular degeneration (AMD) is a clinical diagnosis based upon the presence of characteristic findings on dilated eye examination using a slit lamp instrument (biomicroscopy):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In dry AMD, drusen are visible on dilated eye examination (",
"      <a class=\"graphic graphic_picture graphicRef58340 \" href=\"UTD.htm?32/34/33327\">",
"       picture 2",
"      </a>",
"      ). Round or oval patches of geographic atrophy of the retina may be evident as areas of depigmentation (",
"      <a class=\"graphic graphic_picture graphicRef79129 \" href=\"UTD.htm?2/36/2625\">",
"       picture 3",
"      </a>",
"      ); increased pigmentation may be seen with RPE pigmentary mottling (",
"      <a class=\"graphic graphic_picture graphicRef70148 \" href=\"UTD.htm?18/32/18944\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In wet AMD, dilated examination may reveal subretinal fluid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hemorrhage (",
"      <a class=\"graphic graphic_picture graphicRef68741 \" href=\"UTD.htm?41/19/42303\">",
"       picture 4",
"      </a>",
"      ). Neovascularization appears as a grayish-green discoloration in the macular area (",
"      <a class=\"graphic graphic_picture graphicRef60226 \" href=\"UTD.htm?38/45/39647\">",
"       picture 5",
"      </a>",
"      ). The presence of subretinal hemorrhage or a gray subretinal membrane is strongly suggestive of a subretinal choroidal membrane. These patients require an office-based",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      angiogram delineate and characterize the neovascular membrane and optical coherence tomography to identify the presence of subretinal fluid or retinal edema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Fluorescein dye retinal angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiogram can demonstrate fluorescein coursing through the choroid and retinal vessels, as well as any abnormal choroidal neovascular complex. Fluorescein dye is injected intravenously as a bolus and a sequence of photographs of the retina are taken five seconds to 10 minutes later. Color fundus photography is often taken at the same time (",
"    <a class=\"graphic graphic_picture graphicRef65957 \" href=\"UTD.htm?1/6/1126\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In contrast to normal retinal vessels, newly formed choroidal neovascular vessels will leak",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    , which occurs late in the angiogram. Choroidal neovascular membranes are classified as classic or occult membranes, based on the definition of the edges of the membranes. The location of the blood vessels, either subfoveal or perifoveal, is important for determining appropriate therapy. Unfortunately, there is only moderate interobserver and intraobserver agreement when performing such angiographic classifications [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32450?source=see_link\">",
"     Indocyanine green",
"    </a>",
"    angiography uses a dye with different absorption characteristics and can better detect certain neovascular variants of AMD, such as polypoidal choroidal vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/52/6986/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Optical coherence tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optical coherence tomography (OCT) is an imaging technique that produces high resolution cross sectional images of the retina. It is based on the optical reflectivity of the tissues, in an analogous manner to sound in B-scan ultrasonography and x-rays in computed tomography (CT). The use of light waves enables OCT to achieve an axial resolution of 10 micrometers.",
"   </p>",
"   <p>",
"    OCT provides high-resolution anatomic images of the posterior vitreous, retina, retinal pigment epithelium and anterior choroid. These images can be used to identify retinal edema",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subretinal fluid (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68205 \" href=\"UTD.htm?39/63/40946\">",
"     image 1",
"    </a>",
"    ). OCT has made a significant impact in the diagnosis and management of wet AMD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4546919\">",
"    <span class=\"h3\">",
"     Fundus autofluorescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;This new imaging technique allows identification of lipofuscin accumulation, a sign of cellular metabolism and aging, and can be used to characterize and follow the progression of geographic atrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24754?source=see_link\">",
"       \"Patient information: Age-related macular degeneration (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11826?source=see_link\">",
"       \"Patient information: Age-related vision loss (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age-related macular degeneration (AMD) is the leading cause of adult blindness in industrialized countries. AMD is a degenerative disease of the central portion of the retina (the macula) that results primarily in loss of central vision. AMD is classified as dry (atrophic) or wet (neovascular or exudative). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of AMD increases with age. Smoking is the major modifiable risk factor for AMD. A common polymorphism in the CFH gene appears to explain about 50 percent of cases of AMD. Complement activation and inflammation appear to play a role in the etiology of AMD. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients be counseled not to smoke to decrease their risk of AMD as well as other smoking-related disorders (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Presentation and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with dry AMD may complain of gradual loss of vision in one or both eyes. Wet AMD may present as acute visual distortion or loss of central vision as a result of subretinal hemorrhage or fluid accumulation. Symptoms of wet AMD usually appear in one eye, although the disease is often present in both eyes. Distortion of straight lines (metamorphopsia) is one of the earliest changes with wet AMD. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the primary care setting, a patient presenting with a complaint of visual disturbance should be asked about the rate of vision loss, whether one or both eyes are involved, and whether the vision loss is for distance vision, near vision, or both. Vision loss that occurs acutely (over a period of days or weeks) may represent wet AMD and requires urgent ophthalmic evaluation. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/1\">",
"      Felson DT, Anderson JJ, Hannan MT, et al. Impaired vision and hip fracture. The Framingham Study. J Am Geriatr Soc 1989; 37:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/2\">",
"      Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/3\">",
"      Lord SR, Dayhew J. Visual risk factors for falls in older people. J Am Geriatr Soc 2001; 49:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/4\">",
"      Hyman L. Epidemiology of eye disease in the elderly. Eye (Lond) 1987; 1 ( Pt 2):330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/5\">",
"      Weih LM, VanNewkirk MR, McCarty CA, Taylor HR. Age-specific causes of bilateral visual impairment. Arch Ophthalmol 2000; 118:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/6\">",
"      Holz FG, Wolfensberger TJ, Piguet B, et al. Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors. Ophthalmology 1994; 101:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/7\">",
"      Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998; 116:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/8\">",
"      Bressler NM. Age-related macular degeneration is the leading cause of blindness... JAMA 2004; 291:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/9\">",
"      van Leeuwen R, Klaver CC, Vingerling JR, et al. The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch Ophthalmol 2003; 121:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/10\">",
"      Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008; 358:2606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/11\">",
"      Ferris FL, Davis MD, Clemons TE, et al. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol 2005; 123:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/12\">",
"      Yang Z, Stratton C, Francis PJ, et al. Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med 2008; 359:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/13\">",
"      Gass JD, Agarwal A, Lavina AM, Tawansy KA. Focal inner retinal hemorrhages in patients with drusen: an early sign of occult choroidal neovascularization and chorioretinal anastomosis. Retina 2003; 23:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/14\">",
"      Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology 2001; 108:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/15\">",
"      Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol 1997; 115:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/16\">",
"      Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/17\">",
"      Owen CG, Jarrar Z, Wormald R, et al. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol 2012; 96:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/18\">",
"      Friedman DS, O'Colmain BJ, Mu&ntilde;oz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/19\">",
"      Rein DB, Wittenborn JS, Zhang X, et al. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol 2009; 127:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/20\">",
"      Klein R, Klein BE, Knudtson MD, et al. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2007; 114:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/21\">",
"      Wang JJ, Rochtchina E, Lee AJ, et al. Ten-year incidence and progression of age-related maculopathy: the blue Mountains Eye Study. Ophthalmology 2007; 114:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/22\">",
"      Friedman DS, Katz J, Bressler NM, et al. Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology 1999; 106:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/23\">",
"      Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2010; 117:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/24\">",
"      Lim LS, Mitchell P, Seddon JM, et al. Age-related macular degeneration. Lancet 2012; 379:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/25\">",
"      Johnson LV, Anderson DH. Age-related macular degeneration and the extracellular matrix. N Engl J Med 2004; 351:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/26\">",
"      Seddon JM, George S, Rosner B, Rifai N. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol 2005; 123:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/27\">",
"      Vine AK, Stader J, Branham K, et al. Biomarkers of cardiovascular disease as risk factors for age-related macular degeneration. Ophthalmology 2005; 112:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/28\">",
"      Kalayoglu MV, Bula D, Arroyo J, et al. Identification of Chlamydia pneumoniae within human choroidal neovascular membranes secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2005; 243:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/29\">",
"      Friedman E, Krupsky S, Lane AM, et al. Ocular blood flow velocity in age-related macular degeneration. Ophthalmology 1995; 102:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/30\">",
"      Friedman E. A hemodynamic model of the pathogenesis of age-related macular degeneration. Am J Ophthalmol 1997; 124:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/31\">",
"      Grunwald JE, Metelitsina TI, Dupont JC, et al. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci 2005; 46:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/32\">",
"      Ciulla TA, Harris A, Kagemann L, et al. Choroidal perfusion perturbations in non-neovascular age related macular degeneration. Br J Ophthalmol 2002; 86:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/33\">",
"      Zarbin MA. Age-related macular degeneration: review of pathogenesis. Eur J Ophthalmol 1998; 8:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/34\">",
"      Hogan MJ. Role of the retinal pigment epithelium in macular disease. Trans Am Acad Ophthalmol Otolaryngol 1972; 76:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/35\">",
"      Young RW. Pathophysiology of age-related macular degeneration. Surv Ophthalmol 1987; 31:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/36\">",
"      Zack DJ, Dean M, Molday RS, et al. What can we learn about age-related macular degeneration from other retinal diseases? Mol Vis 1999; 5:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/37\">",
"      Combadi&egrave;re C, Feumi C, Raoul W, et al. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J Clin Invest 2007; 117:2920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/38\">",
"      Friedman E, Ivry M, Ebert E, et al. Increased scleral rigidity and age-related macular degeneration. Ophthalmology 1989; 96:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/39\">",
"      Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004; 122:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/40\">",
"      Ciulla TA. Evolving pathophysiological paradigms for age related macular degeneration. Br J Ophthalmol 2001; 85:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/41\">",
"      Folkman J. Endogenous angiogenesis inhibitors. APMIS 2004; 112:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/42\">",
"      Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/43\">",
"      Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/44\">",
"      Michaelson I. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal disorders. Trans Ophthalmol Soc UK 1948; 68:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/45\">",
"      Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/46\">",
"      Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/47\">",
"      Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 1997; 13:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/48\">",
"      Tolentino MJ, McLeod DS, Taomoto M, et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002; 133:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/49\">",
"      Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 2006; 90:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/50\">",
"      de Oliveira Dias JR, Rodrigues EB, Maia M, et al. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy. Br J Ophthalmol 2011; 95:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/51\">",
"      Hampton T. Genetic research provides insights into age-related macular degeneration. JAMA 2010; 304:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/52\">",
"      Despriet DD, van Duijn CM, Oostra BA, et al. Complement component C3 and risk of age-related macular degeneration. Ophthalmology 2009; 116:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/53\">",
"      Schaumberg DA, Hankinson SE, Guo Q, et al. A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors. Arch Ophthalmol 2007; 125:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/54\">",
"      Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/55\">",
"      Edwards AO, Ritter R 3rd, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/56\">",
"      Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/57\">",
"      Kondo N, Bessho H, Honda S, Negi A. Complement factor H Y402H variant and risk of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2011; 118:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/58\">",
"      Raychaudhuri S, Iartchouk O, Chin K, et al. A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. Nat Genet 2011; 43:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/59\">",
"      Zareparsi S, Branham KE, Li M, et al. Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Hum Genet 2005; 77:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/60\">",
"      Despriet DD, Klaver CC, Witteman JC, et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA 2006; 296:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/61\">",
"      Magnusson KP, Duan S, Sigurdsson H, et al. CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med 2006; 3:e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/62\">",
"      Li M, Atmaca-Sonmez P, Othman M, et al. CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. Nat Genet 2006; 38:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/63\">",
"      Hughes AE, Orr N, Esfandiary H, et al. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet 2006; 38:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/64\">",
"      Yates JR, Sepp T, Matharu BK, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 2007; 357:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/65\">",
"      Ennis S, Jomary C, Mullins R, et al. Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study. Lancet 2008; 372:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/66\">",
"      Lee AY, Kulkarni M, Fang AM, et al. The effect of genetic variants in SERPING1 on the risk of neovascular age-related macular degeneration. Br J Ophthalmol 2010; 94:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/67\">",
"      Stone EM, Braun TA, Russell SR, et al. Missense variations in the fibulin 5 gene and age-related macular degeneration. N Engl J Med 2004; 351:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/68\">",
"      Dewan A, Liu M, Hartman S, et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 2006; 314:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/69\">",
"      Yang Z, Camp NJ, Sun H, et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 2006; 314:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/70\">",
"      de Jong PT. Age-related macular degeneration. N Engl J Med 2006; 355:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/71\">",
"      Gorin MB. A clinician's view of the molecular genetics of age-related maculopathy. Arch Ophthalmol 2007; 125:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/72\">",
"      Maller J, George S, Purcell S, et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet 2006; 38:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/73\">",
"      Seddon JM, Francis PJ, George S, et al. Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA 2007; 297:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/74\">",
"      Sheffield VC, Stone EM. Genomics and the eye. N Engl J Med 2011; 364:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/75\">",
"      Klein ML, Francis PJ, Rosner B, et al. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology 2008; 115:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/76\">",
"      Galan A, Ferlin A, Caretti L, et al. Association of age-related macular degeneration with polymorphisms in vascular endothelial growth factor and its receptor. Ophthalmology 2010; 117:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/77\">",
"      McKibbin M, Ali M, Bansal S, et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol 2012; 96:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/78\">",
"      Schaumberg DA, Christen WG, Buring JE, et al. High-sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular degeneration in women. Arch Ophthalmol 2007; 125:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/79\">",
"      Boekhoorn SS, Vingerling JR, Witteman JC, et al. C-reactive protein level and risk of aging macula disorder: The Rotterdam Study. Arch Ophthalmol 2007; 125:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/80\">",
"      Klein R, Knudtson MD, Klein BE, et al. Inflammation, complement factor h, and age-related macular degeneration: the Multi-ethnic Study of Atherosclerosis. Ophthalmology 2008; 115:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/81\">",
"      Nussenblatt RB, Ferris F 3rd. Age-related macular degeneration and the immune response: implications for therapy. Am J Ophthalmol 2007; 144:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/82\">",
"      Hyman L, Neborsky R. Risk factors for age-related macular degeneration: an update. Curr Opin Ophthalmol 2002; 13:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/83\">",
"      Klein R, Klein BE, Moss SE. Relation of smoking to the incidence of age-related maculopathy. The Beaver Dam Eye Study. Am J Epidemiol 1998; 147:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/84\">",
"      Christen WG, Glynn RJ, Manson JE, et al. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA 1996; 276:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/85\">",
"      Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 1996; 276:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/86\">",
"      Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of Age-Related Macular Degeneration. Arch Ophthalmol 2006; 124:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/87\">",
"      Tan JS, Mitchell P, Kifley A, et al. Smoking and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Arch Ophthalmol 2007; 125:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/88\">",
"      Clemons TE, Milton RC, Klein R, et al. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology 2005; 112:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/89\">",
"      Klein R, Knudtson MD, Cruickshanks KJ, Klein BE. Further observations on the association between smoking and the long-term incidence and progression of age-related macular degeneration: the Beaver Dam Eye Study. Arch Ophthalmol 2008; 126:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/90\">",
"      Chakravarthy U, Augood C, Bentham GC, et al. Cigarette smoking and age-related macular degeneration in the EUREYE Study. Ophthalmology 2007; 114:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/91\">",
"      Khan JC, Thurlby DA, Shahid H, et al. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 2006; 90:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/92\">",
"      Delcourt C, Diaz JL, Ponton-Sanchez A, Papoz L. Smoking and age-related macular degeneration. The POLA Study. Pathologies Oculaires Li&eacute;es &agrave; l'Age. Arch Ophthalmol 1998; 116:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/93\">",
"      DeAngelis MM, Ji F, Kim IK, et al. Cigarette smoking, CFH, APOE, ELOVL4, and risk of neovascular age-related macular degeneration. Arch Ophthalmol 2007; 125:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/94\">",
"      Klein BE, Klein R, Lee KE, et al. Risk of incident age-related eye diseases in people with an affected sibling : The Beaver Dam Eye Study. Am J Epidemiol 2001; 154:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/95\">",
"      Hammond CJ, Webster AR, Snieder H, et al. Genetic influence on early age-related maculopathy: a twin study. Ophthalmology 2002; 109:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/96\">",
"      Seddon JM, Cote J, Page WF, et al. The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. Arch Ophthalmol 2005; 123:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/97\">",
"      Tan JS, Mitchell P, Smith W, Wang JJ. Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2007; 114:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/98\">",
"      Friedman E. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol 2000; 130:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/99\">",
"      Tan JS, Wang JJ, Liew G, et al. Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br J Ophthalmol 2008; 92:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/100\">",
"      Sun C, Klein R, Wong TY. Age-related macular degeneration and risk of coronary heart disease and stroke: the Cardiovascular Health Study. Ophthalmology 2009; 116:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/101\">",
"      Fernandez AB, Wong TY, Klein R, et al. Age-related macular degeneration and incident cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. Ophthalmology 2012; 119:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/102\">",
"      Coleman HR, Chan CC, Ferris FL 3rd, Chew EY. Age-related macular degeneration. Lancet 2008; 372:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/103\">",
"      Wang JJ, Klein R, Smith W, et al. Cataract surgery and the 5-year incidence of late-stage age-related maculopathy: pooled findings from the Beaver Dam and Blue Mountains eye studies. Ophthalmology 2003; 110:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/104\">",
"      de Jong PT, Chakravarthy U, Rahu M, et al. Associations between aspirin use and aging macula disorder: the European Eye Study. Ophthalmology 2012; 119:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/105\">",
"      Klein BE, Howard KP, Gangnon RE, et al. Long-term use of aspirin and age-related macular degeneration. JAMA 2012; 308:2469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/106\">",
"      Liew G, Mitchell P, Wong TY, et al. The association of aspirin use with age-related macular degeneration. JAMA Intern Med 2013; 173:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/107\">",
"      Chong EW, Kreis AJ, Wong TY, et al. Alcohol consumption and the risk of age-related macular degeneration: a systematic review and meta-analysis. Am J Ophthalmol 2008; 145:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/108\">",
"      Klein R, Rowland ML, Harris MI. Racial/ethnic differences in age-related maculopathy. Third National Health and Nutrition Examination Survey. Ophthalmology 1995; 102:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/109\">",
"      Bressler SB, Mu&ntilde;oz B, Solomon SD, et al. Racial differences in the prevalence of age-related macular degeneration: the Salisbury Eye Evaluation (SEE) Project. Arch Ophthalmol 2008; 126:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/110\">",
"      Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology 2000; 107:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/111\">",
"      Delcourt C, Michel F, Colvez A, et al. Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study. Ophthalmic Epidemiol 2001; 8:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/112\">",
"      Klein R, Klein BE, Marino EK, et al. Early age-related maculopathy in the cardiovascular health study. Ophthalmology 2003; 110:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/113\">",
"      Klein R, Klein BE, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam eye study. Ophthalmology 2003; 110:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/114\">",
"      Seddon JM, Cote J, Davis N, Rosner B. Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol 2003; 121:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/115\">",
"      Moeini HA, Masoudpour H, Ghanbari H. A study of the relation between body mass index and the incidence of age related macular degeneration. Br J Ophthalmol 2005; 89:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/116\">",
"      Taylor HR, West S, Mu&ntilde;oz B, et al. The long-term effects of visible light on the eye. Arch Ophthalmol 1992; 110:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/117\">",
"      Darzins P, Mitchell P, Heller RF. Sun exposure and age-related macular degeneration. An Australian case-control study. Ophthalmology 1997; 104:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/118\">",
"      Delcourt C, Carri&egrave;re I, Ponton-Sanchez A, et al. Light exposure and the risk of age-related macular degeneration: the Pathologies Oculaires Li&eacute;es &agrave; l'Age (POLA) study. Arch Ophthalmol 2001; 119:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/119\">",
"      Khan JC, Shahid H, Thurlby DA, et al. Age related macular degeneration and sun exposure, iris colour, and skin sensitivity to sunlight. Br J Ophthalmol 2006; 90:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/120\">",
"      Tomany SC, Cruickshanks KJ, Klein R, et al. Sunlight and the 10-year incidence of age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol 2004; 122:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/121\">",
"      Seddon JM, Reynolds R, Yu Y, et al. Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. Ophthalmology 2011; 118:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/122\">",
"      Quillen DA. Common causes of vision loss in elderly patients. Am Fam Physician 1999; 60:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/123\">",
"      Holz FG, Jorzik J, Schutt F, et al. Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study). Ophthalmology 2003; 110:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/52/6986/abstract/124\">",
"      Yannuzzi LA. Indocyanine green angiography: a perspective on use in the clinical setting. Am J Ophthalmol 2011; 151:745.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6901 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-806F72AFFC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_52_6986=[""].join("\n");
var outline_f6_52_6986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dry type AMD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Wet type AMD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dry type AMD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Wet type AMD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Role of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Initial primary care evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ophthalmologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Fluorescein dye retinal angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Optical coherence tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4546919\">",
"      - Fundus autofluorescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6901\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6901|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/63/40946\" title=\"diagnostic image 1\">",
"      OCT AMD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6901|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/6/13418\" title=\"figure 1\">",
"      Macula lutea with AMD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/36/39497\" title=\"figure 2\">",
"      Amsler grid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6901|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/32/18944\" title=\"picture 1\">",
"      Dry AMD w pigment mottling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/34/33327\" title=\"picture 2\">",
"      Dry AMD with drusen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/36/2625\" title=\"picture 3\">",
"      Dry AMD with atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/19/42303\" title=\"picture 4\">",
"      Wet AMD with hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/45/39647\" title=\"picture 5\">",
"      Wet AMD with disciform scar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/6/1126\" title=\"picture 6\">",
"      Fluorescein AMD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26074?source=related_link\">",
"      Age-related macular degeneration: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10666?source=related_link\">",
"      Amaurosis fugax (transient monocular or binocular visual loss)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26888?source=related_link\">",
"      Approach to the adult with acute persistent visual loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3385?source=related_link\">",
"      Approach to the evaluation of older drivers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=related_link\">",
"      Cataract in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=related_link\">",
"      Falls in older persons: Risk factors and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=related_link\">",
"      Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24754?source=related_link\">",
"      Patient information: Age-related macular degeneration (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11826?source=related_link\">",
"      Patient information: Age-related vision loss (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/38/32362?source=related_link\">",
"      Prevention and treatment of diabetic retinopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_52_6987="E coli diarrhea syndromes";
var content_f6_52_6987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical syndromes associated with diarrheagenic Escherichia coli",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Strain",
"       </td>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enterotoxigenic E. coli (ETEC)",
"       </td>",
"       <td>",
"        Watery diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteropathogenic E. coli (EPEC)",
"       </td>",
"       <td>",
"        Infantile diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enterohemorrhagic E. coli (EHEC)",
"       </td>",
"       <td>",
"        Hemorrhagic colitis and hemolytic uremic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteroinvasive E. coli (EIEC)",
"       </td>",
"       <td>",
"        Dysentery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteroaggregative E. coli (EAEC)",
"       </td>",
"       <td>",
"        Persistent diarrhea in children and patients infected",
"with HIV",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_52_6987=[""].join("\n");
var outline_f6_52_6987=null;
var title_f6_52_6988="Increased osmolal and O2 gaps";
var content_f6_52_6988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Increased osmolal and oxygen saturation gaps",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Increased osmolal gap (normal 5 &plusmn; 7 [SD] m0sm/L)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acetone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ethanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ethylene glycol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Glycerol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypermagnesemia (&gt;9.5 mEq/L)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Isopropyl alcohol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mannitol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Propylene glycol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Benzyl alcohol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sorbitol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ethyl ethers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Glycol ethers",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Increased oxygen saturation gap (&gt;5 percent difference)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbon monoxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyanide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfhemoglobinemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hydrogen sulfide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methemoglobin",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_52_6988=[""].join("\n");
var outline_f6_52_6988=null;
var title_f6_52_6989="ACC AHA diagnosis evaluation AR";
var content_f6_52_6989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Diagnosis and initial evaluation of aortic regurgitation (AR)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general",
"agreement that the following tests are indicated for the diagnosis and",
"initial evaluation in patients with AR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;&nbsp; Echocardiography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. To confirm the diagnosis and to estimate the severity of acute or chronic AR.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. To determine the cause of chronic AR, including",
"assessment of valve morphology and the size and morphology of the",
"aortic root.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. To determine left ventricular function and",
"detect left ventricular hypertrophy and left ventricular dimensions or",
"volumes in chronic AR.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Among patients with an enlarged aortic root, to assess both AR and the severity of aortic dilatation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        5. Among asymptomatic patients with chronic AR, to periodically reevaluate left ventricular size and function.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        6. To reassess mild, moderate, or severe AR in patients who have new or changing symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;&nbsp; Radionuclide angiography or magnetic resonance imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. For the initial and follow-up assessment of left ventricular volume and function at rest when echocardiography is suboptimal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;&nbsp; Cardiac catheterization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. With aortic root angiography and measurement of",
"left ventricular pressure to assess the severity of AR, left",
"ventricular function, and aortic root size when noninvasive tests are",
"inconclusive or provide discrepant results from clinical findings.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa -  The weight of evidence or",
"opinion is in favor of efficacy of the following tests in patients with",
"AR in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;&nbsp; Exercise stress testing in chronic AR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. To assess functional capacity and symptom response in patients with a history of equivocal symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. To assess symptoms and functional capacity prior to participation in athletic activity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;&nbsp; Magnetic resonance imaging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. To assess the severity of AR when echocardiography is not satisfactory.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or",
"opinion is less well established for the following test in patients",
"with AR in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;&nbsp; Exercise stress testing with radionuclide angiography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. To assess left ventricular function in asymptomatic or symptomatic patients with chronic AR.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or",
"general agreement that the following test is not useful in patients",
"with AR in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;&nbsp; Cardiac catheterization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. When noninvasive tests are adequate and consistent with clinical findings and coronary angiography is not required.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. In asymptomatic patients in whom noninvasive tests are adequate.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_52_6989=[""].join("\n");
var outline_f6_52_6989=null;
var title_f6_52_6990="AS survival and jet velocity";
var content_f6_52_6990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 513px\">",
"   <div class=\"ttl\">",
"    Event free survival in asymptomatic aortic stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 493px; height: 298px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Event free survival in patients with aortic stenosis who are initially asymptomatic is related to the aortic jet velocity (Vmax) at entry. Aortic jet velocity varies inversely with valve area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Otto CM, Burwash IG, Legget ME, et al. Circulation 1997; 95:2262.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_52_6990=[""].join("\n");
var outline_f6_52_6990=null;
var title_f6_52_6991="Aldosterone escape II";
var content_f6_52_6991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F73932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F73932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Impaired aldosterone escape in renal artery stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 389px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The effect of the administration of aldosterone and a high Na+ diet on mean arterial pressure, cumulative Na+ balance, and urinary Na+ excretion in dogs. If renal perfusion pressure is held constant by use of a suprarenal aortic clamp, Na+ excretion remains at low levels and aldosterone escape does not occur. The net result is progressive Na+ retention and a marked elevation in systemic blood pressure. When, however, renal perfusion pressure is allowed to rise by release of the clamp, there is a spontaneous diuresis, leading to a return in Na+ balance toward normal and much less severe hypertension. (From Hall, JE, Granger, JP, Smith, MJ, Jr, Premen, AJ, Hypertension 1984; 6(2 Pt 2):I-183. By permission of the American Heart Association, Inc.)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_52_6991=[""].join("\n");
var outline_f6_52_6991=null;
